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ABSTRACT 
Alterations of metabolism have been implicated in cancer pathogenesis and 
response to therapy. Autophagy is a metabolic pathway providing the cell with 
intermediates of metabolism and limiting cellular damage via degradation of 
intracellular components in vesicular structures called autophagosomes/ 
autolysosomes. Basal autophagy plays a dual role in cancer: in normal tissues 
suppresses neoplastic transformation, whereas in established cancers sustains 
tumour growth. Therefore, it is important to evaluate the role of basal autophagy in 
CRC. Additionally, oncogenic tyrosine kinases (TKs) inhibit autophagy either directly, 
or indirectly via activation of the PI3K/mTOR pathway. Work from our group and others 
have shown that i) autophagy is induced upon TK-targeted therapeutics and ii) 
autophagy pharmacological inhibition increases sensitivity to TK targeted therapy. In 
colorectal cancer (CRC), which is the 3rd most common cancer type often 
characterised by PI3K and KRAS mutations, targeted inhibition of the Epithelial 
Growth Factor Receptor (EGFR) is used for the treatment of metastatic patients albeit 
with limited therapeutic benefit. It is presently unclear whether autophagy inhibition 
could potentiate EGFR targeted therapy in CRC. More generally, our knowledge on 
whether or how autophagy vice versa could control RTK activation is limited.  
The main aims of this research are: i) investigating the effect of EGFR inhibition on 
autophagy and the potential benefit of autophagy suppression in CRC; ii) exploring the 
role of basal autophagy in CRC and its relationship to signalling. 
I have shown that activating mutations in KRAS and PI3K genes make CRC cells 
resistant to EGFR inhibition as well as to autophagy induction, mainly through 
differential regulation of MAPK/ERK and PI3K/AKT pathways activation; thus 
suggesting that autophagy targeting would have limited impact in CRC. Conversely, 
PI3K mutant CRC cells display basal levels of autophagy despite the presence of 
constitutive PI3K/mTOR signalling and basal autophagy controls RTK activation and 
cell signalling. Finally, basal autophagy is suggested to play a tumour suppressive role 
under anchorage-independent cell growth conditions.  
Overall, these findings suggest a complex relationship between RTKs and 
autophagy: on one hand, autophagy activation upon RTK targeted therapy is 
dependent on PI3K mutational status; on the other hand, inhibition of basal autophagy 
affects RTK activation and downstream AKT and/or MAPK signalling independently of 
KRAS/PI3K mutations.  
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1. Introduction 
1.1. Autophagy 
The term autophagy that derives from the Greek words “auto” (self) and “phagein” 
(to eat) and literally means self-eating was originally described by Christian de Duve in 
1963 primed by his earlier discovery of the lysosome as a degradation organelle, in 
1955. The term autophagy is used to describe observations linked to the transmission 
of cytoplasmic components into lysosomes for degradation. For many years, 
autophagy was considered as a non-selective “bulk” degradation process until 1978 
when the first evidence regarding different types of autophagy was discovered 
(Ohsumi, 2014). Hitherto, autophagy is considered as a tightly regulated catabolic self-
renewal pathway that helps cells to maintain their homeostasis and overcome 
stressing stimuli. Autophagy is conserved through evolution and is categorized into 
three types that differ in their mechanisms of function namely: 1) chaperone-mediated 
autophagy (CMA), 2) microautophagy and 3) macroautophagy (usually referred to as 
autophagy) (Feng et al., 2014). Macroautophagy is the most extensively studied type 
of autophagy and is the main focus of this study. 
In CMA, cytoplasmic proteins are selectively recognized and interact with the 
abundantly expressed chaperone, heat shock-cognate protein of 70kDa (hsc70), 
which is responsible for their translocation to lysosomes. Once at lysosomes, 
cytoplasmic proteins are interacting with the lysosome-associated membrane protein 
type 2A (LAMP-2A). This interaction promotes LAMP-2A multimerisation and in 
association with other proteins the formation of the translocation complex. Ensuing 
translocation and unfolding of the cytoplasmic protein, is its internalisation to the 
lysosomal lumen and degradation (Cuervo and Wong, 2014). 
Microautophagy refers to the degradation of small portions of cytoplasm along with 
its contents into lysosomes following their engulfment into single-membrane vacuoles 
that originate by invagination of the lysosomal membrane. Even though the term 
microautophagy described shortly after the discovery of autophagy, its regulation, 
molecular mechanism and role in disease in mammalian cells is still unclear (Mijaljica 
et al., 2011). 
Macroautophagy (referred to hereafter as autophagy) mediates the degradation of 
cytoplasmic long-lived proteins and organelles into lysosomes via their previous 
engulfment into cytoplasmic double membrane vacuoles, called autophagosomes 
(Mizushima et al., 2008, Ravikumar et al., 2010, Mizushima and Komatsu, 2011). 
Autophagosome formation is a dynamic process where an open-ended, cup-shaped 
double-membrane structure, called phagophore, appears in the cytoplasm and 
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gradually increases in size until it gets closed. Autophagosome formation takes around 
5-10mins to complete and autophagosome diameter varies between 0.5-1.5µm in 
mammals (Shibutani and Yoshimori, 2014). Fusion of an autophagosome with a 
lysosome follows forming an autolysosome. Autolysosome formation could be either 
direct or have an intermediate step where autophagosome initially fuses with late 
endosomes to form an amphisome and then the latter fuses with lysosomes. Inside the 
lysosome the cytoplasmic content along with the inner-autophagosome membrane are 
degraded by lysosomal hydrolases (Birgisdottir et al., 2013). Autophagy could be 
either selective or non-selective depending on the way that the cargo is delivered 
inside the autophagosome. Non-selective autophagy refers to the “bulk” sequestration 
of cytoplasmic compartments into the autophagosome while selective autophagy 
describes the selective sequestration of proteins and organelles like mitochondria (a 
procedure called mitophagy) into the autophagosome through selective autophagy 
receptors such as Sequestosome 1 (SQSTM1/p62) and Neighbor of BRCA1 Gene 1 
(NBR1) (Singh and Cuervo, 2011, Birgisdottir et al., 2013). 
Autophagy can be further subclassified into “basal autophagy” and “induced 
autophagy” based on the absence or presence of an autophagy-inducing stressful 
stimuli, respectively (Mizushima, 2007). As a physiological and homeostatic process 
for the cell, basal autophagy is present in most cells and tissues in a non-stressing 
environment to provide quality control of proteins and organelles. However, under a 
stressing stimulus induced autophagy is massively upregulated in the cell providing 
nutrient and energy precursors that enable survival. Such stressing stimuli include 
nutrient/growth factor deprivation, metabolic stress, endoplasmatic reticulum (ER) 
stress, hypoxia, oxidative stress, pathogen infection and cancer therapy (He and 
Klionsky, 2009, Kroemer et al., 2010, Birgisdottir et al., 2013). Even though the 
majority of in vitro studies are focused on induced autophagy, in vivo studies revealed 
an important role of basal autophagy in the maintenance of organismal physiology. 
Dysfunction of basal autophagy has been linked with various pathophysiological 
conditions from heart-related diseases and neurodegeneration to cancer. Mice with 
cardiac-specific deletion of ATG5 gene develop cardiomyopathy, suggesting that basal 
autophagy represents a homeostatic mechanism in the heart maintaining correct size 
and function of cardiomyocytes and cardiac structure (Nakai et al., 2007). Similarly, 
basal autophagy was identified as an important regulator of neurodegenerative 
diseases since mice with neural-specific deletion of ATG5 gene are presenting 
accumulation of abnormal intracellular proteins forming aggregates and inclusions, 
which ultimately leads to neurodegeneration (Hara et al., 2006). Finally, basal 
autophagy has been found to play an important albeit controversial role in cancer 
initiation and progression that will be discussed in more detail in Chapter 1.2. Briefly, 
Introduction 
25 
basal autophagy is suggested to play a tumour suppressive role in cancer initiation 
while basal autophagy in cancer progression and cancer treatment has a tumour-
promoting role. Increased levels of basal autophagy have been found in a variety of 
cancer tissues including CRC where basal autophagy supports tumour growth and 
confers tumour aggressiveness. 
 
1.1.1. Autophagosome biogenesis machinery 
The revolution in autophagy research came in 1990s when autophagy in yeast was 
established and the isolation and characterization of autophagy genes (refereed as 
ATGs) starts providing important knowledge for the autophagic machinery. Currently, 
38 ATG genes have been identified in yeast, many of which are sharing orthologs with 
mammals (Birgisdottir et al., 2013). The autophagic process and machinery are 
complex and can be divided into four distinct steps based on the molecular effectors 
taking part and the morphological changes of the autophagosome that occur. These 
are the: initiation, elongation, maturation and degradation of the autophagosome 
(Ravikumar et al., 2010, Kimmelman, 2011). 15 ATG genes conserved from yeast to 
human are implicated in these four steps. They are common between non-selective 
and selective autophagy and therefore are composing the autophagic core machinery 
(Shibutani and Yoshimori, 2014). Next I will briefly discuss the most important ATGs in 
the autophagic core machinery in relation to their function in each step of 
autophagosome biogenesis. 
 
1.1.1.1. Initiation of autophagosome biogenesis 
The first step for the initiation of autophagosome biogenesis is the formation and 
nucleation of the membrane that will lead to phagophore formation. The origin of the 
autophagosome membrane is not yet fully elucidated and recent studies indicate 
various membrane sources for autophagosome biogenesis. Even though good 
candidates for membrane sources suggested being the Endoplasmic Reticulum (ER), 
the Golgi apparatus, the ER-Golgi Intermediate Compartment (ERGIC), the outer 
membrane of the mitochondria, the plasma membrane and recycling endosomes, the 
precise mechanism of membrane assembly is not yet clear (Tooze and Yoshimori, 
2010, Shibutani and Yoshimori, 2014). 
The most important molecular components of the autophagic core machinery in this 
step are the Unc-51-Like Kinase (ULK1/2) complex and Class-III phosphatidylinositol 
3-kinase (PI3K) complex. ULK1/2 complex regulates autophagy induction and is the 
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most upstream complex to be formed upon an autophagy-induction stimulus. ULK1/2 
complex is composed of ULK1/2, Atg13, Focal adhesion kinase family-Interacting 
Protein 200kDa (FIP200) and ATG101. ULK1/2 directly interacts with ATG13 and this 
interaction primes the binding of ATG13 to FIP200 to form the ULK1/2 complex (Feng 
et al., 2014, Shibutani and Yoshimori, 2014). Class-III PI3K complex is formed 
downstream of ULK1/2 and is important for nucleation of the phagophore membrane 
and production of PhosphatidylInositol 3-Phosphate (PI3P) lipid; an important 
component of the autophagosome membrane. Class-III PI3K complex is mainly 
composed of PI3K Vacuolar protein sorting 34 (Vps34), p150, and Beclin1. Vps34 
kinase is responsible for production of PI3P and its activity is dependent on the 
formation of either an activation or inhibitory complex of p150:Beclin1 with either 
Beclin1-activating or -inhibitory effector proteins, respectively. There are two Beclin1-
activating complexes structured either by Activating molecule in Beclin1 Regulated 
Autophagy protein 1 (AMBRA1) and ATG14 or UltraViolet irradiation Resistance-
Associated Gene (UVRAG) and Bax-Interacting Factor 1 (BIF-1) proteins. For the 
formation of Beclin1-inhibitory complexes AMBRA1 and BIF-1 proteins are replaced by 
B-cell lymphoma-2 (BCL-2) and RUN domain protein as Beclin 1 interacting and 
cysteine-rich containing (Rubicon), respectively. BCL-2 directly inhibits Beclin1 
whereas Rubicon deactivates UVRAG to de-activate the Beclin1 complex (He and 
Klionsky, 2009, Ravikumar et al., 2010, Kimmelman, 2011, Rubinsztein et al., 2012, 
Feng et al., 2014, Shibutani and Yoshimori, 2014). The accumulation of synthesized 
PI3P triggers more ATGs proteins to the phagophore membrane and primes its 
elongation. 
 
1.1.1.2. Phagophore elongation 
The elongation of the phagophore membrane needs the constant supply of lipids; 
ATG9 protein has been implicated in membrane delivery from membrane sources to 
the phagophore. Elongation of the phagophore is still not well defined but there are 
evidence supporting that ATG2 - WD repeat domain phosphoinositide interacting 1 or 
2, (WIPI-1/2) - ATG9 complex to play a role in this process (Shibutani and Yoshimori, 
2014). 
Key molecular events of the phagophore elongation step are the formation of two 
ubiquitin-like conjugation systems: 1) ATG8 and 2) ATG12. In mammals there are two 
ATG8 subfamilies composed of microtubule-associated protein light chain 3 (LC3) and 
γ-amino butyric acid receptor-associated protein (GABARAP) proteins. LC3 subfamily 
has 3 isoforms: LC3A, LC3B and LC3C whereas GABARAP subfamily has two: 
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GABARAPL1 and GABARAPL2. In mammals LC3B isoform is the best-studied marker 
used for autophagy research (Birgisdottir et al., 2013). Two post-translational 
modifications conform LC3B able to associate to phagophore membrane. Firstly, a 
proteolytic cleavage in its C-terminal tail catalysed by ATG4 enzyme, creates a free 
cytoplasmic form of LC3B called LC3-I. Secondly, LC3-I protein is conjugated to 
phosphatidylethanolamine (PE) at its cleaved-C-terminal tail to create a phagophore-
associated form of LC3 protein, called LC3-II. Lipidation of LC3-I is a reaction involving 
the E1-and E2-like ubiquitin enzymes, ATG7 and ATG3, respectively. ATG7 protein 
binds, activates and then facilitates LC3-I transfer to ATG3. Even though the 
mechanism of PE conjugation is not clear yet, it is believed that ATG12 ubiquitin-like 
conjugation complex acts as an E3-like ubiquitin enzyme for LC3-I lipidation. ATG12 
ubiquitin-like system is composed of ATG12, ATG5 and ATG16L1 proteins. Initially 
ATG12 protein is activated by ATG7 through which is transferred to the E2-like 
ubiquitin enzyme, ATG10. An intermediate complex composed of ATG12 and ATG10 
is formed until ATG12 is covalently conjugated with ATG5. Finally, ATG16L1 is 
conjugated to the ATG12-ATG5 complex by directly interacting with ATG5. (He and 
Klionsky, 2009, Ravikumar et al., 2010, Kimmelman, 2011, Rubinsztein et al., 2012, 
Feng et al., 2014). LC3-II in addition to its function in phagophore elongation is an 
important component for selective autophagy since is directly binding to selective-
autophagy receptors such as p62 and NBR1 (Birgisdottir et al., 2013). LC3-II protein is 
associated with both outer- and inner-membranes of the phagophore/autophagosome. 
After the autophagosome is formed, the responsible ATG proteins for phagophore 
elongation are detached and recycled back to the cytoplasm for mediating another 
round of autophagosome biogenesis. The only known exception is LC3-II protein that 
remains associated with autophagosomes until the very last step of the process, 
characteristic that makes it the main marker for autophagy research. While ATG12, 
ATG5 and ATG16L1 are usually used as markers of the early steps of autophagosome 
biogenesis since they are dissociating from the phagophore membrane as long as the 
autophagosome is formed (Shibutani and Yoshimori, 2014).  
 
1.1.1.3. Maturation and degradation of the autophagosome 
After the phagophore closes, follows maturation and degradation of the 
autophagosome. UVRAG is an important component of the maturation step through 
fusion of autophagosomes with late endosomes and lysosomes promotion. 
Additionally, the fusion step involves proteins like ESCRT, SNAREs, Rab7 and the 
class-III Vps proteins. Degradation of the autolysosome consists the last step of the 
autophagic machinery; a process dependent on the proper function of lysosomic 
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hydrolases, proteinases and lipases. At this step the inner-autophagosome membrane 
along with autophagic cargo are degraded and the new precursor molecules are 
released to the cytoplasm in order to maintain cellular homeostasis and physiological 
function (He and Klionsky, 2009, Ravikumar et al., 2010, Kimmelman, 2011, 
Rubinsztein et al., 2012). 
 
1.1.2. Molecular pathways regulating autophagy 
Different molecular pathways controlling signalling cascades of growth 
factor/nutrient availability, energy levels, ER stress, hypoxia, oxidative stress and 
pathogen infection responses in the cell, have been found to control autophagy. The 
majority of them are upstream regulators of ULK1 and/or class III PI3K complexes of 
the core autophagic machinery and thus regulating autophagosome biogenesis. The 
best characterised mechanism that an autophagic stimulatory/inhibitory signal is 
transmitted to the core autophagic machinery for autophagy regulation is through the 
mechanistic Target Of Rapamycin (mTOR) kinase. This type of autophagy is called 
mTOR-dependent or canonical autophagy. However, there are exceptions in this rule 
and accumulating evidence highlight the presence of mTOR-independent mechanisms 
of autophagy regulation, wherein an autophagic stimulus is transmitted to the core 
autophagic machinery without the involvement of mTOR kinase (Sarkar, 2013). Below, 
I am going to discuss how nutrient, growth factor, energy and stress-mediated 
signalling pathways, which are commonly deregulated in cancer, control autophagy in 
mTORC1-dependent and -independent manners. 
 
1.1.2.1. Nutrient-dependent signalling pathway: mTOR pathway 
mTOR is a serine/threonine protein kinase that exists in two distinct complexes, 
named mTOR Complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is activated in 
response to nutrients, growth factors, stress, energy status and oxygen. Full activation 
of mTORC1 requires both nutrients and growth factors (Laplante and Sabatini, 2012, 
Efeyan et al., 2015). In the presence of nutrients, mTORC1 translocates to the outer 
surface of the lysosome where it interacts with Rag Guanosine Triphosphatase 
(GTPase) complexes responsible for its activation. Rag GTPases are localised to the 
lysosome by a complex named Ragulator, which is also necessary for mTORC1 
lysosomal recruitment. Rag GTPases interact with mTORC1 and facilitate its 
translocation to a compartment that mTORC1-kinase activator, Ras homolog enriched 
Introduction 
29 
in brain (Rheb) GTPase resides (Sancak et al., 2008, Sancak et al., 2010). When 
mTORC1 complex is fully active, it controls protein and lipid synthesis as well as 
energy production in the cell. Two best-known downstream substrates of mTORC1 are 
eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and S6 
kinase 1 (S6K1). 
In addition to its anabolic functions, active mTORC1 is a master negative regulator 
of autophagy induction (Yang and Klionsky, 2010, Laplante and Sabatini, 2012, 
Efeyan et al., 2015). Under nutrient replete conditions, mTORC1 is activated and 
directly interacts with components of the ULK1 complex. In particular, mTORC1 
directly phosphorylates ATG13 and ULK1 to restrain ULK1 kinase activity and 
consequently autophagy induction. In turn, upon nutrient-deplete conditions where 
mTORC1 is inactivated, ULK1 and ATG13 are de-phosphorylated and ULK1 complex 
can be activated, leading in that way to autophagy induction (Hosokawa et al., 2009, 
Jung et al., 2009, Kim et al., 2011a, Russell et al., 2014). Apart from regulating 
autophagosome initiation, mTORC1 has been recently suggested to control later 
stages of the autophagic process. Specifically, in nutrient-replete conditions, mTORC1 
phosphorylates UVRAG and this phosphorylation event enhances the interaction of 
UVRAG with Rubicon. This interaction inhibits UVRAG-mediated autophagosome 
maturation (Kim et al., 2015). 
 
1.1.2.2. Growth factor-dependent signalling pathways 
Growth factors bind and activate Receptor Tyrosine Kinases (RTKs) in the plasma 
membrane stimulating in that way downstream signalling cascades such as PI3K/AKT 
and mitogen-activated protein kinase / extracellular - signal-regulated kinase 
(MAPK/ERK) pathways (RTKs are discussed in session 1.5.1.) (Lemmon and 
Schlessinger, 2010). In growth factor deprived conditions, RTKs and their downstream 
effectors are deactivated, thus resulting to autophagy induction in the majority of the 
cases (Galluzzi et al., 2015). Well-characterized growth factor-dependent signalling 
pathways that regulate autophagy are: a) PI3K/AKT and b) MAPK/ERK pathways. 
Additionally, RTKs have been recently found to be direct modulators of autophagy 
induction. 
 
PI3K/AKT pathway 
PI3K is a family of lipid kinases, which catalyse the phosphorylation of the 3-
hydroxyl group of the inositol ring in phosphatidylinositols (PtdIns). Based on structure 
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and substrate specificity differences, PI3K isoforms have been classified into three 
classes: class I, class II and class III. While class III PI3Ks are directly participating in 
autophagy induction (discussed in 1.1.1.), class I PI3Ks could modulate autophagy 
mainly indirectly. 
Class I PI3Ks are downstream effectors of RTKs. They form heterodimers 
composed of a catalytic subunit, p110 (has four isoforms named α, β, γ and δ), and a 
regulator subunit, p85. In basal unstimulated conditions, p85 regulatory subunits 
function to stabilize p110 and inactivate its kinase activity. Whereas in stimulated 
conditions, p85 subunits through their Src homology 2 domains (SH2) domains, recruit 
p110 to the phosphorylated tyrosine residues of RTKs, where they release their p85-
mediated inhibition of p110 enabling p110 kinase activation (Vanhaesebroeck et al., 
2010). They generate phosphatidylinositol 3,4,5 tri-phosphate (PIP3) from 
phosphatidylinositol 4,5 bi-phosphate (PIP2), which recruits AKT protein kinase and 3-
phosphoinositide-dependent kinase 1 (PDK1) to the plasma membrane. AKT is fully 
activated in two-steps reaction. Firstly, PDK1 phosphorylates AKT Tyrosine residue 
308 and secondly mTORC2 phosphorylates its serine residue 473 (Engelman et al., 
2006, Mendoza et al., 2011). Class I PI3K and AKT are upstream regulators of 
mTORC1 and in such an indirect way can regulate autophagy induction. In particular 
when AKT is active, it inhibits autophagy by activating mTORC1. AKT-mediated 
mTORC1 activation is catalysed through inhibition of its upstream negative regulator, 
Tuberous sclerosis 1 and 2 (TSC1/2) complex, responsible for disseminating growth 
factor signals to mTORC1. TSC1/2 is a GTPase-activating protein (GAP) for the Rheb 
GTPase. The GTP-bound form of Rheb directly interacts with mTORC1 and activates 
its kinase function. On the contrary, TSC1/2 as a Rheb GAP, converts Rheb in its 
inactive, GDP-bound form that negatively regulates mTORC1 activity (Laplante and 
Sabatini, 2012). Additionally, RAS signalling has been implicated in autophagy 
regulation through its ability to directly activate Class I PI3K and inhibit autophagy 
induction in an mTORC1-dependent manner (Furuta et al., 2004, He and Klionsky, 
2009, Ravikumar et al., 2010). 
Apart from the indirect, AKT/mTORC1-mediated regulation of autophagy previously 
discussed, an isoform of PI3K, named p110β, was recently found to regulate 
autophagy in an mTORC1-independent manner. Specifically, p110β interacts with 
Rab5 intracellularly and this interaction promotes Rab5 activity over Vps34-Vps15 
complex to induce autophagy both in basal and growth factor deprived conditions (Dou 
et al., 2013). Moreover, AKT can directly regulate autophagy in an mTORC1-
independent manner since it phosphorylates Beclin1 at S295 (and possibly S234) and 
inhibit autophagosome biogenesis (Wang et al., 2012). Finally, AKT can 
transcriptionally regulate and inhibit autophagy induction through phosphorylation-
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dependent inactivation of the transcription factor Forkhead box O3 (FoxO3). Activation 
of FoxO3 has been found to elevate the expression of autophagy related genes such 
as LC3B, GABARAPL1, Vps34, ULK2 and ATG12L and consequently promote 
autophagy induction in an mTORC1-independent manner in skeletal muscle 
(Mammucari et al., 2007, Zhao et al., 2007). 
 
MAPK/ERK pathway 
MAPK/ERK pathway is a downstream RTK effector that is composed of the Raf, 
MAPK/ERK kinase (MEK) and ERK1/2 kinases. When a RTK is active, it can activate 
ERK1/2 through a multistep cascade of phosphorylation events. A key event for 
MAPK/ERK activation in the plasma membrane is the sequestration and binding of the 
adaptor protein Growth Factor Receptor Bound Protein 2 (Grb2) to the phosphorylated 
tyrosine residues of a RTK, through its specific SH2 domain. Concurrently with Grb2, 
Son Of Sevenless (SOS), a GTP Exchange Factor (GEF), translocates to the plasma 
membrane (McKay and Morrison, 2007). SOS physically interacts with rat sarcoma 
protein (RAS) GTPase and catalyses its activation through the exchange of Guanosine 
DiPhosphates (GDP) with GTP. RAS as a GTPase can hydrolyze bound GTP to GDP 
and in that way switches constantly from an inactive GDP-bound state to an active 
GTP-bound state. The activated GTP-bound RAS catalyses the activation of RAF 
protein, which in turn phosphorylates MEK and finally leads to the phosphorylation of 
ERK1/2 proteins (Roberts and Der, 2007). Activated ERK1/2 translocate to the 
nucleus controlling various transcription factors and in that way expression of various 
genes involved in cell proliferation and survival (McKay and Morrison, 2007). 
MAPK/ERK pathway has been suggested to play a role in autophagy induction with 
dichotomous observations though regarding its role. Like AKT, ERK1/2 when is active 
can inhibit autophagy by activating mTORC1 through direct inactivation of its upstream 
inhibitory complex TSC1/2 (Yang and Klionsky, 2010, Laplante and Sabatini, 2012). 
On the other hand, a non-canonical AMPK-MEK/ERK-TSC-mTOR pathway that 
regulates autophagy through controlling Beclin 1 levels has been described. In fact, 
upon various autophagic stimuli MEK/ERK residing downstream of AMPK was 
activated and mediated the disassembly and inactivation of mTORC1 and/or mTORC2 
complexes, resulting in the up-regulation of Beclin 1 levels and autophagy induction 
(Wang et al., 2009). Additionally, it is found that ERK1/2 activates autophagy through 
phosphorylation of the G alpha-interacting protein (GIAP); a regulator of G protein 
signalling (Ogier-Denis et al., 2000, Pattingre et al., 2003, Helgason et al., 2013). In 
particular, autophagy inhibition in the presence of amino acids is correlated with 
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reduced ERK1/2 activation, which mediated GAIP phosphorylation inhibition in 
intestinal derived cancer cells (Ogier-Denis et al., 2000).  
 
RTKs (discussed in 1.5.1 page 49) 
RTKs are traditionally believed to modulate autophagy indirectly in an mTORC1-
dependent manner through their downstream effectors, PI3K and MAPK/ERK that 
described above.  
It was only recently that the first evidence came to light for direct regulation of the 
autophagic machinery by RTKs in an mTORC1/AKT-independent manner and has 
been mainly illustrated for Epithelial Growth Factor Receptor (EGFR). Research from 
Wei et al., (2013) has shown that active EGFR (either ligand-activated WT EGFR or 
constantly active mutant EGFR) binds and phosphorylates Beclin 1 protein. These 
phosphorylation events enhance interaction of Beclin 1 protein with autophagy-
negative regulators Bcl-2 and Rubicon and in turn eliminate interaction with the 
autophagy-positive regulator Vps34 kinase further leading to autophagy inhibition in 
human Non-Small Cell Lung Cancer (NSCLC) cells (Wei et al., 2013). Additionally, a 
recent study has shown a kinase-independent role of EGFR in autophagy regulation. 
They show that EGFR downregulation results in autophagy suppression both in 
normal and starved conditions. The mechanism suggested is that inactive-EGFR 
translocates to lysosomal protein transmembrane 4 beta (LAPTM4B) positive 
endosomal compartments and creates a complex with Sec5 exocyst subunit. Inactive-
EGFR/LAPTM4B/Sec5 complex is responsible for dissociation of Rubicon from Beclin 
1 and in that way initiate autophagy (Tan et al., 2015). 
Additionally, EphB2 receptor ectopic expression was found to increase autophagy 
in 293T cells. EphB2-regulated autophagy induction was proposed to be controlled by 
increased ERK and class III PI3K pathway activity and in turn downregulated AKT 
activity (Kandouz et al., 2010). Recent findings of the same group are showing that 
EphB2 expression upregulates autophagy and the increase in autophagy induction 
downstream EphB2 was associated with increased expression of ATG5 and ATG12 
proteins (Chukkapalli et al., 2014). 
 
1.1.2.3. Energy-dependent signalling pathway: AMPK pathway 
5’-AMP-activated protein kinase (AMPK) is a fundamental regulator for cellular 
metabolism and is a great energy sensor in the cell. AMPK is stimulated upon 
decreased energy levels in the cell that is translated to low ATP/AMP ratio (Efeyan et 
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al., 2015). Since autophagy is induced as a homeostatic mechanism to energetic 
stress, AMPK has been shown to be a positive regulator of autophagy. AMPK has 
been described both as indirect (mTORC1-dependent) and direct modulator of 
autophagy induction (mTORC1-independent) (Russell et al., 2014). Regarding its 
indirect nature of function, when AMPK is activated, phosphorylates TSC2 and 
inactivates Rheb, which leads to mTORC1 inhibition and autophagy induction 
(Laplante and Sabatini, 2012, Russell et al., 2014). Alternatively, AMPK directly 
phosphorylates Raptor subunit of the mTORC1 complex and inhibits mTORC1 activity 
(Gwinn et al., 2008). 
Finally, AMPK can directly phosphorylate and activate ULK1 kinase from the core 
autophagic machinery and in that way induce autophagy in an mTORC1-independent 
manner (Kim et al., 2011a).  
 
1.1.2.4. Other mTORC1-independent pathways regulating autophagy 
Pathways susceptible to chemical perturbations in the cell have been described to 
control autophagy in an mTORC1-independent manner. More specific inositol, 
cAMP/Epac/Inositol 1,4,5-triphosphate (IP3) and Ca2+/calpain pathways have been 
found to inhibit autophagy when activated (Sarkar et al., 2005, Williams et al., 2008, 
Ravikumar et al., 2010, Sarkar, 2013). Components of the class III PI3K pathway, 
such as Beclin 1, have been found to control autophagy induction in an mTORC1-
independent manner in starvation conditions. In particular, activation of the JNK1 
signalling pathway has been identified as a positive regulator of autophagy induction 
during starvation through phosphorylating Bcl-2 protein and resulting in disruption of 
the autophagy-inhibitory complex Bcl-2/Beclin 1 (Wei et al., 2008). Additionally, a 
recent genome-wide siRNA screen has identified a variety of growth factors and 
cytokines that are negatively regulating autophagy under normal nutrient-replete 
conditions through Class III PI3K inhibition (Lipinski et al., 2010). Induction of basal 
autophagy in an mTORC1-independent manner has been previously reported in RAS-
expressing cancer cells with the precise mechanism remaining unknown (Guo et al., 
2011). However, a recent publication by Perera et al., 2015, describes that increased 
levels of basal autophagy in pancreatic ductal adenocarcinoma (PDA) is 
transcriptionally controlled by accelerated nuclear translocation and consequent 
activation of the MiT/TFE proteins that concomitantly regulate lysosome biogenesis 
(Perera et al., 2015).  
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1.2. Role of autophagy in Cancer 
Progress in the scientific field of autophagy over the last two decades revealed 
autophagy to be linked with various pathophysiological conditions such as 
neurodegenerative, cardiovascular and immunological disorders, infectious diseases 
and most importantly cancer (Ravikumar et al., 2010). In this report, I will mainly focus 
on the controversial role of autophagy in cancer initiation and progression.  
 
1.2.1. Tumour suppressive role of autophagy 
Autophagy has been suggested to play a tumour suppressive role in early 
tumourigenesis events due to its ability to mitigate cellular stress, via maintenance of 
cellular homeostasis and prevention of stress-induced transformation in normal tissues 
(Kimmelman, 2011, Rosenfeldt and Ryan, 2011, Yang et al., 2011b, White, 2012).  
Indirect evidence of a tumour suppressive role of autophagy in early tumourigenesis 
comes from the identification of mutations and/or amplifications in a number of cancer-
related genes, in a variety of cancer types that cause malignant transformation and 
result in autophagy suppression. Such examples include inactivation or loss of tumour 
suppressor genes such as PTEN whereas oncogenes like PI3K and AKT1 are 
activated (Galluzzi et al., 2015). 
There is also increasing direct evidence supporting a tumour suppressive role of 
autophagy in cancer initiation, arising mainly from autophagy-deficient mouse models 
studies. The first evidence came from studies on the essential autophagy gene 
Beclin1. It was observed that Beclin1 expression is frequently low in breast carcinoma 
cell lines and tissues compared to normal breast epithelium. Additionally, Beclin1 
overexpression could suppress tumourigenesis of breast cancer cell lines in vitro and 
in a mouse xenograft model (Liang et al., 1999, Kimmelman, 2011). On support of 
these observations, ensuing work from the same group showed that Beclin1 
monoallelic loss in mice results in increased incidence of spontaneous neoplasm 
development and accelerated Hepatitis B virus (HBV)-induced hepatocellular 
carcinoma development (Qu et al., 2003, White, 2012). Moreover a recent study on 
Ambra1 gene, an activator protein of Beclin1, supports the tumour suppressive role of 
autophagy in cancer initiation (Cianfanelli et al., 2015). 
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1.2.1.1.Tumour suppressive mechanisms of autophagy 
A variety of different mechanisms regulating the tumour suppressive function of 
autophagy in cancer initiation have been suggested. Autophagy could suppress 
cancer initiation by maintaining genomic integrity of a cell. Karantza-Wadsworth et al., 
(2007) have shown that autophagy-deficient cells with monoallelic loss in Beclin1 
resulted in increased DNA damage under metabolic stress conditions in breast cancer 
(Karantza-Wadsworth et al., 2007). Another study has shown that ATG7 and ATG5-
mediated autophagy suppression in mouse embryonic fibroblasts impaired 
homologous recombination DNA repair mechanism by downregulating the 
phosphorylation of checkpoint kinase 1 (Chk1) that potentially could lead to 
accumulation of DNA damage (Liu et al., 2015).  
An additional mechanism that autophagy could suppress tumourigenesis is through 
maintenance of mitochondria quality control through mitophagy (a selective lysosomal 
degradation of dysfunctional mitochondria) and by controlling cellular antioxidant 
defense. The latter function of autophagy is supported by a study showing that 
autophagy impairment, results in accumulation of the autophagic substrate protein p62 
known to control indirectly nuclear factor erythroid 2-related factor 2 (NRF2) activation 
leading in that way to the production of reactive oxygen species (ROS)-detoxification 
genes and promotion of cell survival (Inami et al., 2011, Kimmelman, 2011, White, 
2012). 
Inflammation has been suggested as a hallmark of cancer since prolonged 
inflammation could lead to the development of cancer (Colotta et al., 2009). It is 
believed that defects in the autophagic machinery could result in inflammation-induced 
cancer and the best examples describing that phenomenon are inflammatory bowel 
disease (Crohn’s disease) and pancreatitis (Rosenfeldt and Ryan, 2011). In the study 
of Cadwell et al., (2009) was observed that mice with defects in autophagy related 
genes such as Atg16L1, Atg5 or Atg7 present abnormalities in small intestinal Paneth 
cells that resembles the abnormalities occurring in Crohn’s disease patients (Cadwell 
et al., 2009).  
Additionally, autophagy could suppress tumourigenesis by inducing cell death or 
senescence in RAS-induced transformation events. Work from Elgendy et al., (2011) 
suggested that HRAS-induced autophagy upregulation limits clonogenic survival of 
human ovarian surface epithelial cells by accelerating autophagy-mediated cell death. 
Autophagy inhibition (shBeclin1, siRNA ATG5 and ATG7) rescues this phenotype 
(Elgendy et al., 2011). On the other hand, work from Young et al., (2009) showed that 
RAS-induced autophagy upregulation promotes senescence of human diploid 
Introduction 
36 
fibroblasts and autophagy inhibition (shATG5 and shATG7) reversed this phenotype 
(Young et al., 2009). 
Finally, autophagy may suppress cancer initiation by promoting defense against 
viral and bacterial infections with high tumourigenic potential, such as HBV (which 
promotes hepatocellular carcinoma) and Streptococcus bovis (which causes colorectal 
carcinoma), respectively (Galluzzi et al., 2015). 
 
1.2.2. Tumour-promoting role of autophagy  
Opposing to the tumour suppressive role of autophagy in cancer initiation, 
autophagy has been suggested to promote cancer progression. Generally, autophagy 
helps cancer cells to overcome and survive stressing stimuli of the cancer 
microenvironment like nutrient/growth factors deprivation, defects in metabolism, 
hypoxia and cancer treatment (Galluzzi et al., 2015). Additionally, growing evidence 
indicates a positive correlation between high autophagic status and tumour 
invasive/metastatic phenotype as well as poor clinical outcome (Galavotti et al., 2013, 
Galluzzi et al., 2015). 
Recently, direct insight into the tumour-promoting role of autophagy in cancer 
progression came from studies using mouse models for tissue-specific, oncogenic-
driven cancers with or without autophagy. In vivo work on the autophagy-related 
genes, ATG7 and ATG5, are revealing a more complex oncogene-regulated role of 
autophagy in cancer initiation and progression. Even though systemic deletion of 
ATG5 and conditional liver-specific deletion of ATG7 showed autophagy to play a 
tumour suppressive role in hepatocellular carcinoma development (Takamura et al., 
2011), recent studies on pancreatic cancer development failed to prove this 
(Rosenfeldt et al., 2013, Yang et al., 2014). These two studies reported that 
conditional deletion of either ATG5 or ATG7 genes in pancreatic tissue does not lead 
to malignant transformation whereas autophagy-deficient mice present increased 
tissue destruction and die earlier.  
Interestingly though they showed that autophagy plays a tumour suppressive role in 
pancreatic cancer initiation in an activated-KRAS-dependent context (Rosenfeldt et al., 
2013, Yang et al., 2014). Accelerated neoplasmatic initiation upon ATG5 and ATG7-
mediated autophagy suppression was observed in KRAS G12D and BRAF V600E 
driven lung cancer models, respectively. However, benign neoplasms were dependent 
on autophagy to progress into a malignant state (Strohecker et al., 2013, Rao et al., 
2014). In line with the aforementioned observations the study of Rosenfeldt et al., 
(2013) showed that concurrent KRAS G12D activation and ATG7 or ATG5 deletion 
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leads to increased pre-cancerous pancreatic intraepithelial neoplasia (PanIN) 
formation while eliminated the progression of PanINs into pancreatic ductal 
adenocarcinomas (PDAC) (Rosenfeldt et al., 2013). Intriguingly, the role of autophagy 
in KRAS-driven cancer progression was switched from tumour-promoting to tumour 
suppressive when p53 was concurrently deleted, in both pancreatic and lung tissues 
(Rosenfeldt et al., 2013, Rao et al., 2014). The tumour suppressive role of autophagy 
in the p53-deletion context was attributed to increased glucose uptake of autophagy-
deficient cells. On the contrary, in KRAS G12D-driven pancreatic carcinoma mouse 
model where p53 was abolished through loss of heterozygosity, autophagy inhibition 
restricts cancer progression (Yang et al., 2014). Finally, a tumour-promoting role of 
autophagy in intestinal cancer initiation and progression was observed in an APC 
conditional knockout model. Reduced intestinal neoplasms were formed in ATG7-
deficient mice and this inadequacy of ATG7-deficient mice to form intestinal 
neoplasms was due to increased microbiome-induced immune response. However, 
the decreased intestinal tumour growth of ATG7-deficient mice was attributed to 
metabolic defects such as p53-growth arrest and AMPK activation rather that 
increased immune responses (Levy et al., 2015). 
 
1.2.2.1. Tumour-promoting mechanisms of autophagy 
Different mechanisms have been suggested to be responsible for the tumour-
promoting role of autophagy in cancer progression. Cancer cells could depend on 
autophagy for growth, survival and fulfillment of their elevated metabolic requirements. 
A variety of studies have shown that established tumours display autophagy addiction 
(Guo et al., 2011, Kim et al., 2011b, Lock et al., 2011). These tumours are 
characterized by activated RAS oncogene expression resulting in elevated levels of 
autophagy not only in stressed conditions but in basal levels as well. High levels of 
basal autophagy in RAS activated cancers maintain tumour growth, survival and 
mitochondrial function (Guo et al., 2011, Yang et al., 2011a). 
Another interesting aspect of tumourigenesis is the requirement of tumours for 
functional mitochondrial respiration, induced by RAS oncogene. It has been 
demonstrated that autophagy is required for maintaining mitochondrial function and in 
that way promoting tumourigenesis (Guo et al., 2011, White, 2012, Guo et al., 2013, 
Rosenfeldt et al., 2013, Strohecker et al., 2013, Rao et al., 2014, Yang et al., 2014). 
Sustained angiogenesis represents another important hallmark for cancer 
development and progression (Hanahan and Weinberg, 2011). There are some 
studies proposing a role of autophagy in controlling angiogenesis, which could 
Introduction 
38 
possibly support the tumour-promoting role of autophagy. In the study by Du et al., 
(2012) it was observed that pharmacological and genetic (by Atg5 siRNA) inhibition of 
autophagy reduces angiogenesis possibly through elimination of autophagy-mediated 
ROS production and AKT activation (Du et al., 2012). Additionally, the role of 
autophagy in inducing angiogenesis is supported by cancer-related studies showing 
that pharmacological and genetic (ATG5 and Beclin-1) inhibition of autophagy 
potentiates anti-angiogenic cancer treatment in colon cancer cells (Selvakumaran et 
al., 2013). 
Recently, autophagy has also been proposed to regulate migration/invasion in 
cancer. Work from Salomoni’s group and others showed that inhibition of autophagy 
inhibits migration/invasion in glioma-initiating cells and established cell lines 
(Macintosh et al., 2012, Galavotti et al., 2013). Another study showed that autophagy 
is induced in cells undergoing Epithelial to Mesenchymal Transition (EMT) and 
regulates migration in this context (Li et al., 2013a) (unpublished work from our 
laboratory shows the same). Taken together, these findings suggest that autophagy 
could be involved in regulating tumour metastasis, a key factor underlying cancer 
progression. 
Collectively, in healthy tissues autophagy maintains cellular equilibrium and 
eliminates cancer initiation. However, if the autophagic barrier in tumour development 
fails and a malignancy is established then autophagic function needs to be restored in 
order cancer cells to survive (Galluzzi et al., 2015). However, recent contradictory 
observations are indicating the urgency of extensive research in the field in order to 
deconvolute the complex role of autophagy in cancer initiation and progression. 
 
1.3. Autophagy modulation in cancer treatment 
Taking into account the predominant tumour-promoting role of autophagy in cancer 
progression, it was expected that the role and function of autophagy upon cancer 
treatment would favor cancer cell survival. However, some studies in the literature 
suggest an opposing pro-death role of autophagy upon cancer treatment. The pro-
death and pro-survival roles of autophagy upon cancer treatment will be discussed 
below. 
 
Introduction 
39 
1.3.1. Pro-death role of autophagy in cancer treatment 
The role of autophagy as a pro-death mechanism is under a long lasting debate. 
The definition of autophagic cell death (ACD) has been introduced to describe the type 
of cell death caused by autophagy, characterized by increased autophagic flux but not 
increased apoptosis or necroptosis and in which inhibition of autophagy suppresses 
cell death (Marino et al., 2014). Even though there is evidence in the literature 
supporting that autophagy induction could lead to cell death, it is still under question 
whether autophagy could execute cell death by itself or is just present when cell death 
occurs (Fuchs and Steller, 2015). Under physiological conditions, ACD has been 
implicated to the removal of salivary gland and midgut in the fruitfly Drosophila 
melanogaster during development. ACD rather than caspace-dependent apoptosis 
has been found to be responsible for Drosophila melanogaster midgut cell death and 
removal, while both autophagy and caspase-dependent cell death are important for 
salivary gland removal (Berry and Baehrecke, 2007, Denton et al., 2009). In mammals, 
the role of ACD remains elusive under physiological conditions while ACD has been 
described to eliminate cell survival under drug-induced conditions including cancer 
therapy (Marino et al., 2014). Indeed ACD is induced in imipramine-treated glioma cell 
lines and mice bearing glioma tumours. Ticlopidine, which inhibits the purinergic 
receptor P2Y12 and enhances autophagy induction, accelerated imipramine-induced 
autophagy and potentiated imipramine treatment response. Genetic inhibition of 
autophagy (shRNA for Beclin1 and ATG7) blocked imipramine and ticlopidine-induced 
cell death while pharmacological inhibition of apoptosis and necroptosis did not affect 
levels of cell death (Shchors et al., 2015). The best example of a pro-death role of 
autophagy came from studies with apoptosis-deficient cells, lacking both Bak and Bax 
pro-apoptotic proteins. In particular, apoptosis-deficient mouse embryonic fibroblasts 
(MEFs) underwent autophagy-dependent cell death under etoposide treatment. 
Inhibition of autophagy either pharmacologically (3-methyladenine) or genetically 
(siRNA for ATG5 or Beclin1) rescued etoposide-induced cell death in these cells 
(Shimizu et al., 2004). Additionally, it has been shown that the pan-BCL-2 inhibitor (-)-
Gossypol induces autophagic cell death in apoptosis-resistant glioma cells; genetic 
manipulation (Beclin-1 and ATG5 knockdown) reduces the cell death induced by (-)-
Gossypol (Voss et al., 2010). In the study by Goussetis et al., (2010) it is shown that 
autophagy is induced upon arsenic trioxide in leukemia cells and that pharmacological 
(CQ) and genetic modulation (ATG7 and Beclin1 siRNA) of autophagy increased the 
clonogenic potential of these cells upon arsenic trioxide treatment (Goussetis et al., 
2010). Similarly, EGFR targeted therapy by Erlotinib was found to induce autophagy in 
NSCLC cells and mouse xenografts harbouring an Erlotinib-sensitive EGFR mutation. 
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Autophagy induction upon EGFR targeted therapy was due to increased Beclin1 
interaction with Vps34 and genetic inhibition of autophagy (via shATG7 and an 
inhibitory phosphomimetic mutant of Beclin1 were used) resulted in increased 
clonogenic survival in vitro and partial resistance to Erlotinib in mouse xenografts (Wei 
et al., 2013). Although autophagy could function as a compensatory cell death 
mechanism in an apoptotic-deficient context, there are a lot of studies that show a 
concomitant activation of autophagy and cell death mechanisms upon treatment 
(Rebecca and Amaravadi, 2015). For example, although glioma cells found to induce 
autophagic cell death upon arsenic trioxide, pharmacological inhibition of autophagy 
(bafilomycin A1) in combination with arsenic trioxide found to enhance the anti-tumour 
effect of arsenic trioxide through the induction of apoptosis (Kanzawa et al., 2003). 
Additionally, autophagy has been found to increase sensitivity to chemotherapeutic 
agents (mitoxantrone or oxaliplatin) in vivo by increasing immunogenic cell death. In 
particular, autophagy increases the secretion of ATP in dying cells that leads to 
recruitment of dendritic cells and T lymphocytes into the tumour bed and increases 
chemosensitivity (siRNAs and shRNAs against ATG5 or ATG7 were used) (Michaud et 
al., 2011). 
Overall, even though the existence of autophagic cell death is under question, it is a 
matter of fact that in some experimental models autophagy induction reduced cell 
survival. Whether autophagy is directly responsible for cell death execution or other 
cell death mechanisms, like apoptosis or necrosis are it remains to be elucidated. 
 
1.3.2. Pro-survival role of autophagy in cancer treatment 
Following the realization that autophagy could be a survival pathway for tumour 
cells, the hypothesis that it could have a pro-survival role in cancer treatment was 
inevitable. Additionally, the fact that the mode of action of anti-cancer drugs resembles 
some natural stimuli inducing autophagy strengthened this hypothesis. Since then, an 
increasing number of studies investigating the pro-survival role of autophagy upon 
cancer treatment started. In that setting, pharmacological and genetic autophagy 
manipulation approaches are used. 
A variety of pharmacological agents that target different steps in the autophagic 
process have been described in the literature and summarized in Table 1.1. The 
majority of these agents are lysosomotropic compounds targeting later steps in the 
autophagic process; in particular they are inhibiting the autophagosome turnover by 
inhibiting lysosomal function. Agents such as, Chloroquine (CQ), Hydroxychloroquine 
(HCQ) and Mefloquine are Food and Drug Administration (FDA)-approved and have 
been in clinical use for many years for the treatment of diseases such as malaria, 
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autoimmune and psychiatric disorders. It was only recently however that their 
connection with the autophagic pathway has been proven (Amaravadi et al., 2011, 
Yang et al., 2013). Recently, SAR405 and PIK-III Vps34-specific inhibitors, targeting 
Vps34-kinase domain, have been developed and shown to inhibit autophagosome 
formation (Dowdle et al., 2014, Ronan et al., 2014). However, caution should be taken 
when used since Vps34 inhibition may additionally interfere with vesicle trafficking, as 
was already shown for SAR405 inhibitor (Ronan et al., 2014, Galluzzi et al., 2015, 
Rebecca and Amaravadi, 2015). Moreover, an ULK1 kinase inhibitor has been 
developed and shown to block autophagy induction (Egan et al., 2015). Amongst all 
the currently known autophagic inhibitors, CQ and its more potent analog HCQ are the 
most commonly used for in vitro as well as in vivo studies. 
It is possible that cancer therapy induces autophagy by increasing DNA damage, 
metabolic stress and malfunctioned organelles. Indeed, it has been found that 
autophagy is a pro-survival mechanism after radiation and arsenic trioxide in glioma 
cells (Ravikumar et al., 2010). In addition, a variety of chemotherapeutic agents have 
been found to induce autophagy and inhibition of autophagy found to improve their 
therapeutic potential (Amaravadi et al., 2011). Targeted therapy has been also found 
to induce autophagy possibly by resembling nutrient/growth factor deprivation. 
 
Table 1. 1: Agents used for autophagy inhibition 
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1.3.2.1. Pro-survival role of autophagy in tyrosine kinase targeted therapy 
A number of studies in the last few years have proposed a role of autophagy 
downstream inhibition of oncogenic tyrosine kinases via targeted therapy agents. Work 
from our group (Bellodi et al., 2009) has shown that autophagy inhibition potentiates 
BCR-ABL tyrosine kinase targeted therapy (Imatinib) in Chronic Myeloid Leukaemia 
(CML) cells, by using pharmacological and genetic modulation of autophagy (shRNA 
for Atg5 and Atg7). It was observed that Imatinib-induced autophagy was associated 
with ER stress (Bellodi et al., 2009). This work led to a clinical trial for the use of the 
autophagy inhibitor HCQ (See Table 1. 1 and Appendix I, page 231) in combination 
with the BCR/ABL-targeting drug Imatinib (Calabretta and Salomoni, 2011). 
Additionally, Li et al., (2010) showed that autophagy has a pro-survival role upon 
EGFR targeting antibody Cetuximab (See Table 1.2) treatment and that 
pharmacological and genetic modulation of autophagy (Beclin-1 ot Atg7 shRNA) 
sensitise Cetuximab-treated cells to apoptosis. They showed that Cetuximab-induced 
autophagy is controlled by PI3K/mTOR pathway inhibition and it was accompanied by 
activation of the Beclin1/Vps34 complex, by Cetuximab (Li and Fan, 2010). The same 
group published another paper showing that the pro-survival role of autophagy was a 
characteristic only of cancer cells undergoing apoptosis upon Cetuximab treatment (Li 
et al., 2010). These contradictory observations warrant further examination since the 
precise mechanism causing this cell-type specific effect of autophagy upon cetuximab 
treatment was not found. Additionally, work in glioblastoma showed that autophagy 
inhibition can potentiate treatment by the EGFR kinase inhibitor Erlotinib (See Table 
1.2), proposing a pro-survival role of autophagy (Eimer et al., 2011). A similar pro-
survival role of autophagy upon EGFR inhibition (Erlotinib or Gefitinib; See Table 1.2) 
was observed in lung cancer as well. This study also demonstrated that 
pharmacological or genetic inhibition of important autophagy regulators (Atg5 and Atg7 
siRNA) potentiates targeted therapy (Han et al., 2011). In line with in vivo studies 
underlining the importance of autophagy as a tumour-promoting mechanism in an 
oncogene-activation context (KRAS and BRAF) is a recent study in melanoma. It is 
reported that autophagy plays a cytoprotective role in BRAF V600E melanoma cell 
lines and mouse xenografts upon BRAF inhibiting targeted therapy. Additionally, 
increased autophagy was observed in BRAF V600E patients’ samples that were 
resistant to BRAF inhibition treatment. Both pharmacological (Lys05) and genetic 
(shATG5) inhibition of autophagy in vitro and only pharmacological in mouse 
xenografts potentiated BRAF inhibition-mediated cell death in melanoma (Ma et al., 
2014). 
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The continuous need for potentiation of cancer therapy efficacy along with the 
growing evidence supporting a pro-survival role of autophagy in cancer progression 
and cancer treatment led to the development of several clinical trials where 
conventional cancer treatment therapeutics are combined with autophagy modulation 
compounds. Below I will discuss the current status of clinical trials involving autophagy 
inhibitors focusing mainly on targeted therapy compounds. 
 
1.3.3. Modulation of autophagy in clinical trials 
Currently, an increasing number of clinical trials combining different targeted 
therapy agents with autophagy inhibitors is ongoing or are being developed for cancer 
types such as lung, colorectal, prostate and renal carcinomas; melanoma and 
sarcoma (Appendix I, page 231). In a variety of clinical trials in lung and colorectal 
cancer, the antiangiogenic monoclonal antibody Bevacizumab is used in combination 
with different chemotherapeutic agents along with HCQ as an autophagy inhibitor. 
Additionally, EGFR tyrosine kinase inhibitors such as, Erlotinib and Gefitinib are used 
in combination with HCQ in lung cancer clinical trials. AKT or mTOR inhibitors in 
combination with HCQ are in use in prostate and renal carcinomas. 
Recently, results from Phase I and II clinical trial have been published regarding the 
combinational treatment of HCQ autophagy inhibitor with various cancer treatment 
agents (temozolomide and radiation in glioblastoma multiforme; temozolomide in 
melanoma and solid tumours; temsirolimus in solid tumours and melanoma; vorinostat 
in advanced solid tumours; erlotinib in NSCLC) (Goldberg et al., 2012, Mahalingam et 
al., 2014, Rangwala et al., 2014a, Rangwala et al., 2014b, Rosenfeld et al., 2014). 
These trials provided important information for the applicability of autophagy inhibition 
in a clinical setting and for dose-limiting toxicity in cancer patients. The majority of the 
trials found HCQ to be well-tolerated in patients and no dose-limiting toxicity of HCQ 
was observed; with the higher HCQ concentrations tested going up to 1200 mg/day 
(Goldberg et al., 2012, Mahalingam et al., 2014, Rangwala et al., 2014a, Rangwala et 
al., 2014b). The only study that reported dose-limiting toxicity at 800 mg/day HCQ was 
in glioblastoma multiforme patients that HCQ was combined with radiation therapy and 
temozolomide. HCQ treatment at this concentration resulted in myelosuppression 
development in three out of three patients (Rosenfeld et al., 2014). Importantly, all 
these trials evaluated that HCQ can inhibit autophagy in a clinical setting and 
additionally established biomarkers for assessing autophagy modulation in clinical 
trials. Some of the biomarkers consist of: i) monitoring autophagosome accumulation 
by electron microscopy in peripheral blood mononuclear cells, ii) assessment of LC3B 
lipidation by western blotting and iii) investigation of LC3B-positive 
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immunohistochemical samples (Goldberg et al., 2012, Mahalingam et al., 2014, 
Rangwala et al., 2014a, Rangwala et al., 2014b, Rosenfeld et al., 2014, Rebecca and 
Amaravadi, 2015). 
Even though it is too early for generalisation of results, autophagy inhibition was 
shown to prolong stable-disease and partially improved treatment response in some 
patients with melanoma, colorectal cancer (CRC), renal cell carcinoma and NSCLC 
(Goldberg et al., 2012, Mahalingam et al., 2014, Rangwala et al., 2014a, Rangwala et 
al., 2014b). However, inconsistent autophagy inhibition between patients and no 
clinical benefit of HCQ- combinational treatment (temozolomide and radiation therapy) 
versus monotherapy was observed in glioblastoma and metastatic pancreatic patients, 
respectively (Rosenfeld et al., 2014, Wolpin et al., 2014). 
Nevertheless the high number of clinical trials using autophagy inhibitors to 
potentiate efficacy of conventional cancer therapy, a tumour suppressive role of 
autophagy is demonstrated in various cancer types following cancer treatment. These 
observations suggest that autophagy-inhibiting therapeutic approaches should not be 
considered a panacea and in some cases autophagy-inducing agents may potentiate 
cancer treatment outcome. For example ticlopidine, a purinergic receptor P2Y12 
inhibitor, enhanced imipramine-induced autophagic cell death and increased survival 
in glioma-bearing mice (Shchors et al., 2015). Additionally, our knowledge on the 
status of autophagy in different cancer types is limited. Human cancers are 
characterised by high heterogeneity (Vogelstein et al., 2013) and heterogeneity is an 
outstanding issue in cancer biology and cancer therapy having a key role in 
therapeutic resistance. Research from our lab has shown that among the different 
molecular subgroups of glioma, only the mesenchymal subgroup could be associated 
with high autophagy gene expression. This work suggests that only the mesenchymal 
subtype of glioblastoma may respond to autophagy inhibition (Galavotti et al., 2013). 
Apart from the variability characterising tumours of the same subtype, intra-tumour 
metabolic heterogeneity (Cantor and Sabatini, 2012) could also play an important role 
in how tumours respond to autophagy inhibition. Furthermore, the differential role of 
autophagy in oncogene-driven cancers, as discussed above, points out that autophagy 
inhibition approaches could have adverse effects than expected. Heterogeneity of 
autophagic status is expected to be a critical factor affecting response to autophagy 
inhibition therapeutic approaches.  
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1.4 Colorectal Cancer (CRC) 
1.4.1. Epidemiology 
CRC is the 3rd most common cancer type in males and the 2nd in females 
worldwide, accounted for approximately 1.4 million of new cancer cases and 693.900 
deaths on 2012. The incidence rates of CRC are almost twice higher in developed 
countries compared to less developed countries. Australia/New Zealand, Europe and 
North America are the countries exhibiting the highest incidence rates of CRC (Torre 
et al., 2015). CRC incidence markedly varies between countries and this could be due 
to different environmental risks and genetic predisposition between populations 
(Arvelo et al., 2015). Even though there is a marked higher incidence rate of CRC in 
developed countries, the mortality rate is lower compared to less developed countries. 
The increased survival of CRC patients in developed countries could be attributed to 
the improved healthcare system as well as the higher socioeconomic status. CRC 
screening, reduced exposure to high risk factors and better treatment approaches are 
some of the factors that could enhance CRC patient survival (Torre et al., 2015). In 
general, 64.9% of patients with CRC will reach an average of 5-year survival after 
diagnosis. Early diagnosis is an important factor determining CRC patients’ survival; 
90.3% of patients that were diagnosed with a localised tumour will achieve a 5-year 
survival compared to only 12.5% of patients that were diagnosed with a metastatic 
CRC (DeSantis et al., 2014). 
The risks for developing CRC are both environmental and genetic. Consequently, 
CRC is divided into three main categories based on the risk factors affecting its 
development: i) hereditary, ii) sporadic and iii) familial. Hereditary CRC accounts for 
approximately 5% of total CRC cancer cases and develops due to the presence of 
hereditary genetic mutations of known genes. Hereditary CRC can be further 
subdivided into Familial Adenomatous Polyposis (FAP) and hereditary non-polyposis 
colorectal cancer (HNPCC) based on the presence of adenomatous polyps or not, 
respectively. Sporadic CRC is the most common type of CRC cancers and is 
responsible for approximately 75% of total CRC cases. Sporadic CRC cancer 
development has been linked to risk factors such as ageing, western dietary, chronic 
inflammation and various environmental factors. Finally, approximately 20% of total 
CRC cases are classified into the familial group. Familial CRC patients have a family 
history of CRC but hitherto there is no known association with a specific gene, as in 
hereditary CRC (Al-Sohaily et al., 2012, Arvelo et al., 2015). Below the molecular 
alterations that lead to CRC development will be discussed. 
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1.4.2. Molecular pathology of CRC 
CRC develops through the accumulation of genetic and epigenetic alterations 
leading to the transformation of a normal colon mucosa to adenoma, then to a 
carcinoma and finally to a metastatic cancer (Vogelstein et al., 2013). This process is 
heterogeneous regarding the order and grade of genetic alterations taking place as 
well as the location of the colorectum and each patient (Manne et al., 2010). 
Genomic instability is a common characteristic of CRC and three different molecular 
pathways have been linked to this phenomenon. These are the: i) Chromosomal 
Instability (CIN) pathway, ii) Microsatellite Instability (MSI) pathway, and iii) CpG Island 
Methylator Phenotype (CIMP) pathway; these could either act cooperatively or 
independently one from each other to cause genomic instability. Additionally, a variety 
of oncogenes and tumour suppressor genes were found altered in CRC (Lengauer et 
al., 1998, Markowitz and Bertagnolli, 2009, Manne et al., 2010) 
Chromosomal instability is the most common type of genomic instability in CRC and 
involves the loss/gain of a chromosome or a part of it. This type of instability could lead 
to loss/gain of important tumour suppressor genes/oncogenes resulting in CRC 
malignant transformation (Markowitz and Bertagnolli, 2009). Amplifications in a big 
part of the chromosome usually appear at chromosomes 8q, 13, and 20q and losses 
at chromosomes 8p, 17p, and 18q in CRC (Fearon, 2011). 
Microsatellite instability is a consequence of loss of function of important proteins 
implicated in the DNA mismatch repair (MMR) pathway. Microsatellites are short 
nucleotide sequences present all over the genome that they are prone to errors during 
replication. MMR proteins are responsible for correcting such base-pair errors. A 
variety of different MMR genes were found mutated in HNPCC patients with the most 
common being the MSH2 and MLH1 genes. Even though only 2%-4% of sporadic 
CRC patients found to harbour mutations in MMR genes, a higher percentage (~15%) 
of patients occurred with MSI characteristics. In sporadic CRC patients with high MSI 
occurrence, MLH1 gene was silenced due to hypermethylation of its promoter (Fearon, 
2011, Al-Sohaily et al., 2012). 
The existence of a hypermethylated MLH1 promoter along with observations of 
methylation in other genes termed the CIMP pathway in CRC. CIMP refers to 
epigenetic alterations in gene expression due to DNA methylation. Usually methylation 
of a gene promoter results to silencing of the gene (Issa, 2004). Even though CRC 
cells are characterized by low methylation rates compared to normal surrounding 
tissue, a variety of gene promoters are found to be hypermethylated, resulting to gene 
silencing. Genes found to be silenced by hypermethylation of their promoter in CRC 
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are Adenomatous Polyposis Coli (APC) and O6- Methylguanine DNA 
Methyltransferase (MGMT) (Fearon, 2011, Al-Sohaily et al., 2012). 
Finally, a broad range of oncogenes and tumour suppressor genes have been 
found mutated in CRC. The first gene identified to be in association with hereditary 
CRC was the APC, which is responsible for FAP development. In the majority of FAP 
cases, APC gene found to harbour frameshift mutations leading to truncation of APC 
protein. Additionally, APC mutations have been found to be present in sporadic CRC 
as well. Approximately 70-80% of CRC patients appear to harbour APC inactivating 
mutations. APC gene is characterised as a “gatekeeper” gene since it is believed to be 
one of the first mutation events leading to malignant transformation in CRC (Fearon, 
2011, Vogelstein et al., 2013). The small malignant clone that appears and grows after 
APC inactivation, named adenoma, needs a second mutation event in order to 
enhance its clonal growth and form a carcinoma. Usually, KRAS activating mutations 
are responsible for carcinoma development. This process continues with mutations in 
other genes such as PI3K, TGF-β and p53 to develop a metastatic cancer that can 
expand to lymph nodes and distant organs (Vogelstein et al., 2013). The most 
common mutated pathways in CRC are WNT, RAS/MAPK, PI3K, TGF-β and p53 
(Fearon, 2011, Cancer Genome Atlas, 2012).  
 
1.4.3. CRC treatment 
Treatment of CRC depends on the stage of the cancer at the time of diagnosis. At 
early-diagnosed CRC, patients are referred to surgeons for tumour resection. At later 
stages of CRC, patients are treated by surgery that is followed by approximately 6 
months of chemotherapy. Chemotherapy is usually the main treatment of patients with 
advanced metastatic CRC (DeSantis et al., 2014). The main chemotherapeutic agents 
used for CRC treatment are 5-fluorouracil, irinotecan and oxaliplatin. Additionally, 
targeted therapy agents against two different RTKs have been recently used either as 
combinational treatment with chemotherapy or as a monotherapy to total refractory 
metastatic CRC patients. These are two monoclonal antibodies against EGFR, 
Cetuximab and Panitumumab and a monoclonal antibody against VEGF receptor, 
bevacizumab. Part of this thesis will be focused on the role of autophagy upon EGFR 
targeted therapy (Cetuximab) in CRC. EGFR targeted therapy will be therefore 
discussed below. 
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1.5. Epidermal Growth Factor Receptor (EGFR) and EGFR targeted therapy 
1.5.1. EGFR  
RTKs are a family of cell surface receptors with an intrinsic, growth factor-regulated 
tyrosine kinase activity (Gschwind et al., 2004). As tyrosine kinases, they catalyse the 
transfer of the γ phosphate of ATP to hydroxyl groups of tyrosines on other target 
proteins (Schlessinger, 2000). 58 different RTKs have been discovered in humans and 
are categorized into 20 families. All RTKs share similar structural characteristics: i) a 
ligand-binding domain in their extracellular region, ii) a single transmembrane helix 
and iii) a cytoplasmic region containing a conserved protein tyrosine kinase domain 
and additional carboxy-terminal and juxtamembrane regulatory domains. Even though, 
different growth factors act as RTKs’ ligands, the mechanism of activation as well as 
the downstream intracellular signalling pathways stimulated by RTKs are common 
between them. The majority of RTKs, with the exception of insulin receptor (IR) and 
IGF1 receptor, are monomers in the plasma membrane and they dimerise only upon 
ligand binding in their extracellular domain. Dimerisation stimulates activation of their 
tyrosine kinase domains and transphosphorylation of tyrosines in adjacent RTKs. The 
phosphorylated RTKs will then recruit proteins of intracellular downstream pathways 
and prime signalling cascades (Lemmon and Schlessinger, 2010). 
RTKs are controlling various cellular processes such as proliferation, differentiation, 
metabolism, survival and migration. Interestingly, more than half of the RTKs have 
been found deregulated in cancer. Such examples are members of the ErbB, PDGFR, 
HGFR and FGFR families (Gschwind et al., 2004, Lemmon and Schlessinger, 2010). 
 
1.5.1.1. EGFR architecture and function 
EGFR RTK was identified by G. Carpenter on 1978, (Carpenter et al., 1978) an 
important discovery in the RTK signalling field along with the earlier discoveries of 
nerve growth factor (NGF) and epithelial growth factor (EGF) by R. Levi-Montalcini and 
S. Cohen, respectively (Levi-Montalcini, 1952, Cohen, 1962, 1965). Since then our 
knowledge on RTKs has massively increased and EGFR consists one of the best 
studied amongst RTKs (Gschwind et al., 2004, Schlessinger, 2014).  
The Epidermal Growth Factor Receptor (EGFR/ErbB1/HER1) is a 170kDa 
transmembrane glycoprotein belonging to the ErbB family, one of the 20 RTKs’ 
families. Along with EGFR another three RTKs consist ErbB family: i) ErbB2/HER2, ii) 
ErbB3/HER3 and iii) ErbB4/HER4 proteins. All four members share common structure 
and an activation mechanism that is dimerisation dependent (either homodimers or 
heterodimers could be formed between ErbB RTKs). Like all RTKs, they are 
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composed of an extracellular ligand-binding region, a transmembrane region and a 
cytoplasmic tyrosine kinase region. Their extracellular region can be further subdivided 
into four domains, named I, II, III and IV. The single transmembrane helix is connected 
with both extracellular and intracellular regions via a small extracellular and 
intracellular juxtamembrane domain, respectively. The tyrosine kinase domain in their 
cytoplasmic region is linked with a carboxy-terminus tail that contains tyrosine 
residues, responsible for autophosphorylation events of the RTK (Hynes and Lane, 
2005, Zandi et al., 2007, Lemmon and Schlessinger, 2010, Lemmon et al., 2014). With 
the exception of ErbB2, all other ErbB family members are competent for growth 
factor-ligand stimulation. Epidermal Growth Factor (EGF), Transforming Growth 
Factor-alpha (TGF-a), amphiregulin (ARG) and epigen (EGN) ligands can only activate 
EGFR. Another class of ligands that bind and activates ErbB4, such as betacellulin 
(BTC), Heparin-Binding EGF (HB-EGF) and epiregulin (EPR), can also activate EGFR. 
ErbB3 and ErbB4 RTKs are stimulated by another class of ligands, which is called 
neuregulins (NRGs). While NRG-1 and 2 bind both ErbB3 and ErbB4, NRG-3 and 4 
are ErbB4 specific (Hynes and Lane, 2005, Lemmon et al., 2014). EGFR ligands are 
usually type I transmembrane proteins with their amino-terminus domain exposed 
extracellularly. In their amino-terminus a conserved motif is located, named EGF 
domain that is responsible for EGFR binding (with exception EGF ligand that has eight 
EGF domains). They also have a transmembrane domain that links the extracellular 
amino-terminus domain with a cytoplasmic carboxy-terminus tail. Ligands cannot bind 
to RTKs in their transmembrane form; therefore they need to be processed by 
proteases in order to become activated secreted ligands. Known proteases 
responsible for EGFR-ligand proteolytic cleavage are ADAMs (Adrain and Freeman, 
2014). 
Upon ligand binding (to a pocket structure formed by I and III extracellular EGFR 
subdomains), the extracellular domain of EGFR totally changes conformation enabling 
its dimerisation with another receptor. It needs to be mentioned that in contrast to all 
other RTKs where usually ligand plays an active role in receptor-receptor dimerisation, 
dimerisation of EGFR is solely mediated by receptor-receptor contacts; mainly 
between the extracellular domains II (dimerisation arm). This dimerisation event 
results in activation of the cytoplasmic tyrosine kinase domain of the dimer in an 
allosteric mediated way. Activation of EGFR cytoplasmic tyrosine kinase domains is 
accompanied by the formation of an asymmetric dimer, whereby one kinase acts as an 
activator while the other one as the receiver. Both the activator and the receiver have 
an amino-lobe (N-lobe) and a carboxy-lobe (C-lobe). The model suggested for 
allosteric EGFR tyrosine kinase activation describes that the C-lobe of the activator 
tyrosine kinase, contacts the N-lobe of the receiver tyrosine kinase and in a 
Introduction 
50 
conformation change-dependent manner switch the inactive state of the receiver to 
active. Finally, the active-receiver transphosphorylates tyrosine residues in the 
carboxy-terminus tail of the activator (Lemmon and Schlessinger, 2010, Lemmon et 
al., 2014). Activated tyrosines in EGFR recruit adaptor proteins such as Grb2 and 
PI3K to activate the two major downstream signalling pathways MAPK/ERK and 
PI3K/AKT, respectively (previously discussed in session 1.1.2.2.) (Zandi et al., 2007). 
EGFR signalling is controlling various physiological cellular processes, thus it was 
no surprise when deregulations in its activation were linked with cancer development 
and progression. In 1980s, studies reported the presence of EGFR overexpression in 
epithelial tumours and linked EGFR with cancer. Since then more mechanisms 
contributing to disruption of EGFR tight regulation have been described such as: i) 
increased ligand production, ii) EGFR mutations and iii) defective EGFR 
downregulation (Gschwind et al., 2004, Zandi et al., 2007). 
The linkage between EGFR and other members of the ErbB family with the biology 
of various cancer types such as colorectal, lung, breast, glioblastoma as well as head 
and neck cancer led to the development of drugs specifically targeting EGFR 
activation (Lemmon et al., 2014). 
 
1.5.2. EGFR Targeted Therapy  
Targeted therapy is a major advance in cancer therapeutics and it refers to the 
generation of drugs that specifically target and regulate molecular alterations 
exclusively for tumour cells. Two different categories of EGFR-targeting agents are 
currently available in the cancer-pharmaceutical market including: monoclonal 
antibodies that specifically bind to EGFR extracellular domain and tyrosine kinase 
inhibitors (TKIs), which target the intracellular tyrosine kinase domain of EGFR 
(Gschwind et al., 2004, Lemmon and Schlessinger, 2010). In Table 1. 2, EGFR-
targeting agents used clinically are summarised. Although these agents represent a 
major step forward for personalized cancer therapy their clinical outcome is still limited. 
In this report I will focus on the monoclonal antibody category and more specifically to 
the chimeric antibody called Cetuximab (distributed under the trade name Erbitux).  
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Table 1. 2: Summary of FDA approved EGFR targeting agents  
 
 
1.5.2.1. Cetuximab 
Cetuximab is a 152 kDa chimeric human-murine immunoglobulin G1 developed 
from the full murine M-225 antibody by replacement of its murine backbone with a 
human one in order to reduce hypersensitivity reactions to patients. The variable 
antigen binding domain of the murine M-225 antibody, responsible for EGFR 
recognition, was kept intact through Cetuximab development (Vincenzi et al., 2008). 
Cetuximab structural studies have shown that Cetuximab binds to domain III of the 
EGFR extracellular domain antagonizing in that way ligand binding. Cetuximab 
prevents EGFR from obtaining its post ligand-binding specific structural conformation 
that blocks EGFR dimerisation and in that way ensures that ligand will not displace 
bound-Cetuximab even in ligand-high abundance conditions. In such way Cetuximab 
directly inhibits EGFR activation and the subsequent activation of its downstream 
pathways (Li et al., 2005). Although direct inhibition of EGFR activation is believed to 
be the main anti-tumour mechanism of Cetuximab action, there are other mechanisms 
suggested to play important role in Cetuximab-mediated anti-tumour activity. Firstly, 
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antibody-dependent cellular cytotoxicity (ADCC) has been implicated to play a role in 
Cetuximab anti-tumour action by recruiting cytotoxic host cells like monocytes and 
natural killer cells to the tumour microenvironment; a positive correlation between 
EGFR expression levels and ADCC was observed (Ashraf et al., 2012). EGFR 
internalisation was also suggested to play key role in Cetuximab-mediated anti-tumour 
activity since the intracellular fate of EGFR-Cetuximab complex seems to differ from 
the EGFR-ligand complex. It is found that EGFR-Cetuximab complex is more stable to 
endosomal acidic pH, avoiding in that way EGFR endosomal sorting and promoting 
EGFR lysosomal degradation; EGFR degradation leads to downregulation of its levels 
(Li et al., 2005, Vincenzi et al., 2008). Inhibition of cell cycle progression through 
increased levels of p27 Kinase Inhibitory Protein (p27KIP) is suggested by studies as 
another anti-tumour effect of Cetuximab. p27KIP is bound to cyclin dependent kinase 
2 (CDK2) resulting in its decreased activation and G1-phase cell cycle arrest in DiFi 
colorectal cell line (Vincenzi et al., 2008). Increased apoptotic capacity has also been 
suggested as an anti-tumour effect of Cetuximab and the main pathways involved in 
this process were p27KIP/CDK2, NF-kB and Insulin Growth Factor Receptor (IGFR) 
(Vincenzi et al., 2008). Inhibition of angiogenesis through the decreased production of 
angiogenesis growth factors such as, Vascular Endothelial Growth Factor (VEGF), 
Interleukin-8 (IL-8) and basic Fibroblast Growth Factor (bFGF) and inhibition of 
invasion and metastasis through decreased expression and activity of the Matrix 
Metalloproteinase 9 (MMP-9) are two other mechanisms of the anti-tumour activity of 
Cetuximab (Vincenzi et al., 2008). 
Food and Drugs Administration (FDA) has approved Cetuximab use for the 
treatment of KRAS WT, EGFR-expressing metastatic colorectal cancer (mCRC) as 
single agent or in combination with irinotecan-based chemotherapy. Cetuximab is also 
used for recurrent locoregional and/or metastatic head and neck squamous cell 
carcinoma (HNSCC) in combination with platinum-based chemotherapy as a first-line 
treatment. 
Unfortunately, treatment response to Cetuximab is limited and with poor outcome in 
a subset of patients mainly due to the presence of primary or the development of 
acquired resistance (Bertotti and Sassi, 2015). 
 
1.5.3. Molecular mechanisms controlling Cetuximab resistance 
1.5.3.1. Primary resistance 
Molecular heterogeneity of CRC is a factor with pivotal role in Cetuximab treatment 
response and a variety of studies have focused their research identifying the molecular 
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components that are responsible for primary resistance to Cetuximab treatment. The 
main mechanisms underlying primary Cetuximab resistance are i) EGFR genetic 
alterations (including mutations and gene copy number), ii) genetic alterations of 
EGFR downstream effectors and iii) genetic alterations of other RTKs such as ErbB2 
and c-MET.  
EGFR mutations are not found in CRC while increased EGFR copy number has 
been positively correlated with Cetuximab response. Additionally, increased 
expression of the EGFR ligands amphiregulin and epiregulin has been positively 
correlated with response to Cetuximab treatment. However, these biomarkers are not 
in use for the selection of CRC patients in clinic (Bardelli and Siena, 2010). 
Until now the most important biomarker that is clinically used for patient selection in 
Cetuximab treatment is KRAS gene mutational status (Misale et al., 2014). 
Specifically, the mutational status of KRAS gene has been suggested to be the most 
important mechanism regulating primary Cetuximab resistance since KRAS activating 
mutations in the codon 12 and 13 of exon 2 have been shown to be negative 
predictors of Cetuximab response (Lièvre et al., 2006, Benvenuti et al., 2007). 
Additionally, activating mutations in NRAS oncogene are found in CRC (De Roock et 
al., 2010, Vaughn et al., 2011) and have been implicated to primary EGFR-targeted 
therapy resistance (Misale et al., 2014). However, not all KRAS WT patients benefit 
from Cetuximab treatment and research focused on identifying other molecular 
biomarkers to explain heterogeneity in Cetuximab treatment response. Genetic 
alterations and specifically gene amplification of the RTKs ErbB2 (Bertotti et al., 2011, 
Yonesaka et al., 2011) and c-MET (Inno et al., 2011, Bardelli et al., 2013) have been 
found to deteriorate Cetuximab response mainly by maintaining MAPK/ERK pathway 
active.  
Beyond KRAS, other EGFR downstream signal transducers, which have been 
implicated to Cetuximab primary resistance, compose of activating mutations in BRAF 
(V600E) and PIK3CA (encoding for the PI3K catalytic subunit, p110) genes as well as 
loss of function mutations in Phosphatase and Tensin (PTEN) gene. However, no 
robust statistical correlation with Cetuximab response was observed for these genes 
yet (Bardelli and Siena, 2010, Sartore-Bianchi et al., 2010, De Roock et al., 2011) 
(Misale et al., 2014).  
 
1.5.3.2. Acquired Cetuximab resistance 
Another important issue implicated in Cetuximab response is the development of 
acquired Cetuximab resistance after a period of 3-12 months in patients that were 
initially responsive to treatment (Bardelli et al., 2013). The main mechanisms 
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implicated in acquired Cetuximab resistance are: i) ErbB2 up-regulation, ii) Met 
amplification, iii) EGFR ectodomain mutation acquisition, iv) selection of mutations in 
the KRAS gene or KRAS amplification, v) Nuclear EGFR up-regulation and vi) 
deregulation of EGFR internalisation and degradation. 
A recent study described increased signalling through ErbB2 as responsible for 
development of acquired resistance and in some cases primary resistance of CRC 
patients. They found that either amplification of ErbB2 or overexpression of the 
ERBB3/ERBB4 ligand heregulin are responsible through sustained activation of 
ERK1/2 (Vlacich and Coffey, 2011). 
In a work of Bardelli et al., (2013) it was demonstrated that MET gene amplification 
observed in circulating tumour DNA was responsible for acquired and primary 
Cetuximab resistance in KRAS WT metastatic CRC patients (Bardelli et al., 2013). The 
same group has also recently shown that secondary mutations in KRAS gene were a 
frequent phenomenon in metastatic CRC patients that acquired Cetuximab resistance 
(Misale et al., 2012). In contrast, another group suggested that Cetuximab acquired 
resistance caused by KRAS activating mutations is due to the existence of expanded 
KRAS mutant subclones within the tumour before treatment initiation (Diaz et al., 
2012). It was also found that amplification of the KRAS gene even though a rare event 
could account for Cetuximab resistance in small resistant patient subgroups (Misale et 
al., 2012, Valtorta et al., 2013). 
The acquired EGFR ectodomain mutation S492R has been suggested to play an 
important role in Cetuximab resistance by blocking Cetuximab antibody binding to 
EGFR receptor (Montagut et al., 2012). In a study using as a NSCLC model of 
Cetuximab resistance, it was observed that increased levels of nuclear EGFR may 
represent an additional mechanism underlying Cetuximab resistance (Li et al., 2009). 
Finally, there is evidence showing that alterations of EGFR internalisation and 
degradation represent another mechanism of acquired resistance. In particular, it was 
shown that Cetuximab resistant cell lines presenting higher levels of EGFR compared 
to their parental cell lines due to reduced association of EGFR with Casitas B-lineage 
lymphoma protein (Cbl) ubiquitin ligase E3 leading to decreased EGFR degradation 
(Brand et al., 2011). 
 
1.6. Outstanding questions 
Extensive research is still needed to improve survival and life quality of the CRC 
patient aiming the development of new effective therapeutic strategies. 
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Targeting metabolism in cancer is a promising therapeutic approach (Tennant et al., 
2010). Cancer cells have evolved survival mechanisms like autophagy to overcome 
metabolic challenges of stressing stimuli of the tumour microenvironment and/or 
cancer therapeutics (Rabinowitz and White, 2010). Additionally, autophagy has been 
linked with the regulation of many acquired capabilities of a cancerous cell. This 
knowledge led to the development of new therapeutic strategies where conventional 
cancer treatment is combined with autophagy enhancing/inhibiting compounds. 
Although research in the autophagy field the last decades answered fundamental 
questions, the role of autophagy in cancer and cancer treatment remains controversial 
and needs further research in order to revolutionize cancer therapy and improve 
clinical outcomes. In particular, contrary to the high number of ongoing clinical trials 
our knowledge in CRC heterogeneity regarding autophagy regulation and function 
under basal and cancer treatment-induced conditions is still limited. Intensive research 
in these fields is still needed to ensure beneficial outcome of clinical trials testing the 
effect of autophagy inhibition in combination with conventional cancer therapy in CRC. 
Previous published work from our lab has shown that autophagy inhibition 
potentiates BCR-ABL tyrosine kinase targeted therapy efficacy in CML cells (Bellodi et 
al., 2009). This work prompted us to investigate in more detail the role of autophagy in 
the context of RTK inhibition in epithelial cancers, such as CRC. Specifically in CRC, 
our knowledge about the role of autophagy upon targeted therapy remains limited. It is 
known that RTKs could regulate autophagy either directly or indirectly through 
downstream effectors. PI3K/mTOR pathway residing downstream of RTKs is an 
established master negative regulator of autophagy induction and PI3K activating 
mutations are frequently present in a variety of cancers including CRC (Samuels et al., 
2004). Therefore, an open question remains whether tumours with constantly active 
PI3K pathway would induce autophagy downstream of RTKs inhibition and whether 
autophagy inhibition approaches would potentiate RTK inhibition therapy. Although 
increasing evidence in the autophagy field supports a direct regulation of autophagy 
via RTKs, our knowledge on whether or how autophagy vice versa could control RTK 
activation is limited. 
Most cell biology studies use starvation or inhibition of PI3K/mTOR models for 
autophagy induction. However, the majority of in vivo studies are investigating 
autophagy inhibition in the absence of specific stimuli (apart from 
intratumoural/intratissutal stress) and are revealing a differential impact of basal 
autophagy in cancer progression depending on tumour-type and -mutational status. 
Therefore, it is important to evaluate the role of basal autophagy in CRC. Recent 
studies have identified a novel, non-catabolic role of autophagy in regulation of cell 
signalling albeit the relationship between autophagy and cell signalling in cancer and 
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specifically in CRC remains elusive and requires further investigation. Characterisation 
of basal autophagy even in the absence of stressful stimuli like cancer treatment would 
provide insight on the response to autophagy inhibitors in clinical settings.  
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1.7. Aims of the project 
The main aims of this research are: 
1. To investigate the effect of RTK inhibition on autophagy induction and the 
potential benefit of autophagy suppression in CRC  
2. To explore the role of basal autophagy in CRC and its relationship to signalling 
 
Potential impact 
By achieving these objectives we will be able to better understand the role of 
autophagy as part of the metabolic rewiring used by CRC cells to expand and 
resist stress. This knowledge would not be limited to CRC only, as novel insights 
into the fundamental mechanism underlying the role and regulation of autophagy in 
cancer would be uncovered. Finally, this work will potentially inform clinicians on 
how to rationally design clinical trials based on autophagy inhibitors and RTK 
targeted therapy. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Cell lines 
HCT-116 and DLD-1 KRAS WT and G13D isogenic cell lines were kindly provided 
by Prof. Bert Vogelstein (Johns Hopkins University, USA). SW48 KRAS isogenic cell 
lines were purchased from the Horizon Discovery Company. DiFi cells were kindly 
provided by Prof. Alberto Bardelli (University of Torino, Italy). CaCo2 cells were in 
stock in Prof. Daniel Hochhauser’s laboratory. HEK 293T and Phoenix A cell lines, 
which were used for virus production procedures, were available in Prof. Paolo 
Salomoni’s laboratory. 
 
2.1.2. Chemical compounds and drugs 
All chemical compounds and drugs were dissolved to the indicated stock 
concentration and then in cell culture media to reach the final working concentration. 
Sterile conditions were followed throughout the preparation of all reagents and sterile 
filtering through a 0.22 µm pore hydrophilic polyethersulfone (PES) membrane was 
applied when required. Fresh aliquots were used for each independent experiment.  
Chloroquine diphosphate salt (CQ) (C6628, Sigma) was dissolved in sterile 
Phosphate Buffered Saline (PBS) at a stock concentration of 10 mM and was used at 
a working concentration of 10 µM. Doxycycline hyclate (DOX) powder (D9891, Sigma) 
was resuspended into sterile H2O at a stock concentration of 50 mg/ml and was stored 
protected from light. DOX, which was used for stimulation of shRNA expression in the 
pLKO-Tet-On inducible CRC cell lines, was used at the optimal working concentration 
of each CRC cell line (10 ng/ml for HCT-116 and 100 ng/ml for DLD-1, SW48 and 
CaCo2 cells). Clinical-grade Cetuximab, Gefitinib and Lapatinib were used. Cetuximab 
(Merck Serono, Germany) was already diluted in a colorless solution for infusion at a 
stock concentration of 5 mg/ml. All following drugs were dissolved in dimethyl sulfoxide 
(DMSO) (D2650, Sigma). Clinical-grade Gefitinib (Iressa; AstraZeneca) was used at a 
concentration of 1 µM and Lapatinib at 2 or 5 µM (Tykerb; GSK). The dual PI3K and 
mTOR inhibitor, PI103 hydrochloride (2930, R&D systems), was dissolved at a stock 
concentration of 10 mM and 1 µM was used to assess competence of CRC cells to 
autophagy induction. The selective AKT inhibitor vIII (124018, Calbiochem) was 
prepared in a stock concentration of 9 mM. 2 and 5 µM of AKT vIII inhibitor were used 
to investigate the role of AKT activation in Cetuximab-mediated autophagy induction in 
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CRC cells. The proteasome activity inhibitor MG132 (C2211, Sigma) was resuspended 
at a stock concentration of 10 mM and 2.5 µM was used to inhibit proteasome activity 
in HCT-116 cells. The specific c-MET kinase inhibitor, SGX 523 was kindly provided 
by Prof. Tony Ng (University College London, UK). SGX 523 was prepared at a stock 
concentration of 5 mM and 0.5 µM was used to treat HCT-116 cells. In all experiments 
wherein cells were treated with compounds diluted in DMSO, the corresponding 
untreated conditions were treated with equal concentrations of DMSO.  
EGF (Sigma-Aldrich) and HGF (R&D) ligands were dissolved in accordance to 
supplier instructions and were used at concentrations of 100 ng/ml and 50 ng/ml, 
respectively. 
For endocytosis studies, Transferrin-555 and the clathrin inhibitor Pitstop2 were 
kindly provided by Prof. Clare Futter (University College London, UK). Dynamin 
inhibitor, Dynasore, was a kind gift by Prof. Kerry Chester (University College London, 
UK).  
Iodonitrotetrazolium Chloride (A6248.0001, VWR), which was used at anchorage 
independent cell growth assay, was kindly provided by Dr Pablo Rodriguez-Viciana 
(University College London, UK). Iodonitrotetrazolium Chloride was dissolved in sterile 
PBS at a stock concentration of 8 mg/ml and was used at a final working concentration 
of 145 µg/ml. 
The phosphatase inhibitors Sodium Fluoride (NaF) (201154, Sigma-Aldrich) and 
Sodium Orthovanadate (Na3VO4; S6508, Sigma) were prepared at a stock 
concentration of 1 M and 100 mM, respectively. The protease inhibitors Pepstatin A 
(P5318, Sigma), Aprotinin (A6279, Sigma) and Leupeptin (L8511, Sigma) or the 
protease inhibitor cocktail (11697498001, Roche) were used at corresponding 
concentrations (See 2.1.6.) to supplement cell lysis buffers. 
 
2.1.3. Plasmids 
pGIPZ vectors were purchased from the UCL Cancer Institute, pGIPZ lentiviral 
shRNA human library. pLKO-Tet-On backbone was purchased from Addgene. pLXSN 
and pLXSN_myrAKT plasmids were kindly provided by Dr Pablo Rodriguez-Viciana 
(University College London, UK). 
 
2.1.4. Antibodies 
Tables 2.1-2.4 are summarizing all primary and secondary antibodies used in this 
work. Important information such as supplier name, catalogue number as well as 
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working concentrations are provided. Anti-Ubiquitin, anti-PP2A, anti-pRb, anti-total 
IGF-IR beta and anti-HGF antibodies were kindly provided by Prof. Henning Walczak, 
Dr Pablo Rodriguez-Viciana, Dr Alexander Hergovich, Prof. Bart Vanhaesebroeck and 
Prof. Adrienne Flanagan (University College London, UK), respectively. 
Table 2. 1: Primary antibodies used for western blotting. Antibodies noted as ♯ were diluted 
into 5% BSA in TBS-T. All other antibodies were diluted into 5% milk in PBS-T. 
Note: Anti-LC3B antibody * was discontinued and replaced with the Anti-LC3B antibody from 
Cell Signalling. 
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Table 2. 2: Secondary antibodies used for western blotting.  
 
 
Table 2. 3: Antibodies used for immunoprecipitation studies. 
 
 
Table 2. 4: Primary and Secondary antibodies used for immunofluorescence studies. 
 
 
2.1.5. Oligonucleotides 
Polymerase chain Reaction (PCR) primers and pLKO-Tet-On cloning oligos were 
generated and purchased from Invitrogen. Lyophilized oligos were resuspended in 
appropriate volume of sterile nuclease free H2O to yield a stock of 100 µM and were 
thoroughly mixed by vortexing. PCR primers were further diluted using sterile nuclease 
free H2O in a working concentration of 5µM. 
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Table 2. 5: Primers used for determination of PIK3CA and KRAS mutational status by 
sequencing. 
 
 
Table 2. 6: Single-stranded oligos used to develop the desired shRNA duplex sequence, 
which was cloned into the pLKO-Tet-On vector 
 
 
2.1.6. Buffer Recipes 
2X HEPES Buffer, pH 7.05: 280 mM NaCl; 10 mM KCl; 1.5 mM Na2HPO4; 12 mM 
D(+)-Glucose Monohydrate and 50 mM HEPES. 
5X Polyethylene glycol (PEG), pH 7.2: 50 mM PEG; 0.41 M NaCl and 0.2% Tris 1 M, 
pH 7.5. 
10X annealing Buffer: 1 M NaCl and 100 mM Tris-HCl pH 7.4. 
RIPA Lysis Buffer: 20 mM Tris pH 7.4; 150 mM NaCl; 1 mM EDTA pH 8; 1 mM EGTA 
pH 8; 0.5% (w/v) Sodium Deoxycholate; 0.1% (v/v) sodium dodecyl sulfate (SDS); 1% 
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(v/v) Nonidet P-40. Prior cell lysis 1X protease inhibitors cocktail and 1 mM Na3VO4 
and 50 mM NaF of the phosphatase inhibitors were added. 
Non-denaturing Lysis Buffer: 20 mM Tris pH 7.4; 137 mM NaCl; 2 mM EDTA pH 8; 
1% (v/v) Nonidet P-40. Prior cell lysis 10 µg/ml of each protease inhibitor: i) Aprotinin, 
ii) Pepstatin A and iii) Leupeptin as well as 1 mM Na3VO4 and 50 mM NaF of the 
phosphatase inhibitors were added. 
Protein Loading Buffer (5X Laemmli sample buffer): 10% (w/v) SDS; 50% (w/v) 
glycerol; 0.125% (w/v) bromophenol blue; 250 mM Tris pH 6.8; 2 mM 2-
mercaptoethanol.  
1X Running Buffer: 0.186M Glycine; 0.02 M Trisma Base and 0.15% (v/v) SDS. 
1X Transfer Buffer: 0.186M Glycine; 0.02 M Trisma Base and 20% (v/v) Methanol. 
PBS-T: 1X PBS pH 7.4 supplemented with 0.1% (v/v) Tween 20. 
TBS-T: 1X TBS pH 7.4 (19.8 mM Trisma Base; 0.13 M NaCl; 0.05% (v/v) HCl) 
supplemented with 0.1% (v/v) Tween 20. 
Tris-Acetate-EDTA Buffer (TAE 1X): 40 mM Trisma Base; 0.001% (v/v) Acetic acid; 
1 mM EDTA pH 8. 
5X DNA Loading Buffer: 100 mM Tris pH 8; 10 mM EDTA pH 8; 50% Glycerol and 
0.5%w/v bromophenol blue. 
 
2.2. Methods 
2.2.1. Cell Culture 
2.2.1.1.Cell line maintenance and cryopreservation 
Eight different CRC cell lines were used and maintained in culture. Human 
colorectal carcinoma cell lines, HCT-116, DLD-1 and SW48 as well as their KRAS 
mutant isogenic versions were maintained in McCoy’s 5A medium containing 2 mM L-
Glutamine. The human colorectal carcinoma cell line, CaCo2, was maintained in 
Minimum Essential Medium (MEM) medium containing 2 mM L-Glutamine. The human 
rectal carcinoma cell line, DiFi, was maintained in Ham’s F12 Nutrient mixture medium 
containing 1 mM L-Glutamine. The human embryonic kidney cell line HEK-293T 
(expresses the large T antigen from SV40 virus), which was used for lentiviral 
production, was maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
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supplemented with 4.5 g/L D-Glucose and Sodium Pyruvate. The human embryonic 
kidney cell line, Phoenix A, which was used for retrovirus production, was maintained 
in Iscove’s Modified Dulbecco’s Medium (IMDM) containing 4.5 g/L D-Glucose and 
Sodium Pyruvate. All cell culture media were supplemented with 10% Fetal Bovine 
Serum (FBS, Life Technologies), and 1% Penicillin/Streptomycin (Gibco). 
All inducible pLKO-Tet-On shRNA-expressing (shEGFP, shATG7-E8, -G7 and -
F12) stable cell lines were maintained in corresponding medium supplemented with 
10% Tet-Free Certified FBS (Life Technologies, 16000-044, Lot number 1221032) in 
the presence of puromycin selection (0.25 µg/ml for SW48, 0.5 µg/ml for HCT-116, 1.5 
µg/ml for DiFi, 3 µg/ml for DLD-1 and 1.5 µg/ml for CaCo2 cells). DiFi LXSN and 
LXSN_myrAKT-expressing cells were cultured in the corresponding medium in the 
presence of neomycin selection (750 µg/ml). All experiments were conducted in the 
absence of either puromycin or neomycin selection. 
Cells were cultured in tissue culture dishes at 37oC in a humidified atmosphere of 
5% CO2. Cell culture procedures were carried out in sterile conditions in Class II 
biological safety cabinets. Cells were cultured until 80-90% confluence was reached 
and then were passaged to new culture dishes (every 2-3 days). Briefly, adhered cells 
were washed once with appropriate volume of sterile PBS, dependent on size of tissue 
culture dishes. PBS was removed and followed incubation with 1X Trypsin (Gibco) at 
37oC for 1-3 mins. Trypsin was used for efficient cell detachment of tissue culture 
dishes and neighboring cells. Adding cell culture medium deactivated trypsin and cells 
were pelleted down by centrifugation at 1200 rpm for 5 mins. Trypsin-containing cell 
culture medium was removed and replaced by fresh medium to resuspend cell pellet. 
Appropriate numbers of cells were replated to new tissue culture dishes for cell culture 
maintenance and/or experimental procedures. Cell number counting and cell viability 
examination was conducted using the Beckman coulter Vi-Cell XR machine and 
software. Optimization experiments were performed for each independent cell line in 
order to evaluate correct cell number plating for maximum cell viability. The maximum 
cell passage reached in culture was 20 wherein fresh cell cultures were set up. 
Cryopreservation of cell lines was conducted by long-term storage in liquid nitrogen 
containers. Exponentially growing cells were trypsinised and pelleted down as 
previously described. Cell pellets were resuspended in freezing medium (45% 
corresponding medium for each cell line supplemented with 45% FBS and 10% 
DMSO) transferred in cryovials and were short-term stored in -80oC to allow gradual 
decrease of temperature until their long-term storage in liquid nitrogen. For retrieval of 
frozen cell stocks from liquid nitrogen, cryovials were quickly thawed by incubation at 
37oC waterbath and cell suspensions were supplemented with 6 ml of fresh cell culture 
medium. Cells were pelleted down by centrifugation at 1200 rpm for 5 mins to remove 
Materials and Methods 
66 
traces of DMSO. Cell pellets were resuspended in fresh cell culture medium and 
plated in appropriate tissue culture dishes. 
 
2.2.1.2. Transient transfection for small interfering RNAs (siRNAs) delivery 
RNA interference (RNAi) technology was used to knock down EGFR and LC3B 
gene expression. siRNAs sequences were received as lyophilized powders and 
dissolved in RNAse free H2O at a stock concentration of 50 µM. Intermediate dilutions 
in RNAse free H2O were applied to yield working concentrations. 
Two different transfection reagents were used for the delivery of EGFR and LC3B 
siRNAs to CRC cell lines. SMARTpool: ON-TARGETplus EGFR siRNA (L-003114-00, 
Thermo Scientific) and siRNA negative control (Scramble, Thermo Scientific) were 
used in a concentration of 25 nM and/or 50 nM using DharmaFECT reagent 1 (T-
2001-02, GE Dharmacon) in HCT-116 and DLD-1 cell lines. Silencer select LC3B 
siRNA (s37749 and s224886, Life Technologies) and negative control (Scramble, 
4390843, Life Technologies) were used in a concentration of 10 nM using 
Lipofectamine RNAiMAX reagent (13778075, Thermo Scientific) in HCT-116 cells. 
Both DharmaFECT and Lipofectamine RNAiMAX transfection reagents are cationic 
liposome formulations that make complexes with siRNAs and allow efficient delivery of 
siRNAs into the cell through the cell membrane barrier. 
Forward transfection protocol was followed with both transfection reagents. One 
day prior transfection, 1.0 - 1.5 x 105 cells were plated in 6-well tissue culture dishes 
and let to adhere overnight at 37oC. The following day, cells were transfected 
according to the protocol of each manufacturer. Briefly, appropriate volume of each 
transfection reagent and siRNA was diluted in separate tubes containing Opti-MEM I 
reduced serum medium without serum. The diluted Opti-MEM siRNAs were combined 
with Opti-MEM containing the corresponding transfection reagent and let to incubate at 
room temperature for 20 mins. The transfection reagent-siRNA mixture was added 
dropwise to each corresponding well containing cells and let to incubate at 37oC. 
Transfection medium was replaced with fresh complete medium after 24 hours. Cells 
were harvested 48 and/or 72 hours post-transfection by scraping. Protein knock down 
was assessed using western blotting (See 2.2.2.3.). 
For examination of protein knock down by immunofluorescence (IF) (See 2.2.4.1.), 
the same experimental conditions were followed but cell number, volume of siRNAs 
and volume of transfection reagents were proportionally adjusted to the relative 
surface area of a 24-well tissue culture dish. 
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2.2.1.3. Calcium Phosphate transfection for virus particle production 
The calcium phosphate transfection method was used to generate lenti- and retro-
virus particles by transfecting HEK 293T and Phoenix A cells with the corresponding 
plasmids. Calcium phosphate transfection method is based on the generation of 
precipitates through the interaction of the negative charged phosphate groups 
contained in the HEPES buffer with the positive charged calcium groups in the calcium 
chloride solution. DNA is bound in the surface of these precipitates and in that way 
inserts the cell (Kingston et al., 2001). 
 
Lentivirus Particle Generation 
Lentivirus particle production was employed for generation of stable CRC cell lines 
by viral transduction approaches (See 2.2.1.5.). 6 x 106  HEK 293T cells were plated in 
15 cm dishes (two different dishes were combined for each different virus generation) 
containing 20 ml complete DMEM medium and were let to adhere overnight at 37oC. 
The following day the calcium phosphate transfection approach was followed to 
perform a triple co-transfection of HEK 293T cells with lentivirus packaging vectors 
(pCMV-VSV-G and pCMV-HIV-1) and desired plasmid DNA. Briefly, 7.2 µg of pCMV-
VSV-G (expressing VSV-G envelope gene), 15.6 µg pCMV-HIV-1 (expressing Gag, 
Pol, Rev and Tat genes) vectors along with 24 µg of shRNA encoding lentivirus vector 
(i.e. pLKO-Tet-On shATG7, pLKO-Tet-On shEGFP or pGIPZ) were diluted in sterile 
nuclease free H2O containing 10% (v/v) 2.5 M calcium chloride to a final volume of 1 
ml. The DNA-calcium chloride mixture was thoroughly mixed and allowed to equilibrate 
at room temperature for 30 mins. 37oC pre-warmed 2X HEPES buffer (See 2.1.6.) was 
added to the DNA-calcium chloride solution in a ratio 1:1 and the mixture was 
thoroughly mixed for 1 min. DNA-calcium chloride-HEPES mixture was added 
dropwise to each 15 cm dish containing HEK 293T cells. Transfection medium was 
replaced with normal culture medium after 8 hours. Transfected HEK 293T cells were 
let to incubate for additional 48 hours when supernatants containing lentiviral particles 
collected. Viral particles concentration by PEG precipitation was followed. 
 
Retrovirus Particle Generation 
Retrovirus particle production was employed for generation of stable DiFi cell lines 
expressing myristoylated AKT by viral transduction approaches (See 2.2.1.5.). 2.5 x 
106  Phoenix A cells were plated in 10 cm dishes (four different dishes were combined 
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for each different virus generation) containing 10 ml complete IMDM medium and were 
let to adhere overnight at 37oC. The following day the calcium phosphate transfection 
approach was followed to co-transfect Phoenix A cells with 1.2 µg SARAIII retrovirus 
packaging vector and 20 µg desired plasmid DNA (i.e. pLXSN or pLXSN_myrAKT). 
DNA was diluted in sterile nuclease free H2O containing 25% (v/v) 1 M calcium 
chloride to a final volume of 1 ml. The DNA-calcium chloride mixture was thoroughly 
mixed and allowed to equilibrate at room temperature for 30 mins. 37oC pre-warmed 
2X HEPES buffer was added to the DNA-calcium chloride solution in a ratio 1:1 and 
the mixture was thoroughly mixed for 1 min. DNA-calcium chloride-HEPES mixture 
was added dropwise to each 10 cm dish containing Phoenix A cells. Transfection 
medium was replaced with normal culture medium after 8 hours. Transfected Phoenix 
A cells were let to incubate for additional 36 hours when supernatants containing 
retrovirus particles collected and virus particle concentration by PEG precipitation was 
followed. 
 
Virus Particle Concentration by PEG Precipitation 
Supernatants containing lenti- or retro- virus particles were centrifuged at 3000 g for 
15 mins to eliminate cells and cellular debris. Further cellular debris elimination was 
achieved by 0.45 µm PVDF filtration of the supernatant. 5X PEG solution (See 2.1.6.) 
was added to the supernatant containing the viral particles in a volume ratio 1:4 to 
concentrate the virus particles. Solution was refrigerated at 4oC overnight. The next 
day the concentrated virus particles were pelleted down through centrifugation at 1500 
g for 30 mins and PEG containing medium was discarded. Virus particle pellets were 
resuspended in sterile cold PBS in a volume ratio 50:1 and were aliquoted and stored 
at -80oC. Fresh concentrated virus particles aliquots were used in each independent 
viral transduction experiment. 
 
2.2.1.4. Virus tittering by antibiotic selection 
For virus tittering, 1.0 x 105 HCT-116 cells were plated in 6-well plates and 
incubated overnight at 37oC. Cell culture medium was replaced by medium 
supplemented with 5 µg/ml polybrene to enhance absorption and transduction of the 
virus particles. Cells were transduced by different serial dilutions of the virus particles. 
Two untransduced control wells were included. Transduced cells were let to incubate 
overnight at 37oC and followed replacement of the virus-containing medium with fresh 
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medium. Cells were incubated for additional 24 hours at 37oC to allow for sufficient 
expression of the antibiotic resistance gene in the transduced cells prior antibiotic 
selection. The following day, cell culture medium supplemented with appropriate 
volume of antibiotic was added in all viral transduced wells including one untransduced 
control well, named “mock-transduced”. Cell viability was assessed daily in the “mock-
transduced” well by light microscopy. Antibiotic-containing medium was replaced every 
48 hours and antibiotic selection was conducted as long as all cells in the “mock-
transduced” well were eliminated. Followed quantitative assessment of virus titter by 
trypsinising and counting cells in each different viral transduced well. Percentage (%) 
of infectivity was expressed as number of cells in each of virally transduced wells 
divided by the number of cells in the positive control well (“no transduced/no 
antibiotic”) multiplied with 100. Multiplicity of infection (MOI) of 1 considered as equal 
to 50% of infectivity.  
 
2.2.1.5. Viral Transduction of CRC cell lines 
Viral transduction method was used to generate stable (pGIPZ) and inducible-
expressing (pLKO-Tet-On) shRNA CRC cell lines as well as myristoylated AKT-
expressing (pLXSN) DiFi cells. 1.0 x 105 of each cell line was plated in 6-well plates 
and let to incubate overnight at 37oC. Cells were transduced with the appropriate 
volume of each virus based on virus tittering at an MOI of 10 in media containing 5 
µg/ml polybrene. Selection of transduced cell populations was performed using 
TurboGFP expression sorting for pGIPZ shRNA-expressing cells; puromycine 
selection for pLKO-Tet-On-shRNA expressing cells and neomycin selection for 
LXSN_myrAKT and control cells. Subsection 2.2.1.1. annotates the specific 
concentration of puromycin and neomycin was used for each CRC cell line. Of note, 
for generation of pLKO-Tet-On CRC cell lines all transduction steps were performed 
by using medium containing 10% (v/v) Tetracycline-Free Certified FBS in order to 
avoid stimulation of shRNA expression by traces of tetracycline contained in the 
regular FBS. 
 
2.2.2. Biochemistry 
2.2.2.1. Total cell protein extraction 
2.5 - 4 x 105 of CRC cells (depending on each CRC cell line) were plated in 6 cm 
tissue culture dishes and let to adhere for approximately 48 hours at 37oC until 
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approximately 70% of confluence was reached. Drug treatment was applied under 
sterile conditions for the indicated incubation time and total cell protein extraction 
followed. Cell culture medium was removed and adhered cells were washed once with 
PBS. 100 - 150 µl of RIPA Lysis Buffer or Non-Denaturing Lysis Buffer supplemented 
with protease and phosphatase inhibitors was added to the cells on ice. Cell scraping 
was used to harvest cells from the culture dishes and cell lysates were transferred to 
microcentrifuge tubes. Cell lysates were incubated on ice for 30 mins and then 
centrifuged at 13200 rpm for 15 mins at 4oC. Supernatants containing total cell protein 
extracts were transferred to new microcentrifuge tubes and kept on ice as long as the 
total cell protein concentration of extracts was quantified (See 2.2.2.2.). Following total 
cell protein concentration quantification, 5X protein loading buffer was added to cell 
lysates in a ratio 1:4 in order to yield a final concentration of 1X protein loading buffer 
to the cell extracts. Total cell extracts were boiled at 95oC for 5 mins and then were 
stored at -20oC until further use. 
 
2.2.2.2. Determination of total cell protein concentration 
For total cell protein concentration determination the BCA protein assay kit (23227, 
Pierce) or Bradford assay (500-0006, BioRad) were used dependent on the Lysis 
Buffer used. For RIPA Lysis Buffer only the BCA protein assay kit was performed 
being compatible with SDS content. Both assays were conducted according to 
instructions of the manufacturer. A standard linear curve, which was designed by using 
known concentrations (0.5 - 10 µg/µl) of BSA, was employed for quantification of 
undetermined protein concentration of total cell extracts. Optical Density (O.D.) was 
measured in a spectrophotometer at 562 nm and 595 nm for BCA protein assay kit 
and Bradford assay, respectively.  
 
2.2.2.3. Western Blotting 
Equal concentration of total cell extracts (30 - 50 µg) were separated in 8%, 10%, 
15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Criterion™ TGX Stain-
Free™ Precast Gels as required and transferred for 21/2 hours onto nitrocellulose 
membrane in a wet blotter. 1X Running Buffer was used for protein electrophoresis 
and 1X Transfer Buffer was used for protein transfer (See 2.1.6.). Efficiency of protein 
transfer onto nitrocellulose membranes was examined by shortly incubating 
membranes in Ponceau S (Sigma) solution that reversibly removed by PBS-T or TBS-
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T washes. Nitrocellulose membranes were blocked in 5% BSA (w/v) TBS-T for 
phosphorylated studies and in 5% milk (w/v) PBS-T for all other studies with 1 hour 
incubation time. Immunodetection performed by incubating the membranes with 
different primary antibodies (Table 2. 1) overnight at 4oC. After 3 washes in TBS-T 
(phosphorylated proteins detection) or PBS-T, membranes were incubated with a 
secondary antibody conjugated with horseradish peroxidase (HRP) or fluorescent dye 
diluted in 5% milk (w/v) PBS-T (Table 2. 2) for 1 hour. Protein expression was 
detected on medical X-Ray films (Fujifilm) using the Enhanced Chemiluminescence 
System (ECL) when HRP-conjugated secondary antibodies used. The LI-COR 
Odyssey Imaging System scanner was used for detection of protein expression when 
fluorescent dye-conjugated secondary antibodies were used. 
 
2.2.2.4. Densitometric Analysis 
LI-COR Odyssey software or Fiji (Image-J) software was used for densitometric 
analysis of protein bands detected either via LI-COR Odyssey Imaging System 
scanner or ECL, respectively. For both densitometric methods, the protein bands of 
interest were selected in high quality (minimum 300 dpi) images and background 
intensity was subtracted.  
 
2.2.2.5. Phospho-RTK array 
The human phospho-RTK array (ARY001B, R&D) was used for the determination 
of changes in phosphorylation of RTKs between autophagy-proficient and -
compromised samples. The Phospho-RTK array includes nitrocellulose membranes 
whereby mouse antibodies from 49 different RTKs and control antibodies are 
previously captured. The array was conducted with the specific reagents provided and 
based on the instructions of the manufacturer. Briefly, 1.5 - 2 x 106 autophagy-
proficient or -compromised cells (depending on the cell line used) were plated in 10 cm 
tissue culture dishes at day 3 of DOX treatment and let to adhere for another 48 hours 
at 37oC in the presence of DOX. Then cells were lysed using Lysis Buffer 17 
supplemented with protease and phosphatase inhibitors and protein quantification of 
total cell extracts was conducted using Bradford assay (See 2.2.2.2.). 1500 µg of total 
cell extracts was diluted into array buffer 1 to reach a volume of 1.5 ml and samples of 
each autophagy-proficient or -compromised condition were applied onto the 
nitrocellulose membrane with the RTK-captured antibodies. Followed overnight 
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incubation at 4oC on a rocking platform shaker and the next day nitrocellulose 
membranes were washed and incubated with a pan anti-phospho-tyrosine antibody 
conjugated to HRP in a dilution 1:5000 for 2 hours at room temperature. The 
phosphorylated tyrosines on RTKs were detected by chemilluminescence using X-ray 
Films and multiple exposure times (20 secs - 10 mins) were used to detect the majority 
of RTKs. Nitrocellulose membranes incubated with autophagy-proficient or -
compromised lysates were placed into the same autoradiography cassette and 
developed concomitantly to allow comparison between conditions. For densitometric 
analysis of phospho-RTK array results, X-ray films were scanned in high resolution 
(1200 dpi) and the GS-800 Calibrated Densitometer (BioRad) was used to quantify the 
intensity of each independent RTK spot. Numerical results were analysed by 
determining the average signal (pixel intensity) of the pair of duplicate spots presenting 
each RTK and followed by subtraction of an averaged background signal for each RTK 
independently. Differences in RTK phosphorylation were determined by comparing 
phosphorylation of RTKs between autophagy-proficient and -compromised cells.  
 
2.2.2.6. Immunoprecipitation (IP) 
Preparation of protein A Sepharose beads slurry 
Protein A Sepharose beads (71-7090-00AF, GE Healthcare) were supplied 
lyophilized and 50 ml of distilled H2O was used to hydrate them with overnight 
incubation at 4oC by rolling. Beads were pelleted down by centrifugation at 450 g for 5 
mins at 4oC and the supernatant was removed by aspiration. Followed two washes in 
50 ml of distilled H2O and 3 washes in sterile 1X PBS with intermediate centrifugations 
as described above for pelleting down the beads. Hydrated protein A Sepharose 
beads were diluted in a ratio 1:2 into sterile 1X PBS solution containing 25% (v/v) 
Ethanol and Sodium Azide. The stock solution containing beads was stored at 4oC 
until further use. 
 
Coupling of Antibodies to Protein A Sepharose 
Antibodies used in IP studies (Table 2. 3) were firstly coupled to protein A 
Sepharose beads. Briefly, the Sepharose protein A slurry was gently mixed by 
vortexing and 10 µl of beads were washed twice with non-denaturing lysis buffer by 
intermediate centrifugations of 20 secs at 13200 rpm to remove the excess of the 
slurry solution containing ethanol. Followed coupling of beads with the required 
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volume of antibody in 300 µl of non-denaturing lysis buffer via rotation at 4oC for 4 
hours. Preceding IP, antibody-Sepharose A coupled beads were washed 4 times in 
non-denaturing lysis buffer containing protease and phosphatase inhibitors with 
intermediate centrifugation steps as abovementioned. 
 
IP 
IP was performed via incubating 500 - 1000 µg of total cell protein extracts (into 
non-denaturing lysis buffer containing phosphatase and protease inhibitors; 0.5% (v/v) 
Nonidet P-40 instead of 1% (v/v) was used in non-denaturing lysis buffer for c-MET/p-
c-MET and LC3B co-immunoprecipitation experiments) with 10 µl antibody-Sepharose 
A coupled beads in a total volume of 1000 µl with rotating for 3 hours at 4oC. Then 
beads were washed 4 times with 1000 µl non-denaturing lysis buffer containing 
phosphatase and protease inhibitors followed by centrifugation for 20 sec at 13200 
rpm. The pellet was resuspended in 50 µl of 1X protein loading buffer, incubated at 
95oC for 5 mins and centrifuged at 13200 rpm for 1 min. The supernatant containing 
the immunoprecipitated proteins was then analysed using western blotting (See 
2.2.2.3.). 
 
2.2.3. Functional Assays 
2.2.3.1. Sulforhodamine B (SRB) Cell Proliferation / Survival assay 
Using the Sulforhodamine B (SRB) colorimetric assay, cell proliferation/survival was 
assessed upon normal conditions and drug treatments. SRB assay is used for cell 
density determination by measuring cellular protein content. SRB binds through its 
sulfonic groups to basic amino acids under acidic condition and it releases from them 
under basic conditions. The amount of dye released from the cells is proportional to 
the cell number (Vichai and Kirtikara, 2006). 
3000 cells / 200 µl of medium were seeded in each well of flat 96-well plates. 48 
hours post-seeding cells were treated with Cetuximab (0, 0.01, 0.1, 1, 5, 10, 50, 100 
µg/ml) or Cetuximab (0, 10, 50 and 100 µg/ml) -/+ 10 µM CQ, depending on the 
experiment. A separate control plate that has been seeded with the same number of 
cells was fixed before treatment and considered as the “day 0” control. The control 
plate was stored at room temperature and processed along with the experimental 
plates. Cetuximab/Cetuximab along with CQ-treated cells were incubated for 87 hours 
at 37oC. Cell proliferation in autophagy-proficient and -compromised HCT-116 KRAS 
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WT and G13D cells was assessed by plating 2000 - 3000 cells / 200µl of medium in 
each well of 96-well plates and cell density measured every day for 10 days. Briefly, 
media was aspirated from the wells and cells fixed in 10% (w/v) of Trichloroacetic acid 
for 20 mins at 4oC. Cells stained in 0.4% (w/v) SRB solution for 20 mins at room 
temperature. Traces of the unbound dye were removed by washing cells 5 times with 
1% (w/v) Trichloroacetic acid and the plates air-dried overnight. The dye was 
solubilized with 10 mM Tris base (pH 10.5) for 30 mins at room temperature and 
absorbance was measured at 540 nm. 
 
2.2.3.2. Anchorage-independent cell growth Assay 
Anchorage independent cell growth assay was used to examine differences in cell 
growth of HCT-116 KRAS WT cells in autophagy-proficient and -compromised 
conditions. Briefly, 6% (w/v) low melting point agarose (16520, Invitrogen) was 
prepared in distilled H2O and mixture was autoclaved. The following day, 6% agarose 
was solubilized via microwaving until uniformly in solution and was diluted in cell 
culture medium to reach a concentration of 2%. 2% agarose was thoroughly mixed by 
pipetting and was further diluted in cell culture medium to reach a concentration of 
0.6%. The remaining 2% agarose was kept at 40oC waterbath for use in later steps of 
the procedure. 2 ml of 0.6% agarose was plated in 6-well culture dishes and let to 
polymerase at room temperature to create the agarose bottom layer. In the meantime, 
cells were trypsinised, counted (See 2.2.1.1.) and 2000 cells were transferred to tubes 
containing the appropriate volume of medium to further dilute 2% agarose in a 
concentration of 0.35%. 2 ml of 0.35% agarose containing cells was placed onto the 
0.6% agarose bottom layer. The top layer of agarose containing cells was shortly 
incubated at room temperature to enable polymerization and then placed at 37oC in a 
humidified atmosphere of 5% CO2 incubator. The next day, 2 ml of medium was added 
on top of the 0.35% agarose layer and followed regular medium changes every 3 days 
for a duration of 21 days. For visualisation of cell colonies 145 µg/ml of 
Iodonitrotetrazolium Chloride dye was added in each well and cells let to incubate for 
another 24 hours at 37oC. Images were acquired using the Image Quant LAS 4000 
machine and automatic quantification of cell colonies was conducted by using the 
ImageQuant software by following instructions of the manufacturer. 
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2.2.3.3. Cell Migration/Invasion Assay 
Cell migration and invasion assays were performed using BD FalconTM cell culture 
inserts and BD BioCoatTM MatrigelTM Invasion Chambers (BD Biosciences, 353097, 
354480), respectively. 5 x 104 cells in cell culture medium not containing FBS were 
seeded at migration or invasion chambers of a 24-well plate and allowed to migrate or 
invade for 60 hours through 8-micron pore Polyethylene Terephthalate (PET) 
membrane or 8-micron pore PET membrane coated with matrigel, respectively. As a 
chemoattractant, cell culture medium containing 10% FBS was used at the bottom of 
each well. Untreated and 10 µM CQ-treated conditions were included. Non-migrated 
and non-invaded cells were removed from the top of the PET membranes by gently 
cleaning with cotton swabs. Migrated and invaded cells fixed in 100% methanol for 2 
mins and stained with 1:5000 Hoescht/PBS for 30 mins at room temperature. Inserts 
kept in PBS at 4oC. To quantitate migratory or invasive cells, the surface of each well 
was photographed under inverted fluorescence microscope at 10X magnification. The 
total number of cells per condition was counted by using the Cell profiler program. 
Invasion was calculated by dividing the number of cells that invaded through the 
matrigel insert membrane with the number of cells that migrated through the control 
insert membranes (For schematic representation of the procedure see Figure 4. 28). 
Histograms represent the average ±Standard Deviation (SD) of three independent 
experiments. 
 
2.2.3.4. Determination of Proteasome activity 
Proteasome-Glo assay (G8660, Promega) was used for determination of 
proteasome activity of CRC cells based on the instructions of the manufacturer. 
Briefly, 6 x1 03 HCT-116 KRAS WT and G13D cells were plated in white-walled 96-well 
plates, containing 100 µl of cell culture medium and let to adhere overnight at 37oC. 
The next day cells were treated with appropriate compounds for the indicated 
timepoints based on each experiment. For proteasome activity dose response, HCT-
116 KRAS WT cells were treated with serial dilutions of the proteasome inhibitor 
MG132 (0.01, 0.05, 0.1, 0.25, 0.5, 1 and 2.5 µM) for 6 hours. For determination of 
proteasome activity between autophagy-proficient and -compromised conditions, HCT-
116 cells (5 days in the presence of DOX) were treated with 10 µM CQ or 2.5 µM 
MG132 for 6 hours to pharmacologically inhibit autophagy or proteasome activity, 
respectively. After drug treatment cells were equilibrated at room temperature for 
approximately 10 mins and the Proteasome-Glo Cell-Based Reagent was added to 
each corresponding well in a ratio 1:1. Plates were kept on dark and the content of the 
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wells were mixed by shaking at 700 rpm for 2 mins. Followed an additional incubation 
for 10 mins at room temperature and luminescence of each sample was measured in a 
Varioskan Flash plate-reader. 
 
2.2.4. Microscopy 
2.2.4.1. Immunofluorescence (IF) 
6 x 104 HCT-116 KRAS WT cells were plated on sterile glass coverslips in 24-well 
plates and let to adhere for 48 hours at 37oC. Cells were either untreated or treated 
with 10 µM CQ for 6 hours or stimulated with 50 ng/ml hrHGF for 3 hours (on ice) -/+ 
10 µM CQ. Cells were fixed with 100% methanol for 15 mins in -20oC and followed 
three washes in 1X PBS for 5 mins each. Fixed cells were blocked in blocking buffer 
(5% goat serum in PBS - 0.3%Triton-X100) for 1 hour at room temperature and were 
stained with primary antibody (Table 2. 4) overnight at 4oC. After primary antibody 
incubation, cells were washed 3 times with PBS-T to remove traces for unspecifically 
bound antibody and followed incubation in dark with secondary fluorescent-conjugated 
antibodies (Table 2. 4) at room temperature for 1 hour. Traces of secondary antibody 
were removed by washing 3 times with PBS-T. Nuclear staining was performed via 
incubating cells with Hoechst dye in a dilution 1:5000 in PBS for 30 mins. Coverslips 
were mounted on microscope slides, let to dry and stored at 4oC. Images were 
acquired using a Zeiss epifluorescence microscope or a Zeiss LSM 700 confocal 
microscope using x63 objective/1.4 numerical aperture. Z-stack images thickness was 
set to 0.4 µm and images in each experiment were acquired at same settings and 
exposure times. Post-acquisition brightness adjustments were identical between 
images of the same experiment and performed in Fiji software. Quantification of 
intracellular c-MET was performed by manually specifying the intracellular region of 
interest (ROI) of every cell in a single z-stack image using Fiji software. Plasma 
membrane staining was excluded from quantification analysis. Colocalisation analysis 
was performed via using Image J plugin JaCoP enabling manual adjustment of 
threshold of single channel z-stack images to eliminate background staining. Manders’ 
coefficients were used for evaluation of colocalising fractions. Autophagosomes/cell 
were calculated automatically by using Imaris software. A manual adjustment of 
threshold of single channel z-stack images to eliminate background staining was 
performed identically to images from the same experiment.  
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2.2.4.2. Transferrin Internalisation Assay 
Transferrin internalisation assay was employed to assess differences in 
endocytosis between autophagy-proficient and -compromised HCT-116 KRAS WT 
cells. 7 x 104 HCT-116 cells (3 days in the presence of DOX) were plated on sterile 
glass coverslips into 24-well plates containing 1 ml medium supplemented with DOX 
and let to adhere for 48 hours at 37oC. Then medium was removed and replaced with 
300 µl fresh medium not containing FBS (FBS high in transferrin) supplemented with 
0.5% BSA and DOX. Cells were incubated at 37oC in the absence of FBS for 4 hours 
and followed treatment with or without the endocytosis inhibitors Pitstop2 (10 or 20 
µM) and Dynasore (80 µM) for 100 mins at 37oC. Cells were placed on ice for 5 mins 
and Transferrin-555 was added to the corresponding conditions. Followed short 
incubation at 37oC for 15 mins to let transferrin get endocytosed and cells were fixed 
using 4% Formaldehyde for 15 mins at room temperature. Formaldehyde traces were 
removed by washing 3 times with 1X PBS and cells were permeabilised in 0.1% (w/v) 
Saponin (S4521, Sigma) in 1X PBS for 15 mins. Nuclear staining was performed via 
incubating cells with Hoechst dye in a dilution 1:5000 in PBS for 30 mins. Coverslips 
were mounted on microscope slides, let to dry and stored at 4oC. Images were 
acquired using a Zeiss LSM 700 confocal microscope as described above.  
 
2.2.5. Molecular Biology 
2.2.5.1. RNA Extraction 
2 x 106 CRC cells were harvested by trypsinisation, pelleted down and subjected to 
RNA extraction by using the RNeasy Plus Mini Kit (74134, Qiagen). The procedure 
conducted based on the instructions of the manufacturer. Briefly, cells were lysed in 
the appropriate volume of RLT Plus buffer containing 1% (v/v) β-mercaptoethanol and 
cell lysates were homogenized by vortexing for 30 secs. Homogenized lysates were 
transferred to gDNA eliminator spin columns and followed centrifugation at 10000 rpm 
for 30 secs to eliminate genomic DNA from lysates. One volume of 70% (v/v) ethanol 
was added to the flow-through to enable binding conditions of RNA and samples were 
transferred to an RNeasy mini spin column. Total RNA (longer than 200 nucleotides) 
bound to the RNeasy spin column membrane was washed twice using RPE buffer and 
RNA was eluted in 30 µl RNase-free H2O. 
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2.2.5.2. Reverse-Transcription PCR 
The high capacity cDNA reverse transcription kit (4368814, Thermo Fisher 
Scientific) was used to retrotranscribe 1 µg of RNA isolated from CRC cells based on 
the instructions of the manufacturer. Briefly, reverse-transcription PCR reaction was 
performed in a total volume of 20 µl containing RNA and 2X RT mastermix (10X RT 
buffer; 25X dNTP Mix; 10X RT random primers; multiscribe reverse transcriptase; 
RNA inhibitors and nuclease-free H2O) in a 1:1 ratio. The conditions of reverse-
transcription PCR were 25oC for 10 mins, 37oC for 120 mins and 85oC for 5 mins. 
cDNAs were stored in -20oC until further use. 
 
2.2.5.3. PCR 
PCR reactions were performed in a total volume of 50 µl, containing 5 µM of each 
forward and reverse primers (Table 2. 5), 46 µl PCR Master Mix (MgCl2 buffer; dNTPs; 
and nuclease-free H2O) with 1 Unit of FastStart Taq DNA Polymerase (Roche). The 
conditions of PCR reactions were for KRAS fragments: 35 cycles of 95oC for 1 min, 
62.1oC for 45 secs and 72oC for 45 secs with an initial denaturation cycle of 95oC for 5 
mins and a final extension cycle of 70oC for 7 mins; and PIK3CA fragments: 35 cycles 
of 95oC for 1 min, 60oC for 45 secs and 72oC for 1 min with an initial denaturation cycle 
of 95oC for 5 mins and a final extension cycle of 72oC for 10 mins. 
 
2.2.5.4. Determination of oligonucleotide concentration 
The concentration and the quality of DNA/RNA were determined by using the 
NanoDrop Spectrophotometer (Thermo Scientific). 
 
2.2.5.5. Analysis of DNA fragments by Agarose Gel Electrophoresis  
Fractionation of nucleic acids was performed by electrophoresis in 1 - 1.5% 
Agarose (A9539, Sigma) / TAE gel containing ethidium bromide. DNA was mixed with 
5X DNA Loading Buffer (See 2.1.6.) and electrophoresed at 100 V for approximately 
30 mins. DNA bands were visualised under ultraviolet light. 
 
 
Materials and Methods 
79 
2.2.5.6. Purification of DNA fragments from Agarose / TAE gel  
Purification of DNA fragments from Agarose / TAE gel was performed by GeneJet 
Gel Extraction kit (K0691, Thermo Scientific) following the instructions of the 
manufacturer. DNA fragments were visualised in 1.5% Agarose / TAE gel using UV 
Transilluminator (365 nm). The desired DNA fragment was excised from the gel with a 
clean scalpel and an equal volume of Binding Buffer was added to the gel slice. Gel 
slices were solubilised by heating at 60oC for 10 mins and samples were transferred to 
GeneJet purification columns. GeneJet column-bound DNA was washed twice with 
Wash Buffer and DNA fragments were eluted in 50 µl of nuclease-free H20 with 
centrifugation at 13200 rpm for 1 min.  
 
2.2.5.7. DNA Sequence Analysis 
Sequencing of plasmid DNA (insert) or PCR amplified fragments was performed in 
the UCL CI sequencing facility by using the appropriate primers. Sequencing results 
were visualised using Finch TV software and were further analysed by using the 
EMBOSS Pairwise Alignment Algorithm from the EMBL-EBI Database 
(http://www.ebi.ac.uk/Tools/emboss/align/). 
 
2.2.5.8. Cloning of shRNA oligos to pLKO-Tet-On plasmid 
To generate shRNA-expressing plasmids, single-stranded oligos encoding the 
desired shRNA sequence (Table 2. 6) were firstly annealed and then cloned into the 
inducible lentiviral shRNA pLKO-Tet-On vector. 
 
Annealing of single-stranded oligos 
For the annealing of single-stranded oligos, 11.25 µl of each forward and reverse 
oligo (100 µM) were mixed with 2.5 µl of 10X annealing buffer (See 2.1.6.) and a PCR 
program was used to perform the reaction. The conditions of the PCR program used 
are: 10 mins at 98oC, 5 mins at 95oC, 5 mins at 90oC, 5 mins at 88oC, 5 mins at 85oC, 
5 mins at 80oC, 5 mins at 78oC, 5 mins at 75oC, 5 mins at 70oC, 5 mins at 68oC, 5 mins 
at 65oC, 5 mins at 60oC, 5 mins at 58oC, 5 mins at 55oC, 5 mins at 50oC, 5 mins at 
45oC, 5 mins at 40oC, 10 mins at 37oC and cooling down to 4oC. The annealed oligo 
mixture was diluted in 0.5X of annealing buffer in a ratio 1:400 and ligated to the 
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cloning sites of pLKO-Tet-On vector created by AgeI/EcoRI digestion. Transformation 
into Stbl3 E.coli cells (See 2.2.5.9.) of the different ligation reactions followed and 
colonies were grown to purify plasmid DNA (See 2.2.5.10.). Verification of the inserted 
oligos was conducted by sequencing (See 2.2.5.7.). 
 
DNA Restriction Digestion 
pLKO-Tet-On vector was digested by using the restriction endonucleases Age I 
(Promega) and EcoRI (Roche) in Multicore buffer (Promega). The reaction was 
incubated at 37oC for 11/2 hours and the restriction digestion products were visualised 
on 1% Agarose / TAE gel (See 2.2.5.6.). Followed purification of the digested pLKO-
Tet-On vector from Agarose / TAE gel 
 
Ligation of shRNA oligos to pLKO-Tet-On vector 
Ligation reaction was performed in a total volume of 10 µl, containing double-
stranded oligos, the digested pLKO-Tet-On vector, 2X Rapid Ligase buffer (C671B, 
Promega) and T4 DNA ligase (M180B, Promega). Ligation mixture was incubated at 
room temperature for 15 mins and transformation of ligated products in Stbl3 cells 
followed. 
 
2.2.5.9. Transformation of plasmid DNA into High Efficiency Competent E.coli 
cells 
50 µl of chemically competent E.coli cells - DH5α (Invitrogen) or Stbl3 (for pLKO-
Tet-On vector transformation; Invitrogen) were thawed on ice and transformed with 
approximately 10 - 50 ng of plasmid DNA by incubating for 30 mins on ice. DH5α cells 
were heat shocked for 20 secs at 42oC, were placed again on ice for 2 mins and 950 
µl of SOC medium was added. Stbl3 cells were heat shocked for 45 secs at 42oC, 
were placed again on ice for 2 mins and 250 µl of SOC medium was added.  Bacteria 
incubated at 37oC with shaking at 225 rpm for 1 hour and bacteria suspensions were 
spread to Luria Broth (LB)-Agar plates containing 100 µg/ml ampicillin (A9518, Sigma). 
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2.2.5.10. Purification of plasmid DNA  
Plasmid DNA was purified using the JetStar 2.0 Plasmid Purification Kit (Genomed) 
according to the instructions of the manufacturer. For small- and large-scale 
purification of plasmid DNA, 1.5 ml and 200 ml of E.coli cells were cultured overnight 
in LB medium containing 100 µg/ml ampicillin, respectively. Overnight-cultured 
bacteria harvested by centrifugation at 12000 g for 3 mins and then lysed in Lysis 
buffer E2. The lysate was then transferred to the JetStar column in order the plasmid 
DNA to be captured. The column-bound DNA was then washed in wash buffer E5 and 
eluted in Elution buffer E6. Eluted plasmid DNA was precipitated using isopropanol 
and was washed in 70% ethanol at 4oC. Precipitated DNA was air-dried for 10 mins 
and resuspended in appropriate volume of nuclease-free H2O. Purified plasmid DNA 
was long-term sored in -20oC. 
 
2.2.6. Statistical analysis 
Means of at least three independent experiments unless otherwise stated were 
statistically analysed using GraphPad Prism software. Determination of statistical 
significance in single-comparisons was performed using two-tailed unpaired Student’s 
t-test and in multiple means comparisons using one-way or two-way ANOVA followed 
by the Bonferroni post-test. 
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3. EGFR targeted therapy and autophagy in CRC 
3.1. Background 
EGFR targeted therapy is currently a promising approach for the treatment of many 
solid tumours including metastatic CRC. However, patients’ response to EGFR 
targeted treatment is heterogeneous with limited potential mainly due to the presence 
of primary and acquired resistance mechanisms (Bertotti and Sassi, 2015). Autophagy 
has been previously suggested to play a pro-survival role upon targeted therapy and 
autophagy-inhibition combinational approaches have been found to potentiate cancer 
treatment (Bellodi et al., 2009, Ravikumar et al., 2010, Amaravadi et al., 2011, 
Calabretta and Salomoni, 2011, Ma et al., 2014). The activation of EGFR has been 
shown to inhibit either directly or indirectly autophagy induction and in turn EGFR 
inhibition has been shown to induce autophagy (discussed in 1.1.2.2., page 30). 
However, the specific role of autophagy upon EGFR targeted therapy remains 
controversial. On the one hand, EGFR inhibition-mediated autophagy plays a 
cytoprotective role for the survival of cancer cells and inhibition of autophagy 
potentiates cancer treatment (Han et al., 2011, Dragowska et al., 2013, Li et al., 
2013b, Zou et al., 2013, Tang et al., 2015). On the other hand, autophagy induction 
upon EGFR targeted therapy may potentiate treatment and inhibition of autophagy in 
this context may lead to refractory response to cancer treatment (Gorzalczany et al., 
2011, Wei et al., 2013). Hitherto, our understanding on the role of autophagy upon 
EGFR targeted therapy in CRC is limited. 
This chapter investigates the effect of EGFR targeted therapy on autophagy 
induction and aims to unravel the role of autophagy in EGFR targeted therapy 
response of CRC cells.  
 
3.2. Results 
3.2.1. In vitro model system to study autophagy in CRC 
One of the main biomarkers used to predict EGFR targeted therapy response in 
CRC is KRAS status (Lièvre et al., 2006, Benvenuti et al., 2007, De Roock et al., 2011, 
Misale et al., 2014). CRC patients are screened for the presence of activating KRAS 
mutations and only KRAS WT patients are further refereed for EGFR targeted therapy 
with the monoclonal anti-EGFR antibody, Cetuximab. Previous studies have shown 
that activating mutations of the RAS oncogene results in upregulated basal autophagy, 
a phenomenon called “autophagy addiction”. Autophagy addiction is considered to 
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potentiate tumour cell survival in starvation and tumourigenesis (Guo et al., 2011). To 
examine the role of KRAS activation in response to Cetuximab treatment and 
investigate whether KRAS-mediated refractory response is driven by autophagy 
addiction, several isogenic KRAS WT and mutant CRC cell lines were included in our 
study. Table 3.1 summarizes the KRAS mutational status of CRC cell lines utilised in 
this work with information regarding their origin and technology used for their 
generation. To further confirm KRAS mutational status in all CRC cell lines, we 
designed sequencing primers specific for the identification of KRAS point mutations in 
codons 12 and 13 and all CRC cell lines were screened (Figure 3. 1). It was confirmed 
that HCT-116 and DLD-1 isogenic cell lines were homozygous for either KRAS WT or 
KRAS G13D mutation. SW48 isogenic cells were either homozygous for KRAS WT or 
heterozygous for KRAS G12D mutation. Finally, CaCo2 cells were found to be 
heterozygous for KRAS G12S point mutation and DiFi cells were homozygous for 
KRAS WT status. 
 
Table 3. 1: KRAS mutational status of parental and KRAS isogenic CRC cell lines utilised 
in this study. Information regarding the technology used to generate KRAS isogenic cell lines 
as well as their provider is shown. G= Glycine, D= Aspartic acid and S= Serine. 
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Figure 3. 1: Examination of KRAS codon 12 and 13 mutational status. The presence of 
KRAS activating mutations was confirmed in HCT-116, DLD-1 and SW48 KRAS mutant 
isogenic cell lines. DiFi cells were found not to harbour KRAS activating mutations and CaCo2 
cells were found heterozygous for KRAS G12S activating mutation. D= Aspartic acid, S= 
Serine, Green/A= Adenine, Blue/C= Cytosine, Black/G= Guanine and Red/T=Thymine. KRAS 
codon 12 and 13 mutation screening experiment was conducted once in each cell line tested. 
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An in vitro pharmacological system for modulation of autophagy was required to 
examine the role of autophagy upon Cetuximab treatment. For pharmacological 
modulation of autophagy the anti-malaria and anti-rheumatoid drug Chloroquine (CQ) 
was used. CQ is known to inhibit vesicle acidification, including lysosomes, and is 
believed to block the last step of the autophagic process by inhibiting the clearance of 
autophagic vesicles into lysosomes (Solomon and Lee, 2009, Kimmelman, 2011). Due 
to its mode of action, the decreased number of side effects and its low price, an 
increasing number of clinical trials are using CQ in combination with conventional 
cancer therapy (Solomon and Lee, 2009, Kimura et al., 2013). 
Moreover, CQ is extensively used not only as an effective autophagy inhibitor but 
also to help monitoring autophagic flux upon normal and autophagy inducing or 
blocking conditions in vitro (Figure 3. 2.a) (Kimmelman, 2011, Klionsky et al., 2012). 
CQ inhibits the fusion between autophagosomes and lysosomes, consequently 
resulting in accumulation of autophagosomes. The most important marker that is 
widely used for measuring autophagy is the LC3B protein. LC3 is synthesised as a 
proactive form and post-translational modifications give rise to two different forms: 
LC3-I (Carboxy-terminally cleaved) and LC3-II (lipidated LC3-I). LC3-II protein 
migrates faster that LC3-I in SDS-PAGE enabling the discrimination between the two 
forms by western blotting. As LC3-II is the only LC3 form that is present in both inner- 
and outer- autophagosome membranes, its expression level is used to measure 
autophagy. Measuring only LC3-II levels is an approach that does not take into 
account the dynamic nature of autophagy and could easily lead to misinterpretation of 
results. True determination of autophagic activity is obtained only by measuring the 
autophagic flux by using lysosomotropic compounds such as CQ. Since CQ blocks 
autophagosome degradation, an increase in LC3-II/LC3-I ratio in CQ-treated cells 
compared to untreated cells is considered a measure of autophagic flux (Kimmelman, 
2011, Klionsky et al., 2012). To determine differences in autophagic flux upon any kind 
of treatment in this study the CQ approach was used. Therefore, LC3-II/LC3-I ratio 
was compared between treated+CQ and untreated+CQ cells (Figure 3. 2.b).  
10 µM CQ was used to monitor autophagic flux and assess the role of autophagy 
inhibition in CRC cells. 
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Figure 3. 2: Usage of Chloroquine in studying autophagy. a Chloroquine is used as an 
autophagic inhibitor since it blocks the degradation of autophagosomes by interfering with 
lysosomal acidification; b Chroroquine is used to monitor autophagic flux. 
 
3.2.2. Activation of EGFR and its downstream signal effectors is cell-type 
specific 
As a crucial first step preceding Cetuximab treatment experiments, the panel of 
CRC cell lines was screened for activation levels of EGFR and the EGFR downstream 
pathways PI3K and MAPK/ERK. Subsequently, KRAS isogenic cell lines were used in 
an attempt to unravel any differences in EGFR and its downstream effectors pathways 
regulated specifically by KRAS expression. 
To address these, all CRC cell lines were cultured for 48 hours until they reached 
approximately 70% confluence. The levels of EGFR phosphorylation at tyrosine 1068 
residue, as well as the levels of ERK 1/2 and AKT phosphorylation, were analysed in 
total cell lysates using western blotting. Measuring the phosphorylation levels of EGFR 
protein at specific tyrosine residues is a commonly used approach to detect EGFR 
activation/inactivation. Specifically, tyrosine 1068 residue of EGFR has been found to 
be responsible for Grb2 adaptor protein binding and is therefore highly implicated to 
MAPK/ERK downstream pathway activation (Rojas et al., 1996). ERK 1/2 and AKT 
proteins constitute the last effectors of the MAPK/ERK and PI3K pathways, 
respectively (Engelman et al., 2006, McKay and Morrison, 2007). Consequently, 
measurement of their phosphorylation levels is used to detect activation of the 
corresponding pathways, downstream of EGFR. 
It was found that EGFR is highly activated in DiFi cells compared to all other CRC 
cell lines examined, followed by EGFR activation levels of SW48 and DLD-1 KRAS 
WT cells. In these two cell lines it was observed that EGFR was more active in KRAS 
WT cells compared to their mutant isogenic versions. HCT-116 cells showed the 
lowest EGFR activation compared to all other cell lines. Interestingly in these cells the 
presence of KRAS activating mutation accelerated EGFR activation compared to their 
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WT isogenic version (Figure 3. 3). Consequently, EGFR activation is cell-type specific 
and no correlation between EGFR activation and KRAS mutational status was found. 
Discrepancies in MAPK/ERK pathway regulation were observed between the KRAS 
isogenic cell lines. As expected, higher ERK activation levels were observed in KRAS 
G13D HCT-116 cells compared to their KRAS WT isogenic version. No difference in 
ERK activation levels was found between KRAS WT and G12D SW48 cells and, 
surprisingly, lower ERK activation was found in KRAS G13D DLD-1 cells compared to 
their WT isogenic version (Figure 3. 3).  
Regarding PI3K pathway regulation, it was found that AKT activation levels were 
higher at KRAS WT HCT-116 and SW48 cells compared to their KRAS mutated 
isogenic versions whereas the opposite effect was observed between the KRAS 
isogenic versions of DLD-1 cells (Figure 3. 3). 
In conclusion, EGFR and its downstream effector pathways, PI3K and MAPK/ERK 
are regulated in a cell-type specific manner. 
 
Figure 3. 3: Screening of CRC cell lines for EGFR, MAPK/ERK and PI3K activation levels. 
EGFR and its downstream effector pathways MAPK/ERK and PI3K are regulated in a cell-type 
specific manner. Phosphorylation levels of EGFR, ERK and AKT depict EGFR, MAPK/ERK and 
PI3K activation, respectively. Calnexin used as a loading control. p=phosphorylated. The 
experiment was performed once. 
 
3.2.3. CRC cells respond to Cetuximab treatment in a cell-type specific manner – 
Activation of the KRAS oncogene is implicated in Cetuximab resistance 
In order to identify the response of CRC cell lines to Cetuximab treatment, five 
different CRC cell lines, HCT-116, CaCo2, DLD-1, SW48 and DiFi were screened for 
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Cetuximab sensitivity using the SRB assay. Moreover, to investigate any possible 
implication of the KRAS mutational status in Cetuximab resistance three KRAS 
isogenic versions carrying activating mutations of the gene: HCT-116, DLD-1 KRAS 
G13D and SW48 KRAS G12D were also screened by SRB assay. Cetuximab 
response was examined after 87 hours of treatment and percentage (%) of cell growth 
for each condition was calculated by taking into account untreated controls and “day 0” 
of treatment controls for each cell line (discussed in 2.2.3.1). 
The five cell lines examined were grouped into four different categories based on 
their sensitivity to Cetuximab treatment when compared to their untreated controls. It 
was found that HCT-116 KRAS WT and CaCo2 were the most resistant cell lines since 
no significant downregulation in their cell growth was observed compared to the 
untreated control (Figure 3. 4.a and b). SW48 KRAS WT cells showed intermediate 
resistance to Cetuximab treatment. A significant cell growth downregulation was 
observed in the majority of Cetuximab concentrations examined for this cell line but 
not beyond 50% (Figure 3. 4.c). DLD-1 KRAS WT cells were classified as Cetuximab 
sensitive due to a significant reduction in cell growth of 70% and beyond (Figure 3. 
4.d). Finally, DiFi cells were classified to the Cetuximab high sensitivity group since not 
only a high percentage of downregulation in cell growth was observed but also a lower 
cell number compared to “day 0” control (Figure 3. 4.e). This observation could 
indicate that high concentrations of Cetuximab may induce cell death in this specific 
cell line. 
As far as the implication of the KRAS mutational status in Cetuximab resistance is 
concerned, it was found that all isogenic KRAS mutated cell lines were not responsive 
to Cetuximab treatment when compared to their WT isogenic versions. Specifically, 
HCT-116 KRAS G13D cells did not show any difference in cell growth compared to 
their WT isogenic version since the aforementioned cell line did not respond to 
Cetuximab treatment (Figure 3. 4.a). SW48 KRAS G12D cells were more resistant 
compared to their isogenic WT version with approximately 28% higher cell growth, 
although this was not statistically significant (Figure 3. 4.c). Finally, DLD-1 KRAS 
G13D cells showed statistically significant difference in Cetuximab treatment response 
compared to their isogenic WT version since only 37% of cell growth inhibition 
observed in the higher Cetuximab concentration (Figure 3. 4.d). Of note, no KRAS WT 
and mutated isogenic cell lines were available for CaCo2 and DiFi cells, respectively. 
In summary, response to Cetuximab treatment is cell-type specific and activating 
KRAS mutations may be implicated in Cetuximab resistance. 
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Figure 3. 4: Differential sensitivity of CRC cell lines to Cetuximab treatment – Implication 
of the KRAS mutation in Cetuximab resistance. a HCT-116 cells belong to the resistant 
group. No difference between KRAS WT and mutant cells to Cetuximab sensitivity; b CaCo2 
cells are resistant to Cetuximab treatment; c SW48 cells belong to the intermediate resistance 
group. KRAS WT cells are more sensitive to Cetuximab treatment compared to mutant cells; d 
DLD-1 cells classified to the sensitive group. Statistically significant difference between KRAS 
WT and mutant cells in response to Cetuximab; e DiFi cells classified to the high sensitivity 
group. CRC cells were treated with 0, 0.01, 0.1, 1, 5, 10, 50 and 100 µg/ml Cetuximab for 87 
hours. Bar plots represent % of control cell growth assessed by SRB assay. Error bars 
represent standard deviation of 4 independent SRB experiments. One-way ANOVA (CaCo2 
and DiFi cells) or two-way ANOVA (HCT-116, DLD-1 and SW48 KRAS WT and mutant cells) 
statistical analysis followed by the Bonferroni post-test was used. *= p<0.05, **= p<0.01 and 
***= p<0.001. 
 
3.2.4. CRC cells are competent for autophagy induction 
Prior to Cetuximab experiments, examination of autophagy-induction competence 
of CRC cells was important. To address this, the autophagy inducing stressor PI103, 
which inhibits both mTOR and PI3K, was used. Isogenic KRAS mutant cell lines were 
included in this examination in order to test whether activation of the KRAS oncogene 
affects autophagy induction levels under basal and autophagy-stimulated conditions.  
All examined CRC cell lines were cultured either in the presence of 1 µM of PI103 
combined or non-combined with CQ for 6 hours in order to monitor autophagic flux. 
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Based on the rate of LC3-I to LC3-II conversion, it was observed that all DLD-1, HCT-
116, SW48 and CaCo2 CRC cell lines examined were capable of autophagy induction 
upon simultaneous inhibition of PI3K and mTOR, when untreated and PI103 treated or 
untreated+CQ and PI103+CQ conditions were compared (Figure 3. 5). When basal 
autophagy levels between KRAS WT and mutant cells were compared, it was 
observed that only DLD-1 and to a lower extent HCT-116 KRAS mutant cells had 
higher levels of basal autophagy compared to their WT isogenic versions (Figure 3. 
5.a and b). Finally, KRAS activating mutation resulted in accelerated PI103-mediated 
autophagy induction only in SW48 cells compared to WT. In particular, SW48 KRAS 
G12D cells were found to induce higher levels of autophagy (approximately 1 fold 
difference) compared to their WT cells upon PI103 stimulation (Figure 3. 5.a, b and c) 
 
Figure 3. 5: Ability of CRC cell lines to induce autophagy upon PI103 treatment. 
Autophagy induction upon PI103 in a DLD-1; b HCT-116; c SW48 KRAS WT and mutant 
isogenic cell lines and; d CaCo2 cells. 1 µM PI103 used for induction of autophagy 
experiments. 10 µM CQ used to monitor autophagic flux. Protein expression levels were 
examined by western blotting. Beta-actin and calnexin used as loading controls. Bar plots 
represent densitometric analysis of LC3-II/LC3-I levels normalised to loading control. Western 
blotting images are representative of two independent experiments. 
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3.2.5. Cetuximab treatment only induces autophagy in DiFi cells  
After confirming that CRC cells were capable of inducing autophagy upon PI3K and 
mTOR inhibition it was investigated whether Cetuximab targeted therapy induces 
autophagy and more specifically whether autophagy inhibition in this context sensitises 
CRC cells to therapy. Since Cetuximab blocks EGFR activation (Li et al., 2005) it was 
hypothesised that it would induce autophagy by resembling growth factor deprivation 
autophagic stimulus. Another hypothesis examined was whether KRAS activation 
could affect levels of Cetuximab-induced autophagy and whether such an effect would 
affect Cetuximab resistance; KRAS activation plays an important role in Cetuximab 
primary and acquired resistance (Brand et al., 2011, De Roock et al., 2011, Misale et 
al., 2012).  
All cell lines examined were treated with two different Cetuximab concentrations (50 
and 100 µg/ml) with and without CQ for 24 hours and LC3B levels were detected by 
western blotting. Only DiFi cells were found to induce moderate autophagy levels upon 
Cetuximab treatment at both concentrations examined (Figure 3. 6.e). DLD-1, HCT-
116, SW48 both KRAS WT and mutant cells as well as CaCo2 cells failed to induce 
autophagy by Cetuximab treatment at any concentration examined (Figure 3. 6.a - d). 
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Figure 3. 6: Examination of autophagy induction upon Cetuximab treatment. Cetuximab 
did not induce autophagy in a DLD-1; b HCT-116; c SW48 KRAS WT and mutant isogenic cell 
lines and; d CaCo2 cells. Autophagy was induced in e DiFi cells. 1 depicts western blotting 
analysis of LC3 protein levels. Beta-actin or calnexin used as loading controls. 2 Bar plots 
represent densitometric analysis of LC3-II/LC3-I levels normalised to actin or calnexin. Cells 
treated with 50 and 100 µg/ml Cetuximab +/- 10 µM CQ for 24 hours. The experiment was 
performed once in each CRC cell line. 
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3.2.6. CQ fails to sensitise CRC cells to Cetuximab treatment 
Based on the data shown in 3.2.5, most CRC cell lines do not induce autophagy 
upon Cetuximab treatment, suggesting that treatment with the lysosomotropic agent 
CQ would not sensitise CRC cells to Cetuximab with the potential exception of DiFi 
cells. To test this, all examined CRC cell lines were cultured in the presence of 
Cetuximab with or without 10 µM CQ for 87 hours and results were analysed using 
SRB assay.  
Regarding HCT-116, SW48 and DLD-1 KRAS WT cell lines and their mutant 
isogenic versions, it was found that inhibition of autophagy via CQ does not potentiate 
Cetuximab treatment in any concentration examined (10, 50 and 100 µg/ml). In line 
with the aforementioned cell lines, CQ addition to CaCo2 cells did not have any effect 
in Cetuximab treatment response regardless of the concentrations examined (10, 50 
and 100 µg/ml) (Figure 3. 7.a-d). Autophagy inhibition by CQ was found to marginally 
potentiate Cetuximab treatment in DiFi cells (Figure 3. 7.e). As previously described, 
DiFi cells were classified to the high sensitivity to Cetuximab response group and high 
concentrations of Cetuximab in these cells may induce cell death (Figure 3. 4.e). 
Herein SRB experiment in DiFi cells was performed using lower Cetuximab 
concentrations (0.01, 0.05 and 0.1 µg/ml) compared to all other CRC cells. 
Interestingly, CQ treatment alone provoked a statistically significant increase in the 
percentage of cell growth in SW48 KRAS G12D as opposed to the effect observed in 
DiFi cells (Figure 3. 7.c and e). CQ treatment alone did not have any effect on cell 
growth in all other CRC cell lines examined (Figure 3. 7.a, b and d). 
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Figure 3. 7: Sensitivity of CRC cell lines to autophagy inhibition in combination with 
Cetuximab treatment. Autophagy inhibition by CQ does not potentiate Cetuximab treatment 
response in a HCT-116; b CaCo2; c SW48 and d DLD-1 cell lines. Autophagy inhibition by CQ 
potentiates Cetuximab treatment in e DiFi cells. 10, 50 and 100 µg/ml Cetuximal (a-d 
conditions) or 0.01, 0.05 and 0.1 µg/ml Cetuximab (e condition) +/- 10 µM CQ for 87 hours 
were used. Bar plots represent percentage (%) of control cell growth assessed by SRB assay. 
Error bars represent standard deviation of 4 independent SRB experiments. One-way ANOVA 
(CaCo2 and DiFi cells) or two-way ANOVA (HCT-116, DLD-1 and SW48 KRAS WT and mutant 
cells) statistical analysis followed by the Bonferroni post-test was used. **=p<0.01. 
 
3.2.7. Cetuximab has variable effects on EGFR phosphorylation across different 
CRC cell lines 
Amongst the five different CRC cell lines examined for autophagy induction upon 
Cetuximab treatment, it was observed that only DiFi cells were able to induce 
autophagy. Autophagy induction in DiFi cells was shown to have a marginal cyto-
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protective role. The lack of consistent response to Cetuximab treatment, prompted us 
to investigate whether Cetuximab was equally potent at inhibiting EGFR 
phosphorylation across the different CRC cell lines. Cells were cultured in the 
presence of 50 and 100 µg/ml of Cetuximab for 24 hours with or without 10 µM CQ. It 
was found that both KRAS isogenic versions of DLD-1 cells, CaCo2 and DiFi cells had 
decreased phosphorylation levels of EGFR upon Cetuximab treatment (Figure 3. 8.a, 
d and e). For HCT-116 cells, no difference in EGFR phosphorylation level was 
observed upon Cetuximab treatment (Figure 3. 8.b) and SW48 cells showed an 
increase in EGFR phosphorylation levels upon Cetuximab treatment (Figure 3. 8.c). 
Interestingly, CQ treatment alone downregulated EGFR activation levels only in DiFi 
cells (Figure 3. 8.e). 
Collectively, these data show that the response to Cetuximab treatment is variable 
across the CRC cell lines and that in DiFi cells decreased EGFR phosphorylation 
correlates with autophagy induction. 
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Figure 3. 8: EGFR activation levels upon Cetuximab treatment in a DLD-1; b HCT-116; c 
SW48 KRAS WT and mutant isogenic versions; d CaCo2 and e DiFi cells. Phosphorylation 
levels of EGFR depict EGFR activation. 50 and 100 µg/ml Cetuximab +/- 10 µM CQ for 24 
hours were used. 1 µM PI103 used as autophagy induction positive control and EGF as EGFR 
activation positive control. Calnexin used as western blotting positive control. G= gap and p= 
phosphorylation. The experiment was performed once in each CRC cell line. 
 
3.2.8. AKT phosphorylation upon Cetuximab treatment inversely correlates with 
autophagy induction and is affected by CQ treatment 
The examination of EGFR activation levels alone cannot explain the differential 
response of CRC cell lines to Cetuximab treatment and their differential autophagy 
induction. To shed light on the mechanism controlling autophagy induction in response 
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to Cetuximab treatment, it was essential to examine the activation status of the 
PI3K/AKT pathway, which is a key downstream effector of EGFR and a known master 
regulator of autophagy induction (previously discussed in 1.1.2.2.).  
To this end, CRC cell lines were cultured for 24 hours in the presence of 50 and 
100 µg/ml Cetuximab with or without 10 µM CQ and the phosphorylation of AKT was 
analysed by western blotting. It was observed that the phosphorylation of S473 
residue of AKT was not downregulated upon Cetuximab treatment in HCT-116, DLD-1 
and SW48 KRAS WT and mutant cells as well as in CaCo2 cells (Figure 3. 9.a-d). 
Specifically, for DLD-1 and HCT-116 cells it was found that AKT phosphorylation 
levels were increased upon treatment. In contrast, AKT phosphorylation was reduced 
in DiFi cells upon Cetuximab treatment (Figure 3. 9.e). An interesting observation was 
that Cetuximab and CQ combinational treatment resulted in downregulation of AKT 
phosphorylation levels in all CRC cell lines examined (Figure 3. 9.a-e). In addition, 
HCT-116 and SW48 KRAS WT, CaCo2 and DiFi cells showed a downregulation of 
AKT phosphorylation levels following CQ treatment alone (Figure 3. 9.b-e). This 
observation will be further discussed in 4.2.2. 
Collectively, AKT phosphorylation downregulation upon Cetuximab treatment 
correlates with autophagy induction following EGFR inhibition. 
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Figure 3. 9: PI3K activation levels upon Cetuximab treatment in a DLD-1; b HCT-116; c 
SW48 KRAS WT and mutant isogenic versions; d CaCo2 and e DiFi cells. Phosphorylation 
levels of AKT depict PI3K activation. 50 and 100 µg/ml Cetuximab +/- 10 µM CQ for 24 hours 
were used. 1 µM PI103 used as autophagy induction positive control and EGF as EGFR 
activation positive control. Calnexin used as western blotting positive control. G= gap, p= 
phosphorylation and * Cetuximab heavy chain. The experiment was performed once in each 
CRC cell line. 
 
3.2.9. Downregulation of MAPK/ERK phosphorylation correlates with the growth 
suppressive response to Cetuximab treatment 
Another downstream effector of EGFR pathway and known regulator of autophagy 
induction is MAPK/ERK pathway (previously discussed in 1.1.2.2.). In order to 
examine the importance of MAPK/ERK pathway in Cetuximab response and induction 
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of autophagy upon Cetuximab treatment, all CRC cells were cultured in 50 µg/ml or 
100 µg/ml Cetuximab in the presence or absence of 10 µM CQ for 24 hours. ERK 1/2 
protein activation levels, a downstream regulator of MAPK/ERK pathway, were 
analysed by western blotting. Downregulation of the activation levels of ERK protein, 
reflected by downregulation of its phosphorylation levels, was observed in all classified 
Cetuximab-responsive cell lines (Figure 3. 4.c-e) with the exception of the Cetuximab-
resistant CaCo2 cell line (Figure 3. 4.b), which exhibited a marginal decrease in pERK 
levels (Figure 3. 10.d). Specifically, DiFi, DLD-1 and SW48 KRAS WT Cetuximab-
responsive cells showed a decrease in ERK activation levels with DiFi cells having 
abolished pERK levels upon Cetuximab treatment (Figure 3. 10.a, c and e). As 
expected, KRAS mutated isogenic versions of DLD-1 and SW48 cells did not show 
any decrease in ERK activation levels due to the presence of the KRAS activating 
mutations G13D and G12D, respectively (Figure 3.10.a and c). HCT-116 was found to 
be the only cell line that MAPK/ERK pathway was not downregulated by Cetuximab, 
regardless of its KRAS mutational status. An increase in ERK activation levels was 
observed in both HCT-116 KRAS WT and G13D cells (Figure 3.10.b). 
In contrast to the reduced pAKT levels observed upon Cetuximab and CQ 
combinational treatment in all CRC cell lines tested, no difference in pERK levels was 
found under the same conditions (Figure 3. 10). Interestingly, CQ treatment alone was 
found to upregulate pERK levels in both DLD-1 KRAS WT and G13D cells, as well as 
in SW48 KRAS WT and DiFi cells (Figure 3. 10.a, c and e). Finally, CQ treatment 
alone did not alter pERK levels in HCT-116 and CaCo2 cells (Figure 3. 10.b and d). 
Collectively, MAPK/ERK pathway activation reduction is correlated with the growth 
suppressive response to Cetuximab treatment. No correlation could be made between 
MAPK/ERK activation levels and autophagy induction following EGFR inhibition. 
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Figure 3. 10: MAPK/ERK activation levels upon Cetuximab treatment in a DLD-1; b HCT-
116; c SW48 KRAS WT and mutant isogenic versions; d CaCo2 and e DiFi cells. 
Phosphorylation levels of ERK protein depict MAPK/ERK activation. 50 and 100 µg/ml 
Cetuximab +/- 10 µM CQ for 24 hours were used. 1 µM PI103 used as autophagy induction 
positive control and EGF as EGFR activation positive control. Calnexin used as western 
blotting positive control. G= gap and p= phosphorylation. The experiment was performed once 
in each CRC cell line. 
 
3.2.10. EGFR downregulation and treatment with the EGFR tyrosine kinase 
inhibitor Gefitinib recapitulates the effect of Cetuximab on downstream 
signalling pathways 
To further confirm the reliability of the already observed Cetuximab effects on 
EGFR pathway and downstream effectors, PI3K and MAPK/ERK, as well as 
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autophagy induction response upon EGFR inhibition, two different approaches were 
used. Firstly, EGFR protein expression was downregulated by siRNA and secondly 
EGFR activation was downregulated using an EGFR tyrosine kinase inhibitor, named 
Gefitinib. Western blotting was used to assess EGFR, AKT and ERK1/2 activation, 
based on the level of their phosphorylation.  
For the EGFR siRNA approach, one of the most resistant in Cetuximab treatment 
cell line; HCT-116, and the sensitive cell line; DLD-1, as well as their isogenic KRAS 
G13D versions were examined after 48 and/or 72 hours of EGFR downregulation by 
using 25 nM and/or 50 nM of scramble and EGFR siRNAs. In both HCT-116 and DLD-
1 cells EGFR levels were abolished by EGFR siRNA (Figure 3. 11.a.1 and 2). In line 
with Cetuximab results it was observed that both PI3K and MAPK/ERK pathways were 
not affected upon EGFR downregulation in both HCT-116 KRAS WT and G13D cells 
(Figure 3. 11.b.1 and c.1). Again in accordance with Cetuximab results, the 
MAPK/ERK pathway was found to be downregulated only in DLD-1 KRAS WT cells 
and remained stable in their isogenic cell line harbouring the activating KRAS G13D 
mutation (Figure 3. 11.b.2). The PI3K pathway remained stable upon EGFR 
downregulation in DLD-1 KRAS G13D cells and slightly decreased in DLD-1 KRAS 
WT cells (Figure 3. 11.c.2). 
For the Gefitinib approach, HCT-116 KRAS WT and G13D isogenic cell lines were 
cultured in the presence of 1 µM Gefitinib for 6 hours with or without 10 µM CQ. In line 
with Cetuximab results, EGFR activation levels remained stable upon Gefitinib 
treatment in HCT-116 KRAS G13D cells. In contrast to Cetuximab and KRAS G13D 
Gefitinib results, a small decrease in EGFR activation levels was observed upon 
Gefitinib treatment in HCT-116 KRAS WT cells (Figure 3. 11.d). Similarly to Cetuximab 
and EGFR siRNA observations, Gefitinib experiment confirmed that MAPK/ERK and 
PI3K pathways were not affected upon EGFR activation inhibition in HCT-116 cells 
since both pERK and pAKT levels remained stable upon Gefitinib treatment (Figure 3. 
11.e and f). Opposed to Cetuximab results (Figure 3. 10.b), combinational treatment of 
Gefitinib with CQ as well as CQ treatment alone showed a decrease in pERK levels 
compared to untreated controls in both HCT-116 KRAS WT and G13D cells (Figure 3. 
11.e). In agreement with Cetuximab results (Figure 3. 9.b), Gefitinib and CQ 
combinational treatment along with CQ alone treatment resulted in PI3K pathway 
downregulated signalling, as depicted by reduced pAKT levels, in both KRAS isogenic 
versions of HCT-116 cells (Figure 3. 11.f). 
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Figure 3. 11: EGFR downregulation and Gefitinib experiments. Total EGFR expression 
upon EGFR siRNA in a.1 HCT-116 and a.2 DLD-1 KRAS WT and G13D isogenic cell lines. 
MAPK/ERK pathway activation examination upon EGFR siRNA in b.1 HCT-116 and b.2 DLD-1 
KRAS isogenic cell lines. PI3K pathway activation examination upon EGFR siRNA in c.1 HCT-
116 and c.2 DLD-1 KRAS WT and G13D isogenic cell lines. Examination of d EGFR activation; 
e MAPK/ERK pathway and f PI3K pathway activation in HCT-116 KRAS WT and G13D 
isogenic cell lines upon Gefitinib +/- 10 µM CQ treatment. 25 and/or 50 nM of scramble and 
EGFR siRNAs were used and assessed using western blotting after 48 or 72 hours. Cells were 
treated with 1 µM of Gefitinib +/- 10 µM CQ for 6 hours. Phosphorylation levels of EGFR, ERK 
and AKT depict activation of EGFR, MAPK/ERK and PI3K pathways, respectively. Calnexin 
used as western blotting loading control. p= phosphorylated. The EGFR siRNA and Gefitinib 
experiment was performed once in each CRC cell line. 
 
After confirming that the EGFR pathway and its downstream effectors MAPK/ERK 
and PI3K are regulated in a common way upon EGFR inhibition studies both by 
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Cetuximab and Gefitinib and that EGFR downregulation experiments are in line with 
these observations, it was of great importance to investigate whether autophagy 
induction upon EGFR siRNA and Gefitinib treatment follows the same pattern as with 
Cetuximab. 
In order to monitor autophagic flux and to investigate if there is a kinase-
independent role of EGFR in autophagy modulation, HCT-116 KRAS WT cells were 
treated with 25 nM of scramble or EGFR siRNAs for 48 hours; with or without 10 µM 
CQ treatment which started 6 hours prior the end of the experiment. Figure 3. 12.a 
shows that no autophagy induction was observed upon EGFR downregulation in HCT-
116 KRAS WT cells. Similarly, it was observed that Gefitinib is unable to induce 
autophagy in both HCT-116 KRAS WT and G13D cells (Figure 3. 12.b).  
 
Figure 3. 12: Examination of autophagy induction upon EGFR siRNA and Gefitinib 
treatment in HCT-116 cells. Autophagy is not induced upon a EGFR siRNA and b Gefitinib 
treatment. Left: western blotting analysis of LC3B protein levels. Right: Bar plots represent 
densitometric analysis of LC3-II/LC3-I levels normalised to loading control observed by western 
blotting. Beta-actin or calnexin used as loading controls. Cells treated with 25 nM of scramble 
or EGFR siRNAs for 48 hours and +/- 10 µM CQ added to the culture medium 6 hours before 
cell lysis to enable monitoring of autophagic flux. For Gefitinib experiments, cells were treated 
with 1 µM Gefitinib +/- 10 µM CQ for 6 hours. Scr= scramble. Autophagy induction experiment 
following either EGFR siRNA or Gefitinib treatment in HCT-116 cells was performed once. 
 
Overall, these findings show that inhibition of EGFR by multiple approaches fails to 
induce autophagy with the exception of DiFi cells. Autophagy induction following 
EGFR inhibition in DiFi cells correlates with the inhibitory effect of Cetuximab on AKT 
phosphorylation (Figure 3. 6.e). 
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3.2.11. Lack of autophagy induction upon EGFR inhibition correlates with PI3K 
mutational status or EGFR-independent mechanisms for AKT activation 
The observation that there was a correlation between autophagy induction and AKT 
inhibition upon Cetuximab treatment prompted us to investigate in depth the 
mutational status of PI3K across the different CRC cell lines used. To address that, the 
Broad Institute Cancer Cell Line Encyclopedia and the Cosmic websites were used to 
investigate the mutational status of different components of the PI3K pathway in these 
cells.  
It was found that HCT-116, DLD-1 and SW48 cell lines carry various mutations in 
different components of the PI3K pathway (Table 3. 2). For CaCo2 cells no mutations 
in PI3K pathway components were found implying that CaCo2 cells are WT for these 
genes. Finally, for DiFi cells there was no available information in either website.  
 
Table 3. 2: Mutational status of HCT-116, DLD-1 and SW48 CRC cell lines. 
 
 
The mutations found in the PIK3CA gene warranted further investigation. PI3KCA 
encodes the catalytic subunit of PI3K, p110 and its mutations have been previously 
implicated in Cetuximab resistance (De Roock et al., 2011). To confirm the mutations 
reported in the two search engines that were utilised, we designed sequencing primers 
specific for the identification of each point mutation and all CRC cell lines were 
screened for PI3K mutations (residues p.E545, p.D549, p.G914 and p.H1047). DLD-1 
KRAS WT and G13D isogenic cell lines were found to harbour E545K and D549N 
activating mutations of the PIK3CA gene (Figure 3. 13 and 3. 14). SW48 KRAS 
isogenic cell lines instead harbour only the G914R PIK3CA mutation (Figure 3. 15). 
For the H1047R PIK3CA activating mutation, only HCT-116 KRAS isogenic cell lines 
were found to be positive (Figure 3. 16). Finally, CaCo2 and DiFi cells were shown to 
be WT for any of the four different point mutations screened (Figures 3. 13 - 3. 16). 
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Figure 3. 13: Examination of PIK3CA mutational status at E545 residue. Only DLD-1 
KRAS WT and G13D cells were found to harbour E545K PIK3CA activating mutation. E= 
Glutamic acid, K= Lysine, Green/A= Adenine, Blue/C= Cytosine, Black/G= Guanine and 
Red/T= Thymine. PIK3CA mutation screening experiment was conducted once in each cell line 
tested. 
A  
K  
A   G   A  
K  
A  G  
PIK3CA  E545K  Mutation  status
HCT-­116  KRAS  WT HCT-­116  KRAS  G13D
DLD-­1  KRAS  WT DLD-­1  KRAS  G13D
SW48  KRAS  WT SW48  KRAS  G12D
CaCo2DiFi
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Figure 3. 14: Examination of PIK3CA mutational status at D549 residue. Only DLD-1 
KRAS WT and G13D cells were found to harbour D549N PIK3CA activating mutation. D= 
Aspartic acid, N= Asparagine, Green/A= Adenine, Blue/C= Cytosine, Black/G= Guanine and 
Red/T= Thymine. PIK3CA mutation screening experiment was conducted once in each cell line 
tested. 
A  
N  
A  T   A  
N  
A  T  
PIK3CA  D549N  Mutation  Status
HCT-­116  KRAS  WT HCT-­116  KRAS  G13D
DLD-­1  KRAS  WT DLD-­1  KRAS  G13D
SW48  KRAS  WT SW48  KRAS  G12D
CaCo2DiFi
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Figure 3. 15: Examination of PIK3CA mutational status at G914 residue. Only SW48 KRAS 
WT and G12D cells were found to harbour G914R PIK3CA activating mutation. G= Glycine, R= 
Arginine, Green/A= Adenine, Blue/C= Cytosine, Black/G= Guanine and Red/T= Thymine. 
PIK3CA mutation screening experiment was conducted once in each cell line tested. 
A  
R  
G  A   A  
R  
G   A  
CaCo2
PIK3CA  G914R  Mutation  status
DiFi
SW48  KRAS  WT SW48  KRAS  G12D
DLD-­1  KRAS  WT DLD-­1  KRAS  G13D
HCT-­116  KRAS  WT HCT-­116  KRAS  G13D
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Figure 3. 16: Examination of PIK3CA mutational status at H1047 residue. Only HCT-116 
KRAS WT and G13D cells were found to harbour H1047R PIK3CA activating mutation. H= 
Histidine, R= Arginine, Green/A= Adenine, Blue/C= Cytosine, Black/G= Guanine and Red/T= 
Thymine. PIK3CA mutation screening experiment was conducted once in each cell line tested. 
 
C  
R  
G  T  C  
R  
G  T  
PIK3CA  H1047R  Mutation  status
CaCo2DiFi
SW48  KRAS  WT SW48  KRAS  G12D
DLD-­1  KRAS  WT DLD-­1  KRAS  G13D
HCT-­116  KRAS  WT HCT-­116  KRAS  G13D
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In conclusion, PIK3CA activating mutations inversely correlated with inhibition of 
AKT phosphorylation and autophagy induction upon Cetuximab treatment, suggesting 
that the PIK3CA mutational status may be the main factor in dictating the autophagic 
response to EGFR inhibition. However, an exception to this rule is CaCo2 cells, which 
failed to downregulate the PI3K pathway and induce autophagy upon Cetuximab 
treatment despite their PIK3CA WT status. Which is the factor responsible for the lack 
of autophagy induction upon EGFR inhibition in CaCo2 cells? I hypothesised that a 
RTK other than EGFR alone controls PI3K activity in CaCo2 cells. I thought to 
investigate whether ErbB2 RTK is implicated. ErbB2 belongs to ErbB family of 
receptors, is incompetent for growth-factor stimulation and therefore creates 
heterodimers with EGFR, which are responsible for Cetuximab resistance in many 
cases (Vlacich and Coffey, 2011, Lemmon et al., 2014). Thereby the potential 
implication of ErbB2 RTK was investigated. 
To address this, a dual EGFR and ErbB2 tyrosine kinase inhibitor, Lapatinib, was 
used. CaCo2 cells were cultured in the presence of 1 µM or 2 µM of Lapatinib in 
combination with 50 µg/ml Cetuximab and/or 10 µM CQ for 24 hours. Activation levels 
of EGFR pathway and downstream effectors as well as autophagy induction were 
examined by western blotting. Lapatinib alone as well as Lapatinib and Cetuximab 
combinational treatment were more potently downregulating EGFR activation levels 
when compared to Cetuximab treatment alone (Figure 3. 17.b). The MAPK/ERK 
pathway was evenly downregulated in 1 µM Lapatinib and Cetuximab alone conditions 
and more potently upon 2 µM Lapatinib treatment alone or Lapatinib and Cetuximab 
combinational treatment (Figure 3. 17.c). PI3K pathway was downregulated evenly in 
1 µM Lapatinib and Cetuximab alone treatments but more potently in the 2 µM 
Lapatinib treatment and Lapatinib and Cetuximab combinational treatments. 
Additionally, CQ treatment alone or in combination with Lapatinib; Cetuximab 
treatment alone or with Cetuximab and Lapatinib co-treatment downregulated AKT 
activation levels (Figure 3. 17.d). Finally, both 1 and 2 µM of Lapatinib were able to 
induce autophagy in CaCo2 cells with 2 µM of Lapatinib that more potently 
downregulated pAKT to induce autophagy in a higher level (Figure 3. 17.e). Even 
though Lapatinib and Cetuximab co-treatment resulted in a greater downregulation of 
pAKT levels, autophagy was not induced in a proportional way to pAKT 
downregulation (Figure 3. 17.e). This observation could imply that Cetuximab in 
combination with Lapatinib results in downregulation of autophagy. However, further 
investigation is needed since Lapatinib alone and Lapatinib and Cetuximab co-
treatment samples were analysed in different western blotting gels and CQ alone 
control found to have a different pattern between the two examined gels.  
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Figure 3. 17: EGFR and ErbB2 inhibition experiment by Lapatinib in Caco2 cells. a 
Schematic representation of Cetuximab and Lapatinib mode of action; b EGFR; c MAPK/ERK 
pathway; d PI3K pathway activation levels and e autophagy levels upon Lapatinib/Cetuximab 
treatment alone and Lapatinib/Cetuximab co-treatment. Bar plots represent densitometric 
analysis of LC3-II/LC3-I levels normalised to beta-actin observed by western blotting. 1 µM and 
2 µM of Lapatinib, 50 µg/ml Cetuximab and 10 µM CQ were used for 24 hours. Phosphorylation 
levels of EGFR, ERK and AKT proteins reflect activation levels of EGFR, MAPK/ERK and PI3K 
pathways respectively. LC3-II/LC3-I levels normalised to beta-actin depicts levels of autophagy. 
Calnexin and beta-actin used as western blotting loading controls. * Represents heavy chain of 
Cetuximab antibody in Cetuximab treated cells that were detected at 55kDa below pAKT and 
total AKT bands. p= phosphorylated. Note: in d Total AKT antibody did not work well so total 
AKT results were re-blotted and are shown in e. Equal AKT levels were observed between all 
drug-treated conditions. The presented experiment was conducted once. 
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3.2.12 AKT pharmacological inhibition rescues autophagy induction in PIK3CA-
mutated CRC cells, whereas constitutively active AKT inhibits autophagy in 
PIK3CA-WT cells 
We next tested whether the use of the AKT vIII inhibitor could rescue induction of 
autophagy in PIK3CA-mutated cells. It is known that AKT can modulate autophagy 
either in an mTORC1 dependent manner or directly by phosphorylating Beclin1 
(previously discussed in 1.1.2.2.). The E545K and D549N PIK3CA mutant DLD-1 
KRAS WT and mutant cells were cultured in the presence of 2 µM and 5 µM of AKT 
vIII inhibitor alone or in combination with 50 µg/ml Cetuximab and/or 10 µM of CQ for 
24 hours. AKT vIII treatment alone resulted in an upregulation of EGFR activation 
levels in DLD-1 KRAS mutant cells, whereas AKT vIII/Cetuximab co-treatment 
abolished EGFR activation in both KRAS isogenic versions of DLD-1 cells examined 
(Figure 3. 18.a). ERK activation levels were increased in DLD-1 KRAS WT cells but 
were unaffected in DLD-1 KRAS G13D cells upon AKT vIII treatment alone. 
Cetuximab treatment alone or in combination with AKT vIII inhibitor suppressed pERK 
levels in both DLD-1 KRAS WT and G13D cells (Figure 3. 18.b). Additionally, 6 hours 
of CQ treatment alone resulted in downregulation of pERK levels in both KRAS 
isogenic versions of DLD-1 cells examined (Figure 3. 18.b), in contrast to more 
extended CQ treatment (Figure 3. 10.a). Finally, the AKT vIII inhibitor alone or in 
combination with Cetuximab was able to downregulate pAKT levels compared to 
untreated or Cetuximab-only treated controls (Figure 3. 18.c). Critically, in the 
conditions where pAKT levels were abolished, apart from treatments with 5 µM of AKT 
vIII inhibitor or Cetuximab treatment alone, autophagy was induced upon AKT vIII 
inhibitor treatment alone or in combination with Cetuximab. As previously observed, 
Cetuximab treatment alone was unable to induce autophagy in both DLD-1 KRAS WT 
and G13D cells (Figure 3. 18.c). 
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Figure 3. 18: AKT inhibition induces autophagy in PIK3CA mutant cells. a EGFR; b 
MAPK/ERK pathway and c PI3K pathway and autophagy levels upon AKT vIII inhibitor alone or 
in combination with Cetuximab in DLD-1 KRAS WT and G13D cells. Bar plots represent 
densitometric analysis of LC3-II/LC3-I levels normalised to calnexin observed by western 
blotting. 2 µM and 5 µM AKT vIII, 50 µg/ml Cetuximab and 10 µM CQ were used for 24 hours. 
Phosphorylation levels of EGFR, ERK and AKT proteins reflect activation levels of EGFR, 
MAPK/ERK and PI3K pathways respectively. LC3-II/LC3-I levels normalised to calnexin depicts 
levels of autophagy. Calnexin used as western blotting loading controls. * Represents heavy 
chain of Cetuximab antibody in Cetuximab treated cells that were detected at 55kDa below 
pAKT bands. Note: in a Total EGFR antibody did not work for DLD-1 KRAS WT cells and need 
to be repeated. p= phosphorylated. The experiment was conducted once. 
 
Finally, in order to identify a direct link between AKT activation levels and 
autophagy induction upon Cetuximab treatment, I generated DiFi cells stably 
expressing myristoylated-AKT (LXSN_myrAKT). N-Myristoylation is a lipidation 
modification in which a 14-carbon fatty acid, myristate, is covalently attached to the N’-
terminal glycine of a target protein by a N-myristoyltransferase either co- or post-
translationally and results in its plasma membrane localisation (Martin et al., 2011). It 
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has been shown that myristoylated-AKT protein is localised to the plasma membrane 
and remains constitutively active (Klippel et al., 1996, Wang et al., 2012). 
We hypothesised that AKT constitutive activation would decrease Cetuximab-
dependent autophagy induction in DiFi cells, which was the only cell line found to 
induce autophagy upon Cetuximab treatment (Figure 3. 6.e). For that reason, LXSN 
and LXSN_myrAKT DiFi cells were cultured in the presence of 50 µg/ml Cetuximab 
with or without 10 µM CQ for 24 hours. As expected, cells overexpressing myrAKT 
displayed higher pAKT levels at both steady state and upon Cetuximab treatment 
(Figure 3. 19.a). Interestingly, increased pERK levels were observed in LXSN_myrAKT 
DiFi cells at steady state. pERK and pEGFR levels were reduced upon Cetuximab 
treatment in both control and LXSN_myrAKT DiFi cells (Figure 3. 19.b). As initially 
hypothesised, the increased activation levels of AKT in LXSN_myrAKT DiFi cells 
resulted in lower autophagy induction levels upon Cetuximab treatment when 
compared with control DiFi cells (Figure 3. 19.a), implying a direct link between AKT 
activation status and autophagy induction in CRC cells upon Cetuximab treatment. In 
line with previous observations in Figure 3. 8.e and 3. 9.e, CQ treatment alone 
downregulated EGFR and AKT activation levels in control DiFi cells. However, CQ 
inhibited EGFR activation but not AKT activation in LXSN_myrAKT DiFi cells (Figure 3. 
19.a and b). 
 
Figure 3. 19: Reduced autophagy induction upon Cetuximab treatment in myristoylated 
AKT overexpressing DiFi cell line. a autophagy and PI3K; b EGFR and MAPK/ERK pathway 
activation levels in control and myristoylated AKT overexpressing DiFi cell lines. Bar plot 
represents densitometric analysis of LC3-II/LC3-I levels normalised to beta-actin observed by 
western blotting. 50 µg/ml Cetuximab +/- 10 µM CQ for 24 hours were used. Phosphorylation 
levels of EGFR, ERK and AKT proteins reflect activation levels of EGFR, MAPK/ERK and PI3K 
pathways respectively. LC3-II/LC3-I levels normalised to beta-actin depicts levels of autophagy. 
Beta-actin used as western blotting loading controls. * Represents heavy chain of Cetuximab 
antibody in Cetuximab treated cells that were detected at 55kDa below pAKT and total AKT 
bands. 
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3.3. Discussion 
3.3.1. Activation of MAPK/ERK and PI3K pathways may regulate the response of 
CRC cells to EGFR targeted therapy  
EGFR is often deregulated in a variety of solid cancers and the development of 
EGFR targeted therapy revolutionised cancer therapeutics. However, primary or 
acquired resistance to targeted therapy limits the effectiveness of such approaches. 
KRAS oncogene represents the only molecular biomarker that is used for CRC 
patients’ selection in EGFR targeted therapy approaches (information taken from FDA 
website). KRAS oncogene activation has been inversely correlated to Cetuximab 
response and patients with KRAS mutations were not found to benefit from Cetuximab 
treatment (Benvenuti et al., 2007, Karapetis et al., 2008). Although, Cetuximab 
treatment is only approved for KRAS WT metastatic CRC patients, their response to 
therapy is differential and only a small subgroup could benefit from it (De Roock et al., 
2011).  
A panel of KRAS WT and mutant isogenic (when available) CRC cell lines was 
utilised in this work to investigate the response to Cetuximab treatment in vitro. In line 
with the literature, KRAS activating mutations were found to deteriorate responses to 
Cetuximab treatment in SW48 and DLD-1 KRAS isogenic cells (Figure 3. 4). 
Additionally, CaCo2 cells, which were heterozygous for KRAS G12S mutation, were 
resistant to Cetuximab treatment (Figure 3. 4.). However, activation of KRAS 
oncogene is not the only factor controlling response to Cetuximab treatment since 
KRAS WT CRC cells (HCT-116, SW48, DLD-1 and DiFi cells) present differential 
response to EGFR inhibition (Figure 3. 4). This work reinforces the theory that the 
existence of molecular factors other than KRAS activation, affect CRC patients’ 
response to Cetuximab treatment.  
Moroni et al., (2005) suggested EGFR amplification as a positive regulator of 
response to EGFR monoclonal antibody-targeted therapy in CRC (Moroni et al., 2005). 
The correlation of high EGFR levels and sensitivity to Cetuximab that was observed in 
the high sensitivity group (DiFi; Figures 3. 3 - 3. 4) could be explained by the existence 
of EGFR gene amplification in these cells. DiFi cells were the first CRC cell line 
described to harbour EGFR amplification in the range of 60-80 copies per cell 
(Untawale et al., 1993). However, EGFR amplification does not frequently occur in 
CRC (Shia et al., 2005). If Cetuximab response was dictated by EGFR amplification, 
one might expect that refractory CRC cells would be characterised by low EGFR copy 
numbers. Although, HCT-116, DLD-1 and SW48 cells present low EGFR copy 
numbers (Moroni et al., 2005), SW48 and DLD-1 cells have reduced cell growth 
following EGFR targeted therapy (Figure 3. 4). Additionally, EGFR expression in the 
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Cetuximab-sensitive group (DLD-1) is lower compared to the Cetuximab-intermediate 
resistance group (SW48) (Figures 3. 3 - 3. 4). Overall, these observations suggest that 
EGFR expression levels might not be implicated to Cetuximab treatment response. 
Similarly, previous studies have shown that there is no correlation between EGFR 
expression status and response to Cetuximab or Panitumumab treatment (Chung et 
al., 2005, Hecht et al., 2010). A possible scenario to explain the high sensitivity of DiFi 
cells to Cetuximab treatment could be that cells with EGFR amplification are highly 
dependent on EGFR activation for survival. Indeed, DiFi cells present the highest 
EGFR activation and respond to lower Cetuximab concentrations compared to the 
other responsive cells lines SW48 and DLD-1 (Figures 3. 3 - 3. 4). Based on these 
observations, we could hypothesise that EGFR activation may control response to 
Cetuximab treatment. However, SW48 cells, which exhibit higher EGFR activation 
compared to DLD-1 cells, are more resistant to Cetuximab treatment (Figures 3. 3 - 3. 
4). The latter observation may rule out the likelihood EGFR activation to control CRC 
cells to Cetuximab treatment. A positive correlation between high gene expression of 
EGFR-ligands, like EREG and AREG and longer progression-free survival in 
Cetuximab-treated CRC patients has been described (Khambata-Ford et al., 2007). 
Even though a correlation between EGFR-ligand production and Cetuximab response 
was not investigated in this work, a higher autocrine production of EGFR-ligands may 
be present in DLD-1 cells explaining their sensitivity to Cetuximab. Interestingly, EGFR 
expression levels were not positively correlated with activation levels of EGFR in DLD-
1 cells. DLD-1 cells exhibit relatively high EGFR activation albeit low EGFR levels 
compared to SW48 and DiFi cells (Figure 3. 3), an observation that cannot be 
generalised for the other CRC cell lines. Collectively, factors such as: i) high EGFR 
amplification, ii) increased EGFR-ligand production and/or iii) increased dependency to 
EGFR in CRC cells could explain in certain cases the beneficial response to 
Cetuximab.  
High genomic instability and genetic heterogeneity characterise the molecular 
pathology of CRC (discussed in 1.4.2., page 47). Aside from KRAS mutations, 
activation of BRAF and PI3K oncogenes have been described to occur in CRC (Misale 
et al., 2014). A variety of studies have reported an implication of BRAF mutation 
V600E to Cetuximab resistance (Di Nicolantonio et al., 2008, Laurent-Puig et al., 2009, 
De Roock et al., 2011, Ashraf et al., 2012). However, this mechanism cannot explain 
the differential response to Cetuximab in this study, as all CRC cell lines examined 
were BRAF WT (Cosmic website). 
PI3K oncogene activation has been suggested to confer resistance to EGFR 
targeted therapy in pre-clinical (Jhawer et al., 2008, Ashraf et al., 2012) and clinical 
studies (De Roock et al., 2010). PIK3CA exon 9 and 20 activating mutations are 
EGFR targeted therapy and autophagy in CRC 
117 
present in CRC patients, although only mutations in exon 20 positively correlate with 
resistance to Cetuximab (Ashraf et al., 2012). Furthermore, PIK3CA exon 20 mutation 
was found to deteriorate Cetuximab response in HCT-116 PIK3CA isogenic cell lines 
(Jhawer et al., 2008). On the other hand, PIK3CA exon 9 mutations were found unable 
to confer resistance to Cetuximab treatment in both pre-clinical and clinical models 
(Ashraf et al., 2012, Pentheroudakis et al., 2013, Karapetis et al., 2014). Interestingly, 
three out of five CRC cell lines utilised in this work were harbouring activating 
mutations in PIK3CA gene (Figures 3. 13 - 3. 16). In particular, HCT-116 cells were 
heterozygous for H1047 PIK3CA mutation located at exon 20, whereas DLD-1 cells 
were heterozygous for both E545K and D549N PIK3CA mutations located at exon 9. 
The different exon localisation of PIK3CA mutations between HCT-116 and DLD-1 
cells, may explain the total refractory response of HCT-116 cells to Cetuximab 
treatment and responsive phenotype of DLD-1 cells. G914R PIK3CA mutation present 
in SW48 cells has not been correlated to Cetuximab treatment response. A positive 
correlation between PI3K mutational status and sustained AKT activation levels 
following EGFR inhibition was identified in this work (Figure 3. 9). All cell lines with 
sustained AKT activation levels following EGFR inhibition were found to harbour PI3K 
activating mutations, with the exception of CaCo2 cells. CaCo2 cells despite their PI3K 
WT status, sustained AKT activation upon Cetuximab treatment. Nevertheless, when 
ErbB2 was concomitantly inhibited with EGFR in CaCo2 cells, AKT activation levels 
were downregulated (Figure 3. 17.d), suggesting that activation of ErbB2 restricts AKT 
inhibition. Work from Luca et al., (2014) shows that the response of CaCo2 cells to 
Cetuximab treatment was potentiated in EGFR and ErbB2 combinational therapy 
(Luca et al., 2014). Of note, despite the fact that PIK3CA exon 20 mutations have 
been linked to Cetuximab refractory response, regulation of AKT downstream of PI3K 
mutations has not been evaluated in this setting (Jhawer et al., 2008).  
EGFR downstream signalling pathways are primarily MAPK/ERK and PI3K. It was 
therefore reasonable to investigate whether their activation is affecting Cetuximab 
resistance. This work suggests that differential activation/inhibition of MAPK/ERK and 
PI3K pathways downstream of EGFR may define Cetuximab response in KRAS WT 
CRC cells. Response to Cetuximab treatment was found to inversely correlate with the 
activation levels of PI3K/AKT and MAPK/ERK pathways downstream of EGFR. In 
particular, only the Cetuximab-high sensitivity group (DiFi) presenting a potential 
cytotoxic phenotype exhibited concomitantly PI3K/AKT and MAPK/ERK pathway 
inhibition (Figures 3. 9.e and 3. 10.e). On the contrary, the Cetuximab-resistant group 
(HCT-116) exhibiting neither a cytotoxic nor cytostatic phenotype, sustained high 
activation levels of both PI3K/AKT and MAPK/ERK pathways (Figures 3. 9.b and 3. 
10.b). Cetuximab-intermediate resistance (SW48) and sensitive group (DLD-1) 
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presenting an intermediate and more profound cytostatic phenotype respectively, 
showed only MAPK/ERK pathway inhibition (Figures 3. 9 and 3. 10). In support of this, 
ERK activation levels were sustained in KRAS mutant SW48 and DLD-1 cells resulting 
in less potent Cetuximab response (Figures 3. 4 and 3. 10). A possible scenario could 
be that inhibition of ERK reduces cell growth and AKT regulates cell death response 
following EGFR inhibition. Previous studies in DiFi cells have shown that they induce 
apoptosis upon Cetuximab treatment (Karnes et al., 1998, Liu et al., 2000), confirming 
the suggested cytotoxic effect observed in our work. Nevertheless, the potential 
cytotoxic effect of Cetuximab in DiFi cells could be AKT activation-independent since 
DiFi cells are exceptionally sensitive to EGFR inhibition compared to other CRC cell 
lines. Whether ERK and AKT inhibition control cell growth and cell death, respectively 
following EGFR inhibition needs to be determined.  
Genetic deregulation of EGFR, KRAS, BRAF and PIK3CA cannot systematically 
explain the differential response of CRC cells to Cetuximab treatment in our work. A 
more complex network of interactions having as end-point regulators, MAPK/ERK and 
PI3K pathways, may dictate differential response of CRC cells to EGFR inhibition. 
 
3.3.2. The majority of CRC cell lines are refractory to autophagy induction 
following EGFR targeted therapy and do not benefit from EGFR-autophagy 
combinational therapy 
Induction of autophagy following cancer treatment has been previously described 
as a resistance mechanism, enabling cancer cells to survive and fulfil their elevated 
metabolic needs (Amaravadi et al., 2011, Rebecca and Amaravadi, 2015). Autophagy 
is induced in various cancer types such as NSCLC, breast cancer and glioblastoma 
following EGFR inhibition (Eimer et al., 2011, Dragowska et al., 2013, Wei et al., 
2013). Hitherto, the relationship between autophagy and EGFR inhibition in CRC is 
elusive and the role of autophagy in EGFR targeted therapy response of CRC has not 
been studied in depth. As was previously discussed, CRC cell lines present differential 
responses to EGFR targeted therapy and the molecular factors controlling their 
resistance are not fully characterised. This work aimed to identify whether autophagy 
is implicated in differential response and/or resistance of CRC cells to EGFR targeted 
therapy. It was shown that the majority of CRC cell lines tested were refractory to 
autophagy induction following EGFR inhibition by Cetuximab. Autophagy was solely 
induced in DiFi cells (Figure 3. 6). This phenomenon is not attributed to a general 
incompetence of CRC cells to induce autophagy since these cells efficiently respond 
to autophagy-inducing compounds (Figure 3. 5). Additionally, the refractory autophagic 
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response to Cetuximab treatment could not be caused by a specific inefficiency of 
Cetuximab to induce autophagy. Gefitinib and EGFR downregulation approaches that 
we used showed consistently with Cetuximab that EGFR modulation does not induce 
autophagy in HCT-116 cells (Figure 3. 12). Hitherto, there is no published work 
evaluating autophagy induction upon Cetuximab treatment in CRC. The only available 
information is limited to two studies, which included DiFi cells and confirm our findings 
for autophagy induction upon Cetuximab treatment (Li and Fan, 2010, Li et al., 2010). 
Earlier studies reported that autophagy induction upon EGFR inhibition is a 
characteristic of sensitive to therapy-only NSCLC cells and that resistant cells do not 
induce autophagy (Li et al., 2013b, Wei et al., 2013). Other studies described that 
autophagy induction following EGFR inhibition is more pronounced in resistant NSCLC 
cell lines (Han et al., 2011, Zou et al., 2013). However, our results do not indicate such 
a correlation since both resistant (HCT-116 and CaCo2) and sensitive (DLD-1) CRC 
cells are refractory to autophagy induction following EGFR inhibition (Figures 3. 4 and 
3. 6). Additionally, neither EGFR activation nor EGFR expression levels could be 
correlated with variability in autophagy induction following EGFR inhibition in my 
research. High EGFR expressing cells such as SW48 and DiFi cells were either 
refractory or competent to autophagy induction following EGFR inhibition, suggesting 
that EGFR expression levels may not determine autophagic behaviour of CRC cells 
following Cetuximab treatment (Figures 3. 3 and 3. 6.c and e). Similarly, EGFR 
activation levels could not determine autophagy induction upon Cetuximab treatment, 
since DLD-1 and SW48 cells exhibiting high pEGFR are refractory to autophagy 
induction (Figure 3. 3 and 3. 6.a and c). 
The study by Li et al., (2010) reported an apoptosis-dependent concept for 
autophagy induction following Cetuximab treatment in a panel of cancer cells. In 
particular, this study suggested a model where autophagy is induced only in cells 
presenting extensive or moderate levels of apoptosis upon Cetuximab treatment, 
whereas cells having only a cytostatic phenotype following Cetuximab treatment are 
refractory to autophagy induction. DiFi cells were included in this study and it was 
shown that Cetuximab treatment induced both apoptosis and autophagy. In turn, 
inhibition of Cetuximab-induced apoptosis (either by using a broad-spectrum caspase 
inhibitor or Cetuximab-resistant DiFi cells) abolished autophagy induction (Li et al., 
2010). Detailed investigation of apoptosis or cell growth arrest induction following 
EGFR inhibition has not been investigated in our work, however the latter model may 
apply to our findings. As was previously discussed, Cetuximab treatment was 
suggested to play a cytotoxic role in DiFi cells, which were competent for autophagy 
induction following EGFR inhibition. In turn, Cetuximab was suggested to play a 
cytostatic role in DLD-1 and SW48 cells that were refractory to autophagy induction 
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following EGFR inhibition. Further investigation defining any correlation between 
apoptosis and autophagy induction in CRC cells is warranted. However, findings by Li 
et al., (2010) should be considered with caution since results could be attributed to a 
cell-line specific biological behaviour to Cetuximab treatment rather than a 
generalisable biological phenomenon, as only one or two different cell lines in each 
category that originated from different cancer types were examined. 
Earlier studies have reported that autophagy is induced following EGFR inhibition in 
a variety of cancer cell lines. However our work suggests that caution should be taken 
when generalising these findings. Not all cell lines induce autophagy following EGFR 
inhibition. Experimental differences may cause variability and misinterpretation of 
findings between studies. In our work, autophagic flux determination via western 
blotting was used to assess autophagy induction following EGFR inhibition, an 
approach not followed by a number of studies. Autophagy induction was monitored by 
either evaluating only the levels of LC3-II accumulation without using lysosomotropic 
compounds or where lysosomotropic compounds were used basal and EGFR-induced 
autophagic flux was not compared (Han et al., 2011, Li et al., 2013b, Zou et al., 2013). 
Additionally in our work, autophagy induction following EGFR inhibition was mainly 
studied by using Cetuximab, which is a monoclonal antibody specifically targeting 
EGFR and limiting in such way non-specific inhibition/activation of molecular factors 
regulating autophagy. Reliability of findings was confirmed by investigating autophagy 
induction with alternative pharmacological EGFR inhibitors other than Cetuximab (i.e. 
Gefitinib) and EGFR downregulation approaches. Other studies evaluated autophagy 
induction by using solely a single EGFR inhibitor approach, which in some cases 
include TKI, such as Erlotinib and Gefitinib, in non-clinical relevant concentrations. For 
example, the study by Han et al., (2011) reported that autophagy was induced 
following EGFR inhibition in NSCLC in very high concentrations of Gefitinib and 
Erlotinib (up to 25 µM). Additionally these EGFR tyrosine kinase inhibitors failed to 
induce autophagy in an EGFR-dependent manner (Han et al., 2011).  
Even though EGFR targeted therapy has been characterised as a potent 
autophagy-inducing stimulus in cancer cells, the role of autophagy following EGFR 
inhibition remains biphasic. On one hand, autophagy induction following EGFR 
inhibition functions as a resistance mechanism and autophagy inhibition approaches 
potentiate response to EGFR targeted therapy (Han et al., 2011, Dragowska et al., 
2013, Li et al., 2013b, Zou et al., 2013, Tang et al., 2015). On the other hand, 
autophagy induction can potentiate EGFR targeted therapy and autophagy inhibition 
functions as a resistance mechanism (Gorzalczany et al., 2011, Wei et al., 2013). Our 
work aimed to characterise the role of autophagy following EGFR inhibition in CRC 
cells. In accordance with the autophagy-incompetent phenotype characterising the 
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majority of CRC cell lines following EGFR inhibition, concomitant EGFR and 
autophagy inhibition (CQ) did not affect CRC cell growth. However, autophagy was 
found to marginally potentiate Cetuximab treatment response in DiFi cells that were 
proficient for autophagy induction upon Cetuximab treatment, suggesting a pro-
survival role of autophagy (Figures 3. 6 and 3. 7). Our findings suggest that a positive 
correlation between autophagy induction following EGFR inhibition and response to 
EGFR-autophagy combinational treatment occurs. In line with my findings, DiFi cells 
were previously reported to induce cyto-protective autophagy upon Cetuximab 
treatment (Li and Fan, 2010, Li et al., 2010). Earlier studies have shown that 
autophagy inhibition (either genetic or pharmacological) potentiates EGFR targeted 
therapy response of cancer cells by accelerating levels of apoptosis (Li et al., 2010, Li 
et al., 2013b, Zou et al., 2013, Tang et al., 2015). We expect that EGFR targeted 
therapy in combination with autophagy suppression would exert a cytotoxic effect in 
DiFi cells by increasing levels of apoptosis, however further investigation is still 
needed.  
CQ treatment alone did not affect CRC cell growth in the majority of the cell lines 
examined, weakening the possibility that CQ affects CRC cell growth in an autophagy-
independent manner. However, CQ treatment alone diminished and potentiated cell 
growth in DiFi and SW48 KRAS G12D cells, respectively (Figure 3. 7.c and e). In 
particular for DiFi cells, the decrease in cell growth upon CQ treatment alone could be 
positively correlated with the reduced EGFR activation observed (Figure 3. 8.e and 3. 
19.b). CQ treatment did not affect EGFR activation levels in any other CRC cell line 
examined. This may be linked to the high EGFR amplification in DiFi cells (discussed 
in 3.3.1) and a potential dependency of these cells on autophagy for cell 
growth/survival. A recent study reported that EGFR overexpressing cell lines and 
tumours are dependent on autophagy for survival. A positive correlation between 
EGFR and LC3 expression was reported in HNSSC xenografts, which was found to be 
sensitive to CQ treatment alone or in combination with irradiation. Additionally, this 
work revealed that pharmacological inhibition of autophagy (CQ) decreases 
proliferation more potently to high-EGFR expressing cells in comparison to low EGFR 
expressing cells (Jutten et al., 2013). Nevertheless, this cannot explain the cell growth 
stimulatory effect of CQ in SW48 KRAS G12D cells presenting similar EGFR 
expression levels to DiFi cells. It could be that KRAS-driven basal autophagy regulates 
cell number of SW48 KRAS G12D cells by inducing cell death or senescence 
(discussed in 1.2.1.1., page 36) (Young et al., 2009, Elgendy et al., 2011). The role of 
autophagy in EGFR targeted therapy in a KRAS-dependent context could not be 
further evaluated in this work since all KRAS isogenic cell lines utilised, were refractory 
to autophagy induction (Figure 3. 7).  
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Overall, the majority of CRC cell lines were found refractory to autophagy induction 
following EGFR inhibition. The lack of autophagy induction upon EGFR inhibition could 
not be correlated to EGFR activation/expression levels and/or response to Cetuximab 
treatment. Importantly, this work highlights that heterogeneity of autophagy induction 
following EGFR inhibition is an important factor conferring differential response of CRC 
cells to EGFR-inhibition and autophagy combinational therapeutic approaches. 
 
3.3.3. PI3K/AKT activation may render CRC cells refractory to autophagy 
induction following EGFR inhibition 
It is generally accepted that RTKs’ activation modulates autophagy induction. 
Activated EGFR can inhibit autophagy either indirectly through its downstream 
effectors or directly via interaction with Beclin1 protein (discussed in 1.1.2.2, page 30). 
Our work suggests that PI3K/AKT pathway downstream of EGFR may be responsible 
for autophagy induction following Cetuximab treatment in CRC cells. The majority of 
CRC cell lines were found to harbour PI3K activating mutations, which were positively 
correlated with sustained AKT activation levels upon EGFR inhibition (Figures 3. 9 and 
3. 13 - 3. 16). Cells with PI3K activating mutations were refractory to autophagy 
induction following EGFR inhibition and AKT inhibition reversed their impotency to 
autophagy induction upon Cetuximab treatment (Figures 3. 6 and 3. 18). On the 
contrary, PI3K WT-DiFi cells potently downregulated AKT activation levels upon 
Cetuximab treatment and was the only cell line capable of inducing autophagy 
following EGFR inhibition (Figures 3. 6 and 3. 9). In turn, hyper-activation of AKT 
phosphorylation in DiFi cells reduced levels of Cetuximab-induced autophagy (Figure 
3. 19). Even though CaCo2 cells are PI3K WT, they were not able to induce 
autophagy upon Cetuximab treatment (Figure 3. 6). This could be attributed to EGFR-
independent sustained levels of pAKT following Cetuximab treatment, since ErbB2 
and EGFR concomitant inhibition induced autophagy (Figure 3. 17.d and e). A positive 
correlation between autophagy induction and MAPK/ERK pathway upon Cetuximab 
treatment was not observed in our study. CRC cell lines with downregulated ERK 
activation were incompetent for autophagy induction following EGFR inhibition 
(Figures 3. 6 and 3. 10). The aforementioned observations highlight PI3K mutational 
status as a possible negative regulator of autophagy induction following EGFR 
inhibition by sustaining AKT activation levels. A positive correlation between PI3K 
pathway activation and EGFR-induced autophagy has been previously reported in the 
literature (Li and Fan, 2010, Han et al., 2011, Dragowska et al., 2013). The study by Li 
et al., (2010) has shown that PI3K pathway is important for autophagy induction upon 
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Cetuximab treatment in A431 cells since myristoylated -AKT and -PI3K transient 
expression rescued Cetuximab-induced autophagy (Li and Fan, 2010). In our work, 
myristoylated-AKT expression did not abolish but rather reduced Cetuximab-induced 
autophagy in DiFi cells. The remaining levels of Cetuximab-induced autophagy in the 
myristoylated-AKT condition can be attributed to the small albeit reduced AKT 
activation following Cetuximab treatment. PI3K/AKT pathway is known to regulate 
autophagy induction via controlling mTORC1 or Beclin1 activation (He and Klionsky, 
2009, Ravikumar et al., 2010, Laplante and Sabatini, 2012, Wang et al., 2012). We 
can hypothesise that AKT downstream of PI3K may regulate either mTORC1 or 
Beclin1 activation and in that way Cetuximab-induced autophagy in CRC cells. 
mTORC1 or Beclin1 implication in regulating autophagy induction downstream of AKT 
has not been examined in this work and future studies are warranted to identify 
downstream regulators of PI3K/AKT pathway in autophagy regulation upon EGFR 
inhibition in CRC cells.  
Recently, evidence for a direct role of EGFR (either tyrosine kinase -dependent or -
independent) in autophagy regulation was introduced (discussed in 1.1.2.2., page 30) 
showing that EGFR targeted therapy may induce autophagy independently of 
mTORC1/AKT (Wei et al., 2013, Tan et al., 2015). Research from Wei et al., (2013) 
has shown that EGFR inhibition by Erlotinib blocked Beclin1/EGFR interaction at 
endosomes, rescued EGFR-mediated Beclin1 phosphorylation and increased 
autophagy only in Erlotinib-sensitive NSCLC cell lines and in tumour xenografts. 
Constitutively active mTOR could not rescue Erlotinib-induced autophagy (Wei et al., 
2013). Direct interaction of EGFR with Beclin1 in regulating autophagy induction was 
not tested in our work. In this manner we cannot exclude the possibility that 
Cetuximab-induced autophagy in DiFi cells is regulated by an EGFR/Beclin1 
mechanism and future experiments in this direction are needed. Observations from our 
work, however might not support such a hypothesis and more specifically: i) AKT 
hyper-activation reduced Cetuximab-induced autophagy in DiFi cells suggesting an 
AKT-dependent mechanism for Cetuximab-induced autophagy and ii) DLD-1 cells that 
characterised by high EGFR activation levels and are sensitive to Cetuximab 
treatment they do not induce autophagy upon EGFR inhibition as was suggested for 
NSLCC cells in the latter study. Another approach, introduced by Tan et al., (2015) 
described a kinase-independent role of EGFR in autophagy regulation. In that context, 
Erlotinib- or Gefitinib-mediated inactive EGFR translocates to endosomes where a 
complex with Sec5 is created. Inactive EGFR/Sec5 complex dissociates Rubicon from 
Beclin1 and in that way autophagy is induced. This mechanism is suggested to be 
AKT-independent since Erlotinib and Gefitinib treatment potently downregulated EGFR 
activation levels without affecting pAKT. Additionally, EGFR expression was shown to 
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regulate basal autophagy induction in a variety of cells since EGFR downregulation 
abolished basal autophagy (Tan et al., 2015). However, our work clearly shows that 
basal autophagic flux is not affected by EGFR downregulation in HCT-116 cells 
(Figure 3. 12.a) and that DLD-1 cells with sustained AKT activation levels and 
downregulated EGFR activation do not induce autophagy, as it would have been 
expected in the presence of an EGFR-kinase independent mechanism. 
Variability in observations between studies may suggest the existence of various 
mechanisms responsible for autophagy induction following EGFR inhibition in different 
cell lines and tumour types. Collectively, our work suggests that autophagy induction 
downstream of EGFR may be regulated in a PI3K/AKT dependent manner and PI3K 
activating mutations may restrict CRC cells for autophagy induction following EGFR 
inhibition. 
 
3.3.4. CRC cells display basal levels of autophagy independently of PI3K 
mutational status and AKT activation  
PI3K/AKT pathway is a well-described negative regulator of autophagy induction 
through mTORC1-dependent and -independent mechanisms (discussed in 1.1.2.2., 
page 30). Given the fact that the majority of CRC cell lines utilised in this study are 
PI3K mutant and refractory to autophagy induction following a stressing stimulus like 
EGFR inhibition (due to high levels of AKT activation), it would have been expected 
that these cells would be incompetent for autophagy induction also in growth 
factor/nutrient replete basal-autophagy conditions. Interestingly, our work via 
monitoring autophagic flux using CQ clearly shows that all CRC cell lines utilised 
exhibit basal autophagy levels even in the presence of PI3K activating mutations and 
high AKT levels (HCT-116, DLD-1 and SW48 cells) (Figures 3. 5 and 3. 6). This 
observation suggests that basal autophagy levels are regulated in a PI3K/AKT 
independent manner in CRC cells, in contrast to the EGFR-induced autophagy. 
Additionally, basal autophagy in CRC cells occurred despite displaying active 
mTORC1 signalling, as levels of pS6 were found to be high in HCT-116, DLD-1 and 
CaCo2 cells examined (results are presented in 4.2.2., page 137; Figure 4. 6.c). These 
observations suggest the presence of an mTORC1-independent mechanism 
regulating basal autophagy in CRC. Earlier studies have described the presence of 
basal autophagy in cancer cells concomitantly with active mTORC1 signalling (Guo et 
al., 2011, Perera et al., 2015). Further investigation on the mechanism regulating basal 
levels of autophagy in CRC cells is warranted.  
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KRAS activating mutations have been shown to increase basal levels of autophagy 
a phenomenon named “autophagy addiction” (Guo et al., 2011) and autophagy 
suppression in a variety of KRAS-driven cancer types has been found to attenuate 
cancer progression (Guo et al., 2013, Rosenfeldt et al., 2013, Yang et al., 2014). In our 
study, the implication of KRAS activation in regulation of basal levels of autophagy 
was investigated via comparing KRAS WT and mutant CRC cells. It was found that 
KRAS activation increases basal levels of autophagy in a cell-type specific manner 
More specifically, KRAS activation increased basal levels of autophagy in DLD-1 and 
HCT-116 (to a lower extent) cells with the exception of SW48 cells, which exhibited 
marginally lower levels of basal autophagy compared to WT cells (Figure 3. 5). The 
variability in basal autophagy induction in the presence of KRAS could be attributed to 
a potential difference in the extent of KRAS activation between cell lines; HCT-116 and 
DLD-1 cells are homozygous for KRAS G13D mutation whereas SW48 cells are 
heterozygous for the G12D mutation. Furthermore, we cannot exclude the possibility 
that in SW48 cells PI3K activation restricts KRAS mutation to increase basal 
autophagy, since pharmacological inhibition of PI3K resulted in higher levels of PI103-
induced autophagy in KRAS mutant cells. 
 
3.3.5. Does inhibition of basal autophagy affect cell signalling?  
CQ treatment was utilised in this work mainly to monitor autophagic flux and inhibit 
autophagy by a pharmacological manner. However, an interesting observation 
reported in this chapter was that inhibition of autophagic flux using CQ could alter the 
activation of AKT, ERK and EGFR. CQ treatment downregulated AKT activation in all 
CRC cell lines tested even in the presence of PI3K activating mutations. CQ treatment, 
as monotherapy, mainly resulted in attenuation of AKT activation, whereas when 
combined with Cetuximab decrease in AKT activation was not evident in most cell 
lines (Figures 3. 5, 3. 9, 3. 17 and 3. 18). CQ treatment was found to have variable 
outcomes on ERK activation levels in CRC cells and in some cases duration of CQ 
treatment differentially altered ERK activation. In particular, 24 hours of CQ treatment 
resulted in sustained ERK activation in HCT-116 and CaCo2 cells whereas in DLD-1, 
SW48 and DiFi cells pERK was upregulated (Figure 3. 10). CQ treatment for 6 hours 
resulted in reduction of ERK activation in HCT-116 cells, independently of KRAS 
mutational status (Figure 3. 11). As discussed in 3.3.2., DiFi cells were the only CRC 
cell line utilised that exhibited lower EGFR activation upon CQ treatment (Figures 3. 8 
and 3. 19). In line with our findings, an earlier study investigating Erlotinib-induced 
autophagy in NSCLC has reported CQ to downregulate AKT and ERK activation in a 
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cell-type specific manner (Zou et al., 2013). These observations suggest that inhibition 
of autophagic flux by CQ in CRC results in downregulation of AKT phosphorylation in a 
systematic manner, while ERK and EGFR activation are altered in a cell-type specific 
manner. However, pharmacological inhibition of autophagy via CQ cannot prove a 
direct role of autophagy in regulating cell signalling. As a lysosomotropic compound is 
only blocking the fusion of autophagosomes with lysosomes and we cannot exclude 
the possibility the effects on signalling we observed are caused by a non-autophagic-
specific mechanism. 
These observations along with evidence in the literature supporting a role of 
autophagy in regulation of ERK activation (Martinez-Lopez et al., 2013), prompted us 
to investigate in depth whether autophagy plays a role in cell signalling of CRC cells. 
The role of autophagy in cell signalling is presented in Chapter 4. 
 
3.3.6. Summary 
The work presented in this chapter aimed to unravel the regulation and role of 
autophagy following EGFR targeted therapy in CRC cells. Our main findings suggest 
that CRC cells present differential response to EGFR targeted therapy possibly 
through differential regulation of MAPK/ERK and PI3K pathways activation 
downstream of EGFR. PI3K activating mutations and high AKT activation levels may 
render CRC cells refractory to autophagy induction following pharmacological 
inhibition or downregulation of EGFR. Additionally, concomitant EGFR and autophagy 
inhibition does not potentiate EGFR-targeted therapy response in CRC cells refractory 
to Cetuximab-induced autophagy. Only PI3K WT cells with deactivated AKT signalling 
following EGFR inhibition were found to induce cyto-protective autophagy. Even 
though PI3K mutated CRC cells are refractory to EGFR-mediated autophagy 
induction, they display basal levels of autophagy despite the presence of constitutive 
PI3K/mTOR signalling. Finally, inhibition of basal autophagic flux by CQ may affect cell 
signalling in CRC. 
The main conclusions and future directions of this work are presented in Chapter 5. 
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4. Basal autophagy and cell signalling in CRC 
4.1. Background 
An interesting observation described in Chapter 4 was that pharmacological 
modulation of autophagy by CQ treatment altered AKT and/or ERK phosphorylation in 
CRC cell lines. The role of the autophagosome in degradation of proteins either in a 
bulk or selective way is well defined. However, our knowledge on the role of 
autophagosomes and/or ATG proteins in regulation of cell signalling is still limited. 
Recently, publications in the field described a role for autophagy in the control of cell 
signalling and protein phosphorylation (Martinez-Lopez et al., 2013, Cianfanelli et al., 
2015). Martinez-Lopez et al., (2013) described an atypical function of ATG proteins, in 
which ATG proteins and autophagosomes act as subcellular scaffolding compartments 
for MEK and ERK. Specifically, MEK and ERK were found to localise at the cytosolic 
side of the outer autophagosomal-membrane. Interestingly, ATG7 depletion in liver 
explants and brown adipose tissue as well as inhibition of LC3 lipidation in NIH/3T3 
cells resulted in attenuation of ERK 1/2-phosphorylation levels, whereas 
phosphorylation levels of MEK protein remained stable (Martinez-Lopez et al., 2013). 
Furthermore, Ambra1, a protein implicated in the early steps of autophagy (discussed 
in 1.1.1.1., page 26) has been found to control c-Myc phosphorylation by directly 
interacting with and enhancing PP2A phosphatase activity in an mTOR-dependent 
manner. Ambra1 depletion leads to increased c-Myc phosphorylation and stability, 
thus in turn promoting proliferation (Cianfanelli et al., 2015). 
This chapter investigates whether autophagy plays a direct role in regulation of cell 
signalling in CRC cells and aims to provide insights into the underlying molecular 
mechanism.  
 
4.2. Results 
4.2.1. Genetic modulation of autophagy in CRC cancer 
In addition to the pharmacological modulation of autophagy by CQ, it was really 
important to generate an in vitro model system for genetic inhibition of autophagy. 
Genetic modulation of autophagy is the only way to confirm the direct role of 
autophagy in any observed phenotype since CQ can affect other cellular functions 
apart from autophagy (Kimura et al., 2013). For genetic modulation of autophagy, the 
stable pGIPZ and the inducible pLKO-Tet-On (Wee et al., 2008, Wiederschain et al., 
2009) lentiviral systems were used to downregulate the expression of ATG7 protein 
Basal autophagy and cell signalling in CRC 
129 
and consequently autophagy. ATG7 protein downregulation blocks phagophore 
elongation through interruption of LC3-II formation resulting in autophagy inhibition 
(Mehrpour et al., 2010). The mechanism that ATG7 facilitates LC3 lipidation has been 
previously discussed in 1.1.1. and is schematically represented in Figure 4. 1. 
 
 
Figure 4. 1: Autophagy inhibition through ATG7 protein downregulation. ATG4 protein 
cleaves the carboxyl terminus of LC3B protein forming in that way the cytosolic form of LC3, 
called LC3-I. ATG7 protein is important for the lipidation process of LC3-I giving rise to the 
autophagosomal-associated form of LC3, called LC3-II. Autophagy-proficient cells would have 
a lipidated form of LC3 protein enabling their canonical autophagic function. Autophagy-
compromised cells are incapable of inducing autophagy since ATG7 protein is downregulated 
resulting in blockade of LC3-I protein lipidation. 
 
The UCL Cancer Institute has a whole genome shRNA library based on the pGIPZ 
lentiviral system, which enables the simultaneous expression of turbo Green 
Fluorescence Protein (turboGFP) along with shRNA expression through an IRES 
sequence located immediately after shRNA. We tested a number of shRNA vectors 
that were previously used in our lab (Galavotti et al., 2013) for scramble and ATG7 
shRNA (shATG7-E8, -G7 and -F12) expression via lentivirally transducing HCT-116 
KRAS WT cells using an MOI of 10. It was found that both E8 and G7 shATG7 
sequences potently downregulated ATG7 protein expression, while F12 sequence did 
not (Figure 4. 2.a). Then stable HCT-116 isogenic cells carrying WT or mutant KRAS 
were generated using scramble and shATG7 E8 lentivirus at an MOI of 10. Infected 
HCT-116 cells were GFP-sorted and expanded in culture. Western blotting was used 
to assess the efficiency of ATG7 protein downregulation. Approximately 75% of ATG7 
downregulation was observed in both HCT-116 KRAS WT and G13D-shATG7 E8 
expressing cells compared to scramble conditions (Figure 4. 2.b). To investigate the 
ability of autophagy-compromised cells (shATG7 E8) to induce autophagy upon 
autophagy-inducing stressors, we used the PI3K and mTOR dual inhibitor PI103 (Park 
et al., 2008). Infected cells were treated with 1 µM of PI103 for 6 hours with and 
without 10 µM of CQ in order to enable autophagic flux monitoring, and LC3B protein 
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levels were assessed by western blotting. As is illustrated in Figure 4. 2.c, autophagy-
compromised HCT-116 KRAS WT and G13D cells showed lower levels of autophagy 
induction compared to scramble cells. The problem that we encountered with the 
pGIPZ system was that pGIPZ-transduced cells tend to have decreased their ability to 
suppress autophagy through passages (approximately five passages), especially in 
basal conditions (Figure 4. 2.d).  
 
Figure 4. 2: Genetic modulation of autophagy in HCT-116 KRAS WT and G13D cells 
using the stable pGIPZ lentiviral system. a ATG7 protein expression in scramble and 
shATG7 E8, F12 and G7 expressing HCT-116 KRAS WT cells; b Left: Downregulation of ATG7 
protein, Right: Bar plot represents ratio of ATG7 protein downregulation based on densitometric 
analysis of ATG7 protein expression levels normalised to actin; c ATG7 downregulation impairs 
autophagy induction in control and PI103-treated cells; d pGIPZ system for ATG7 
downregulation lost its ability to impair autophagy through passages especially in basal 
autophagy conditions. 1 µM of PI103 used for induction of autophagy experiments. 10 µM of 
CQ used to monitor autophagic flux. Protein expression levels examined by western blotting 
and actin used as a loading control. Bar plots represent densitometric analysis of LC3-II/LC3-I 
levels normalised to actin. 
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To solve that problem and gain a better control of autophagy suppression between 
experiments, we decided to switch to the inducible pLKO-Tet-On system for genetic 
modulation of autophagy, which is described below. 
 
Figure 4. 3: pLKO-Tet-On system mechanism of action. pLKO–Tet-On system contains all 
important elements for lentiviral production and puromycin selection. shRNA and Tet repressor 
(TetR) expression are regulated by two different promoters, H1 and hPGK respectively. This 
allows the inducible expression of a desirable shRNA. In the absence of Doxycycline (DOX) 
TetR is expressed and blocks the expression of shRNA by binding to the Tet-responsive 
elements (TRE) downstream of H1 promoter. Upon DOX introduction TetR binds to DOX 
allowing the expression of the shRNA, thereby inhibiting the binding of TetR to TRE of the H1 
promoter. 
 
Three different shATG7 sequences, called E8, G7 and F12, as well as the control 
shRNA sequence, shEGFP, were cloned into the pLKO-Tet-On vector and lentiviral 
production ensued in HEK 293T cells. Four different CRC cell lines and their isogenic 
KRAS mutated versions where available, were lentivirally transduced at a MOI of 10. 
To assess the knockdown efficiency of ATG7 protein expression, cells were cultured in 
the presence of 10 ng/ml and/or 100 ng/ml doxycycline (DOX) for 72 and 120 hours 
and results analysed by western blotting. The E8 sequence displayed the highest 
downregulation of ATG7 protein expression in both HCT-116 KRAS WT and G13D 
cells after incubation with 10 ng/ml DOX for 120 hours (approximately 68% of ATG7 
protein; Figure 4. 4.a.1 and 2). In DLD-1 KRAS WT and G13D cells, it was again found 
that the shATG7 E8 sequence was the most effective to downregulate ATG7 protein 
expression (approximately 49%) upon 100 ng/ml DOX treatment for 120 hours (Figure 
4. 4.b.1 and 2). Similar results were observed in CaCo2 cells after 120 hours with 100 
ng/ml DOX (approximately 48%; Figure 4. 4.c.1 and 2). In contrast, in SW48 KRAS 
WT and G12D cells all sequences were efficiently downregulated ATG7 protein 
expression (upon 100 ng/ml DOX after 120 and 72 hours, respectively; Figure 4. 4.d.1 
and 2).  
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Figure 4. 4: ATG7 protein downregulation using the inducible pLKO-Tet-On lentiviral 
system. a. 1-2 HCT-116 KRAS WT and G13D; b. 1-2 DLD-1 KRAS WT and G13D; c. 1-2 
CaCo2 and d. 1-2 SW48 KRAS WT and G12D cell lines. Protein expression levels examined 
by western blotting with Beta-actin used as a loading control. Bar plots represent ATG7 protein 
downregulation ratio based on densitometric analysis of ATG7 protein expression levels 
normalised to Beta-actin. E8, G7, F12: refer to different sequences used for ATG7 protein 
downregulation. DOX= Doxycycline. ATG7 protein expression in autophagy-proficient and -
compromised conditions was examined in all western blotting experiments conducted in this 
work. 
 
Next, the reversibility of ATG7 downregulation was assessed by DOX withdrawal 
from the culture media. HCT-116 KRAS WT shEGFP and shATG7 E8 cells were 
cultured in the presence of 10 ng/ml of DOX for 11 days. Then, cells were further 
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cultured with DOX or DOX-free fresh media for a further 120 hours. ATG7 protein 
levels decreased in the presence of DOX but then fully recovered upon DOX 
withdrawal confirming that ATG7 downregulation is reversible (Figure 4. 5.a). 
Finally, the ability of shATG7 E8 cells to induce autophagy upon autophagy-
inducing stressors was assessed. HCT-116 shEGFP and shATG7 E8 cells (WT and 
mutant KRAS) were cultured in the presence of DOX for 168 hours and were then 
treated with the autophagy inducer PI103. Autophagy-compromised KRAS WT and 
G13D HCT-116 cells displayed reduced autophagy induction upon PI103 treatment at 
all three time points analysed (Figure 4. 5.b). 
 
Figure 4. 5: a pLKO-Tet-On system is reversible in vitro. DOX removal can reverse ATG7 
protein downregulation, Right: western blotting, Left: Bar plot represents ratio of ATG7 protein 
downregulation based on densitometric analysis of ATG7 protein expression levels normalised 
to beta-actin. b ATG7 protein downregulation using the pLKO-Tet-On system impairs 
PI103-induced autophagy in three different timepoints. 1 µM of PI103 used for autophagy 
induction experiment after 3, 6 and 9 hours of treatment. Bar plots represent densitometric 
analysis of LC3-II/LC3-I levels normalised to actin. E8= refers to the sequence used for ATG7 
downregulation, DOX= Doxycycline. 
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In conclusion, the pLKO-Tet-On system appeared to be a better model for genetic 
modulation of autophagy compared to pGIPZ. Five days of DOX treatment was found 
to be the best condition for efficient downregulation of ATG7 protein expression in all 
CRC cell lines examined.  
 
4.2.2. ATG7 downregulation affects PI3K/AKT pathway in CRC cells 
Autophagy-proficient (shEGFP) and -compromised (shATG7 E8) CRC cells were 
analysed by western blotting for levels of phosphorylated and total AKT. 
Downregulation of ATG7 protein significantly reduced phosphorylation of AKT (pAKT 
S473) relative to levels of total AKT in all CRC cells examined (Figure 4. 6a). 
Specifically, HCT-116 KRAS WT, DLD-1 KRAS WT and CaCo2 autophagy-
compromised cells displayed approximately 25%, 35% and 30% downregulation of 
pAKT S473, respectively. pAKT downregulation was more marked in the presence of 
KRAS G13D in HCT-116 and DLD-1 cells (35% and 65%, respectively; Figure 4. 6.a). 
The T308 phosphorylation residue on AKT protein, which is directly phosphorylated by 
PDK1 (Laplante and Sabatini, 2012), was examined upon autophagy downregulation 
in CaCo2 cells. T308 phosphorylation was found reduced only in CaCo2 autophagy-
compromised cells (approximately 23%), albeit not to a statistically significant extent 
(Figure 4. 6.b). Finally, we examined phosphorylation of the mTORC1 downstream 
effector S6 ribosomal protein. No statistically significant differences in phosphorylation 
levels of S6 ribosomal protein residues S240/244 were observed. Specifically, HCT-
116 and DLD-1 KRAS WT autophagy-compromised cells showed increased S6 
phosphorylation (~40% and ~15% respectively) when compared with their autophagy-
proficient controls. On the contrary, HCT-116 and DLD-1 KRAS G13D cells maintained 
pS6 ribosomal protein S240/244 levels stable upon autophagy downregulation. CaCo2 
autophagy-compromised cells displayed approximately a 20% non-statistically 
significant reduction in pS6 ribosomal protein S240/244 levels (Figure 4. 6.c). 
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Figure 4. 6: ATG7 knockdown regulates AKT phosphorylation. Autophagy downregulation 
resulted in a reduced AKT phosphorylation at S473 residue. Two-way ANOVA with Bonferroni 
posttests statistical analysis was conducted for HCT-116 (n= 4) and DLD-1 (n= 3) KRAS WT 
and G13D cells and unpaired Student’s t-test statistical analysis was conducted for CaCo2 (n= 
4) cells. b reduced AKT phosphorylation at T308 residue. Unpaired Student’s t-test statistical 
analysis was conducted for CaCo2 cells (n= 3). pAKT T308 levels were too low to be detected 
in HCT-116 and DLD-1 cells. c no difference in phosphorylation levels of S6 ribosomal protein. 
Unpaired Student’s t-test statistical analysis was conducted for HCT-116 KRAS WT (n= 3) and 
CaCo2 (n= 3) cells. For HCT-116 KRAS G13D and both DLD-1 KRAS WT and G13D cells n= 
2. HCT-116 and DLD-1 KRAS WT and G13D isogenic cell lines as well as CaCo2 cells were 
treated with DOX for 5 days and total cell lysates were subjected to western blotting analysis of 
the indicated proteins. Beta-actin, calnexin and total AKT proteins used as loading controls. Bar 
plots represent densitometric quantification of pAKT S473, pAKT T308 and pS6 ribosomal 
protein relative to total AKT and total S6 ribosomal protein or loading control respectively. The 
bars represent mean ± standard deviation; ns= non-statistically significant, * p<0.05, ** p<0.01 
and *** p<0.001. Immunoblots presented are representative of n= 2-4 independent 
experiments. Autophagy-proficient and autophagy-compromised cells are denoted as shEGFP 
and shATG7 E8.  
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4.2.3. Other signalling pathways are not affected in a systematic manner upon 
ATG7 downregulation in CRC cells 
MAPK/ERK pathway  
As mentioned above, our experiments with CQ (Figure 3. 11) and a previous study 
reported a role for autophagy in regulation of the MAPK/ERK pathway (Martinez-Lopez 
et al., 2013). We therefore analysed total cell lysates from shEGFP and shATG7 E8 
CRC cells for total and phosphorylated ERK (pERK) 1/2 proteins. Our findings 
indicated that autophagy regulates phosphorylation of ERK 1/2 protein in a statistically 
significant manner but with a non-consistent pattern between the different cell lines 
tested. Particularly, ATG7 knockdown resulted in attenuated phosphorylation levels of 
ERK 1/2 protein in both HCT-116 KRAS WT and G13D cells (approximately 55% and 
35%, respectively). The same statistically significant pattern of reduced pERK 1/2 was 
also observed in DLD-1 KRAS G13D cells (approximately 40%). On the contrary, 
autophagy downregulation resulted in a statistically significant increase in ERK 1/2 
phosphorylation (approximately 65%) in DLD-1 KRAS WT cells. Downregulation of 
ATG7 protein decreased phosphorylation levels of ERK 1/2 in CaCo2 cells marginally 
and not significantly (Figure 4. 7.a). 
We then set out to investigate whether the reduced ERK phosphorylation upon 
autophagy suppression is due to a direct effect on ERK or via modulation of upstream 
components of the MAPK/ERK cascade. To this end, we analysed phosphorylation of 
the MEK 1/2 proteins, which are upstream kinases regulating ERK phosphorylation. 
HCT-116 KRAS WT and G13D autophagy-compromised cells displayed a reduction in 
phosphorylation levels of MEK 1/2 of approximately 26% and 18%, respectively. pMEK 
1/2 was increased by 50% in DLD-1 KRAS WT cells, whereas it decreased by 10% in 
DLD-1 G13D cells. In CaCo2 cells a slight up-regulation of pMEK 1/2 levels was 
observed upon autophagy downregulation conditions (Figure 4. 7.b).  
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Figure 4. 7: ATG7 knockdown regulates phosphorylation of MAPK/ERK cascade 
components in a cell-type specific way. Autophagy downregulation resulted in a deregulated 
ERK 1/2 phosphorylation. Two-way ANOVA with Bonferroni posttests statistical analysis was 
conducted for HCT-116 (n= 4) and DLD-1 (n= 3) KRAS WT and G13D cells and unpaired 
Student’s t-test statistical analysis was conducted for CaCo2 (n= 4) cells. b altered MEK 1/2 
phosphorylation levels. Unpaired Student’s t-test statistical analysis was conducted for HCT-
116 KRAS WT (n= 3) and CaCo2 (n= 3) cells. Two-way ANOVA with Bonferroni posttests 
statistical analysis was conducted for both DLD-1 KRAS WT and G13D cells (n= 3). For HCT-
116 KRAS G13D cells n= 2. HCT-116 and DLD-1 KRAS WT and G13D isogenic cell lines as 
well as CaCo2 cells were treated with DOX for 5 days and total cell lysates were subjected to 
western blotting analysis of the indicated proteins. Beta-actin, calnexin or total ERK 1/2 protein 
used as loading controls. Bar plots represent densitometric quantification of pERK 1/2 
T202/Y204 and pMEK 1/2 S217/221 relative to total ERK 1/2 and total MEK 1/2 protein, 
respectively. The bars represent mean ± standard deviation; * p<0.05, ** p<0.01 and *** 
p<0.001. Immunoblots presented are representative of n= 2-4 independent experiments. 
Autophagy-proficient and autophagy-compromised cells are illustrated as shEGFP and 
shATG7 E8.  
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PI3K and MAPK/ERK pathways were additionally examined in autophagy-proficient 
and autophagy-compromised SW48 KRAS WT and G12D cells. Preliminary data 
performed once showing that autophagy suppression may not affect PI3K activation 
depicted by pAKT S473 levels in both SW48 KRAS WT and G12D cells (Figure 4. 
8.a). pERK 1/2 activation was found upregulated in both SW48 KRAS WT and G12D 
cells following autophagy inhibition (Figure 4. 8.b). However, the abovementioned 
observations need further investigation. 
 
 
Figure 4. 8: Activation of PI3K and MAPK/ERK pathways following ATG7 downregulation 
in SW48 KRAS WT and G12D cells. Autophagy suppression a did not alter AKT 
phosphorylation at S473 residue and b increased pERK 1/2 activation levels. SW48 KRAS WT 
and G12D cells were treated with DOX for 5 days and total cell lysates were subjected to 
western blotting analysis of the indicated proteins. Total AKT and total ERK 1/2 proteins were 
used as loading controls. Immunoblots presented were only performed once. Note: Autophagy-
compromised sample of SW48 KRAS G12D cells had possibly a protein-degradation problem. 
 
In conclusion, autophagy inhibition in CRC cells leads to decreased AKT 
phosphorylation, whereas the effect on MAPK/ERK cascade components appears to 
be cell-type-dependent (Table 4. 1). 
 
Table 4. 1: Phosphorylation modulation of PI3K and MAPK/ERK cascades upon 
autophagy downregulation. * denotes experiments performed once. 
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Given the fact that autophagy plays a role in metabolism (Guo et al., 2011), it was 
essential to investigate whether autophagy inhibition controls phosphorylation of 
proteins in a systematic manner by reducing ATP production levels or metabolic 
substrates in the cell. To address this, five different signalling pathways were 
assessed for differences in protein phosphorylation in autophagy-compromised CRC 
cells using phospho-specific antibodies by western blotting. 
 
Signal Transducer and Activator of Transcription 3 (STAT3) 
Autophagy inhibition resulted in slightly upregulated and downregulated 
phosphorylation levels of STAT3 protein at Y705 residue in HCT-116 KRAS G13D and 
CaCo2 cells, respectively. STAT3 activation levels in HCT-116 KRAS WT cells were 
not detectable (Figure 4. 9.a). 
 
p38 MAPK kinase 
p38 MAPK T180/Y182 phosphorylation levels were maintained upon autophagy 
inhibition in all HCT-116 KRAS isogenic cell lines and CaCo2 cells (Figure 4. 9.b). 
 
AMPK alpha 
Besides HCT-116 KRAS WT cells that displayed upregulated phosphorylation 
levels of AMPK alpha at T172 residue, HCT-116 KRAS G13D and (KRAS-mutant) 
CaCo2 cells displayed reduced phosphorylation levels of AMPK alpha (Figure 4. 9. c). 
 
Stress-Activated Protein Kinase (SAPK)/Jun N-terminal Kinase (JNK) 
SAPK/JNK kinase showed reduced levels of phosphorylation in HCT-116 cells and 
sustained phosphorylation in CaCo2 cells upon autophagy downregulation. The 
presence of KRAS G13D mutation in HCT-116 cells attenuated the difference in 
phosphorylation levels of SAPK/JNK between autophagy-proficient and autophagy-
compromised cells compared to KRAS WT cells (Figure 4. 9.d). Interestingly, 
SAPK/JNK presents a similar pattern in phosphorylation modulation upon autophagy 
inhibition with ERK 1/2 (Figure 4. 7.a). 
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Retinoblastoma protein (Rb) 
Sustained phosphorylation levels of Rb protein at S807/811 residues were 
observed upon autophagy downregulation in CaCo2 cells (Figure 4. 9.e). 
 
In summary, differences in phosphorylation levels of proteins tested upon 
autophagy inhibition were not consistent to support the hypothesis of a mechanism 
that systematically regulates phosphorylation of all proteins. 
 
Figure 4. 9: Autophagy inhibition does not modulate phosphorylation of proteins in a 
systematic manner. Phosphorylation levels of a STAT3 Y705 residue; b p38 MAPK 
T180/Y182 residues; c AMPK alpha T172 residue; d SAPK/JNK T183/Y185 residues and e Rb 
S807/811 residues. HCT-116 KRAS WT and G13D isogenic cell lines as well as CaCo2 cells 
were treated with DOX for 5 days and total cell lysates were subjected to western blotting 
analysis of the indicated proteins. Beta-actin or calnexin used as loading controls. Immunoblots 
presented were only performed once. Autophagy-proficient and autophagy-compromised cells 
are shown as shEGFP and shATG7 E8. Y= tyrosine, T= threonine and S= serine residues. 
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Based on our abovementioned findings, we expected autophagy to regulate AKT 
phosphorylation via a specific mechanism. Therefore, different hypotheses were 
formulated and investigated that are presented below. The mechanistic studies were 
mainly conducted using HCT-116 cells, which showed both pAKT and pERK 1/2 
downregulation following autophagy suppression.  
 
 
4.2.4. Hypotheses 1 and 2: PP2A and PTEN phosphatases in regulation of 
phosphorylation of AKT and ERK proteins upon autophagy inhibition  
To understand how autophagy may regulate phosphorylation of AKT and ERK 
proteins, it was important to investigate whether autophagy controls degradation of 
phosphatases implicated in their de-phosphorylation (Figure 4. 10.a). Phosphorylation 
is a reversible process in which kinases and phosphatases play opposing roles. A 
literature search prompted us to investigate regulation of the threonine/serine Protein 
Phosphatase 2A (PP2A), accounting for approximately 90% of protein phosphatase 
activity in eukaryotes. PP2A is a heterotrimeric enzyme complex that includes three 
different subunits; a highly conserved catalytic subunit (PP2Ac), a structural core 
subunit (PP2Aa) and a highly variable regulatory subunit (PP2Ab) enabling diverse 
specificities to substrate proteins. Interestingly, PP2A has been previously described 
to negatively regulate PI3K and MAPK/ERK pathways (Sontag, 2001, Eichhorn et al., 
2009). In particular, PP2A has been found to directly de-phosphorylate AKT mainly at 
the T308 residue and to a smaller extent at S473 residue (Kuo et al., 2008). 
Additionally, PP2A can either positively or negatively regulate ERK activation 
(Eichhorn et al., 2009). As far as the negative regulation of ERK is concerned, PR61β 
or PR61γ regulatory subunits are responsible for direct de-phosphorylation of ERK by 
PP2A since their ablation resulted in upregulation of ERK signalling in a MEK-
independent way (Letourneux et al., 2006). Moreover, an indirect de-phosphorylation 
mechanism of ERK exists whereby PP2A de-phosphorylates and inactivates c-SRC, 
which in turn inactivates RAF protein, an upstream kinase in MAPK/ERK cascade, in a 
RAS-independent way. On the contrary, PP2A upon RAS activation directly de-
phosphorylates RAF at S295 residue leading to translocation of RAF to the plasma 
membrane for activation of the RAS/RAF/MAPK pathway and consequent 
upregulation of ERK activation (Eichhorn et al., 2009). Finally, Phosphatase and 
TENsin homolog protein (PTEN) was included in our study due to its known function in 
controlling PI3K activity and consequently AKT phosphorylation. PTEN is a lipid 
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phosphatase enabling the de-phosphorylation of phosphatidylinositol 3,4,5-
trisphosphate (PIP3) to phosphatidylinositol 4,5-bisphosphate (PIP2) and therefore 
reverses PI3K lipid kinase activity. 
To examine whether autophagy inhibition resulted in upregulation of PP2A and 
PTEN protein expression levels, total cell lysates from autophagy-proficient and 
autophagy-compromised cells were subjected to western blotting analysis for PP2Ac 
catalytic subunit and total PTEN expression levels. Autophagy-compromised HCT-116 
cells displayed a slight increase of approximately 15% in PP2A protein levels, whereas 
PP2A expression was not affected in autophagy-compromised CaCo2 cells (Figure 4. 
10.b and c). A marginal increase in PTEN expression levels upon autophagy inhibition 
was observed in CaCo2 cells (Figure 4. 10.d). 
Together these data suggest that diminished phosphorylation of AKT and ERK 
proteins upon autophagy inhibition is not regulated by accumulation of PP2A and 
PTEN phosphatases. 
 
Figure 4. 10: PP2A and PTEN phosphatases are not degraded through autophagy. a 
Schematic representation of hypothesis that PP2A or PTEN are getting degraded through 
autophagy. PP2A catalytic subunit expression levels upon autophagy downregulation in b 
HCT-116 KRAS WT and G13D isogenic cell lines; c CaCo2 cells. d PTEN expression levels 
upon autophagy downregulation in CaCo2 cells. HCT-116 KRAS WT and G13D isogenic cell 
lines as well as CaCo2 cells were treated with DOX for 5 days and total cell lysates were 
subjected to western blotting analysis of the indicated proteins. Beta-actin or calnexin used as 
loading controls. Immunoblots presented were only performed once. Bar plots represent 
densitometric quantification of PP2A expression relative to actin levels. Autophagy-proficient 
and autophagy-compromised cells are denoted as shEGFP and shATG7 E8. p= 
phosphorylation. 
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4.2.5. Hypothesis 3: the Ubiquitin Proteasome System (UPS) in regulation of 
AKT and ERK phosphorylation upon autophagy inhibition  
A crosstalk between the two major degradation pathways present in eukaryotes, 
autophagy and the Ubiquitin Proteasome System (UPS), has been recently revealed in 
the literature. The interplay between the two pathways highlights the importance of 
protein degradation equilibrium maintenance in the cell, since autophagic degradation 
is elevated as a compensatory mechanism when UPS is inhibited and vice versa 
(Pandey et al., 2007, Lamark and Johansen, 2010, Wang et al., 2013, Liu et al., 2015). 
Previous reports have shown that AKT (Adachi et al., 2003, Dickey et al., 2008, 
Wakatsuki et al., 2011, Wu et al., 2011, Noguchi et al., 2014) and ERK (Lu et al., 
2002) proteins are degraded by UPS. Interestingly, phosphorylation at S473 residue of 
AKT has been found to promote AKT ubiquitination by mTORC2 and AKT degradation 
(Wu et al., 2011). 
Firstly, we aimed to investigate whether genetic and pharmacological (CQ) 
modulation of autophagy resulted in upregulation of UPS activity and in that way 
increased degradation of pAKT and pERK 1/2 (Figure 4. 11.a). Since no difference in 
total AKT and ERK 1/2 levels was previously observed upon autophagy 
downregulation, we reasoned this may be due to a compensatory mechanism where 
total protein expression would be proportionally increased in order to diminish 
differences in phosphorylation. To test this hypothesis, autophagy-proficient and 
autophagy-compromised (shATG7 E8 and shEGFP+CQ conditions) cells were tested 
for their proteasome activity using the luminescence-based assay Proteasome-Glo. 
For a proteasome activity negative control in the assay, autophagy-proficient cells 
were treated with 2.5 µM of the proteasome inhibitor MG132. It was found that 
autophagy inhibition did not regulate proteasome activity since no difference was 
observed between autophagy-proficient and autophagy-compromised (shATG7 E8 
and shEGFP+CQ) HCT-116 KRAS WT and G13D cells (Figure 4. 11.c). 
However, this observation does not exclude the possibility that an Ubiquitin E3 
ligase enzyme, responsible for ubiquitination and targeting of pAKT and pERK 1/2 
protein for UPS degradation, could be specifically modulated and degraded by 
autophagy (Figure 4. 11.d). To this end, total cell lysates of autophagy-proficient and 
autophagy-compromised (shATG7 E8 and shEGFP+CQ) cells were non-treated or 
treated with 2.5 µM of MG132 proteasome inhibitor and the levels of AKT and ERK 1/2 
protein phosphorylation relative to total protein levels were assessed by western 
blotting. Proteasome inhibition elevated pAKT S473 and pERK 1/2 levels of both 
autophagy-proficient and -compromised cells in comparison to the autophagy-
proficient untreated control without remarkably affecting total levels of AKT and 
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ERK1/2 proteins, respectively. In particular, MG132 treatment totally and partially 
rescued phosphorylation levels of AKT at S473 residue in HCT-116 KRAS WT and 
G13D autophagy-compromised (shATG7 E8 and shEGFP+CQ) cells, respectively. 
Total rescue of phosphorylation levels of ERK 1/2 protein was observed upon 
autophagy inhibition conditions (shATG7 E8 and shEGFP+CQ) in both HCT-116 
KRAS WT and G13D cells (Figure 4. 11.e). It was this observation that triggered the 
in-depth analysis of ERK 1/2 protein ubiquitination. In order to examine this, pERK 1/2 
protein was pulled-down from total cell lysates of autophagy-proficient and -
compromised HCT-116 KRAS WT cells in -/+ MG132-treated conditions and pERK 1/2 
ubiquitination was examined using western blotting. Even though pERK 1/2 
immunoprecipitation was successful, the presence of ubiquitination in pERK 1/2 
protein was not verified in all conditions tested. Additionally, no rescue upon MG132 
treatment could be observed in both autophagy-proficient and -compromised cells 
(Figure 4. 11.f).  
In summary, no connection between autophagy modulation and proteasome activity 
and/or degradation of an E3-Ubiquitin ligase could be established. 
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Figure 4. 11: Autophagy suppression does not affect the Ubiquitin proteasome system. a 
Schematic representation depicting the hypothesis that autophagy suppression could 
upregulate proteasome activity which in turn may lead to reduced phosphorylation of AKT and 
ERK 1/2 protein. b Bar plot presents proteasome activity dose-response of HCT-116 KRAS WT 
cells after treatment with the proteasome inhibitor MG132 for 6 hours. Proteasome activity was 
assessed using the luciferase-based assay Proteasome-Glo. c Differences in proteasome 
activity between autophagy-proficient and - compromised HCT-116 KRAS WT and G13D cells. 
Proteasome activity was assessed using the luciferase-based assay Proteasome-Glo. Two-
way ANOVA with Bonferroni posttests statistical analysis was conducted for HCT-116 cells (n= 
3). The bars represent mean ± standard deviation; ns= non-significant, *** p<0.001. d Flow 
chart showing the hypothesis that autophagy suppression may degrade an E3 ubiquitin ligase 
enzyme that targets pAKT and pERK for proteasomal degradation. e Activation levels of AKT 
and ERK 1/2 protein in autophagy-proficient and -compromised HCT-116 KRAS WT and G13D 
cells under basal and MG132-treated conditions. f Examination of ERK 1/2 protein 
ubiquitination under basal and proteasome-inhibited conditions in HCT-116 KRAS WT 
autophagy-proficient and -compromised cells. Immunoblots presented were only performed 
once. For proteasome inhibition cells were treated with 2.5 µM MG132 for 6 hours. Cells 
treated with 10 µM CQ for 6 hours in order to pharmacologically inhibit autophagy. Autophagy-
proficient and autophagy-compromised t cells are shown as shEGFP and shATG7 E8. RLU= 
Relative light units. 
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4.2.6. Hypothesis 4: Receptor Tyrosine Kinase (RTK) activation in regulation of 
AKT/ERK phosphorylation upon autophagy suppression 
Based on the findings reported above, we can conclude with some degree of 
confidence that the effect of autophagy suppression on signalling is not dependent on 
the following mechanisms: i) phosphatase degradation, ii) proteasome activity 
regulation or iii) proteasome activity/E3 ubiquitin ligase-dependent degradation. We 
therefore formulated another hypothesis whereby autophagy-mediated effects on AKT 
and ERK 1/2 activation are dependent on its ability to control RTKs, which, as 
previously described, play an important role in pathogenesis of CRC (Figure 4. 12). 
There is increasing evidence supporting RTK-dependent regulation of autophagy 
(discussed in 1.1.2.2., page 30) (Wei et al., 2013, Tan et al., 2015). However, to our 
knowledge nothing is known regarding autophagy-dependent regulation of RTK 
signalling. We set out to investigate this possibility. In support of this hypothesis is our 
finding showing CQ treatment to downregulate EGFR activation levels in DiFi cells 
(Figure 3. 8.e). 
 
 
Figure 4. 12: Schematic representation depicting the hypothesis that autophagy 
suppression may regulate RTK phosphorylation and downstream signalling. 
 
We utilised a phospho-RTK array to evaluate the phosphorylation of 49 different 
RTKs. Activated KRAS G13D isogenic cell lines were also included in this examination 
in order to assess whether the presence of oncogenic KRAS affects autophagy-
dependent RTK regulation, as previous studies have described a reduced dependency 
on RTK activation in cells harbouring KRAS activating mutations (van Houdt et al., 
2010). 
Interestingly, phosphorylation of eight different RTKs was decreased upon 
autophagy suppression in HCT-116 KRAS WT cells. In particular, autophagy-
compromised cells displayed a decrease in phosphorylation levels of the highly 
activated RTKs: i) c-MET (35%), member of HGFR RTK family; ii) Dtk (35%), member 
of AXL RTK family; iii) c-Ret (60%), member of the RET RTK family and iv) RYK 
(40%). In the same cells, RTKs with lower phosphorylation activation levels than the 
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aforementioned also exhibited decreased phosphorylation levels upon autophagy 
downregulation; these were: i) TrkC (90%), belonging to NGFR family of RTKs and ii) 
EphA1 (46%), EphA2  (30%) and EphB2 (60%), members of the Eph family of RTKs. 
A similar pattern of decreased phosphorylation in RTKs upon autophagy suppression 
was also observed in KRAS G13D expressing HCT-116 cells: i) c-Met, ii) Dtk and iii) c-
Ret RTKs displayed a decrease in their phosphorylation levels upon autophagy 
suppression (~47%, 30% and 60%, respectively). Additional RTKs with their activity 
found to be inhibited upon autophagy suppression in HCT-116 KRAS G13D cells 
were: i) Insulin R (26%) and IGF-I R (22%), members of Insulin R family of RTKs; ii) 
Axl (17%), member of AXL RTK family; iii) MSP R (42%), member of HGFR RTK 
family; iv) ROR2 (15%), member of ROR RTK family and v) EphA10 (38%), member 
of the Eph RTK family. In contrast to HCT-116 KRAS WT cells, autophagy 
suppression resulted in upregulated phosphorylation of TrkC RTK (~70%; member of 
NGFR RTK family) in the presence of the KRAS G13D mutation (Figure 4. 13). 
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Figure 4. 13: Decreased phosphorylation levels of RTKs upon autophagy suppression in 
HCT-116 KRAS WT and G13D isogenic cells. Phospho-RTK array membranes, printed with 
49 different anti-total RTK antibodies in duplicate, were incubated overnight with autophagy-
proficient (shEGFP) and -compromised (shATG7 E8) cell lysates. Incubation with phospho-
tyrosine HRP-conjugated antibody detected RTK activation levels. Immunoblots presented are 
from one complete experiment, processed simultaneously for all conditions examined and are 
representative of two independent experiments for KRAS WT and one experiment for KRAS 
G13D cells. Arrow indicates increased exposure time used to develop immunoblots. Bar plots 
depict densitometric quantification of phospho-RTK array spots. Bars represent mean ± 
standard deviation. Red boxes indicate RTKs found to be deregulated upon autophagy 
suppression in both HCT-116 KRAS WT and G13D cells. 
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To exclude the possibility of a cell-type specific effect of autophagy suppression in 
regulating RTK phosphorylation, DLD-1 KRAS WT and G13D cells were also 
examined for RTK activation levels upon autophagy suppression conditions, using the 
phospho-RTK array. In accordance with the reduced RTK-phosphorylation phenotype 
observed in HCT-116 autophagy-compromised cells, both DLD-1 KRAS WT and 
G13D autophagy-compromised cells displayed a decrease in RTK phosphorylation. In 
particular, we found the following reduction in RTK phosphorylation levels: i) c-MET 
(50%) and MSP R (50%), members of HGFR family of RTKs; ii) EGFR (15%), ErbB2 
(35%) and ERBB3 (24%), members of EGFR family of RTKs; iii) IGF-I R (20%), 
member of Insulin RTK family; iv) Dtk (38%), member of Axl RTK family; v) SCF-R 
(26%), member of PDGFR family of RTKs; vi) c-Ret (31%), member of RET RTK 
family in DLD-1 KRAS WT cells. Longer developing time of the phospho-RTK array 
membranes revealed an additional 13 RTKs with reduced phosphorylation levels upon 
autophagy suppression including: i) FGFR1 (49%), FGFR2a (26%) and FGFR3 (25%), 
members of the FGFR family of RTKs; ii) PDGFRβ (49%) and M-CSF R (20%), 
members of PDGFR family of RTKs; iii) VEGF R3 (18%), member of the VEGF R 
family of RTKs; iv) EphA1 (11%), EphA2 (10%), EphA4 (47%), EphA7 (33%) and 
EphB3 (15%), members of the Eph family of RTKs and v) TrkA (50%) and TrkC (26%), 
members of the NGFR family of RTKs. ALK, which belongs to the insulin RTK family 
showed increased phosphorylation levels upon autophagy suppression (30%). 
Reduced RTK-phosphorylation upon autophagy suppression was also observed in 
DLD-1 KRAS G13D cells but to a lesser extent compared to WT cells: c-MET, ErbB2, 
Dtk and EphA4 displayed reduced phosphorylation (20%, 27%, 23% and 33%, 
respectively). Additional RTKs with reduced phosphorylation in DLD-1 KRAS G13D 
cells were: i) ROR2 (13%), member of the ROR RTK family; ii) Tie-2 (50%), member 
of TIE RTK family; iii) ALK (33%), member of Insulin R family and iv) EphA10 (25%), 
member of the Eph family of RTKs. In contrast to DLD-1 KRAS WT autophagy-
compromised cells, autophagy suppression in DLD-1 KRAS G13D cells resulted in 
enhanced phosphorylation of: i) ERBB3 (52%), ii) MSP R (23%) and iii) EphA1 (16%) 
(Figure 4. 14). 
In conclusion, autophagy suppression reduces RTK-phosphorylation in CRC cells, 
in most cases independently of KRAS mutational status. Notably, c-MET, Dtk and c-
RET RTKs were hypo-phosphorylated upon autophagy suppression in both HCT-116 
and DLD-1 cells.  
Basal autophagy and cell signalling in CRC 
150 
 
Figure 4. 14: Decreased phosphorylation levels of RTKs upon autophagy suppression in 
DLD-1 KRAS WT and G13D isogenic cells. Phospho-RTK array membranes, printed with 49 
different anti-total RTK antibodies in duplicate, were incubated overnight with autophagy-
proficient (shEGFP) and -compromised (shATG7 E8) cell lysates. Incubation with phospho-
tyrosine HRP-conjugated antibody detected RTK activation levels. Immunoblots presented are 
from one complete experiment and simultaneously processed for all conditions examined. 
Arrow indicates increased exposure time used to develop immunoblots. Bar plots depict 
densitometric quantification of phospho-RTK array spots. Red boxes indicate RTKs found to be 
deregulated upon autophagy suppression in both DLD-1 KRAS WT and G13D cells. 
Basal autophagy and cell signalling in CRC 
151 
4.2.7. Validation of RTK Array results: c-MET phosphorylation is affected upon 
autophagy suppression  
To validate hits identified by the RTK array, we used immunoprecipitation for total-
RTKs followed by western blotting with an anti-phospho-tyrosine antibody. We decided 
to focus our research on c-MET since its expression and signalling, apart from being 
highly expressed in CRC, have also been implicated in development of primary and 
acquired resistance of mCRC cells and patients to EGFR-targeted therapy (Bardelli et 
al., 2013, Misale et al., 2014). In addition to the high clinical importance of studying c-
MET, plenty of reagents to enable our research were available. 
In line with the phospho-RTK array results, immunoprecipitated total c-MET was 
found to be less phosphorylated in autophagy-compromised cells compared to 
autophagy-proficient HCT-116 KRAS WT cells (Figure 4. 15.a). Moreover, the ratio 
between phosphorylated c-MET and total c-MET was reduced in total cell lysates from 
autophagy-compromised cells by approximately 40%. The decrease in c-MET 
phosphorylation was not a secondary effect caused by reduced total c-MET levels, as 
total c-MET levels were unaltered in autophagy-compromised cells (Figure 4. 15.b).  
In an attempt to validate additional RTKs, we studied phosphorylation levels of c-
Ret but reagents were not reliable (not shown). As expected, phosphorylation levels of 
both IGF-I R and EGFR were not affected, in agreement with phospho-RTK array 
results for HCT-116 KRAS WT cells (Figure 4. 16). Of note, total tyrosine-
phosphorylation levels were not altered upon autophagy suppression (Figures 4. 15 
and 4. 16). 
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Figure 4. 15: Autophagy suppression reduces c-MET activation in HCT-116 KRAS WT 
cells. a Autophagy-proficient and -compromised cells 5 days after DOX treatment, to efficiently 
downregulate ATG7 protein expression, were lysed and total c-MET protein subjected to 
immunoprecipitation. Immunoprecipitated c-MET activity was assessed using western blotting 
for p-Tyrosine 4G10 antibody. Total c-MET was used to examine immunoprecipitation 
efficiency and loading. Beta-actin was used as loading control of total cell lysates. b 
Autophagy-proficient and -compromised total cell lysates derived from HCT-116 KRAS WT 
cells 5 days after DOX treatment, to downregulate ATG7 protein, were subjected to western 
blotting in order to examine p-c-MET Y1234/1235 relative to total c-MET levels. Beta-actin used 
as loading control. Immunoblot presented is representative of n= 3 independent experiments. 
Bar plot represents densitometric quantification of p-c-MET Y1234/1235 relative to total c-MET 
protein. The bars represent mean ± standard deviation; * p<0.05. Unpaired Student’s t-test. 
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Figure 4. 16: Autophagy suppression does not alter phosphorylation levels of IGF-I R 
and EGFR in HCT-116 KRAS WT cells. Autophagy-proficient and -compromised cells 5 days 
after DOX treatment, to efficiently downregulate ATG7 protein expression, were lysed and total 
cell lysates were subjected to immunoprecipitation with a total IGF-I R and b total EGFR 
antibodies. Immunoprecipitated total IGF-I R and total EGFR activity was assessed using 
western blotting for p-Tyrosine 4G10 antibody. Total IGF-I R and total EGFR proteins used to 
assess immunoprecipitation efficiency and loading. Beta-actin was used as loading control of 
total cell lysates. Arrow indicates IGF-I R. 
 
Overall, c-MET but not EGFR or IGF-IR beta activation was altered by autophagy 
suppression in immunoprecipitation studies, as the phospho-RTK array had previously 
indicated for HCT-116 KRAS WT cells. Additionally, the sustained total c-MET levels 
and total tyrosine-phosphorylation levels under autophagy-compromised conditions 
point in the direction of autophagy specifically regulating phosphorylation levels of c-
MET.  
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4.2.8. c-MET colocalises with autophagosomes 
Based on our observations and evidence from the literature showing that RTKs 
may colocalise with autophagic structures (Sandilands et al., 2012, Jones et al., 2014), 
we formulated the hypothesis that internalised c-MET colocalises with autophagic 
vesicles. To explore this possibility, HCT-116 KRAS WT cells were examined using 
confocal microscopy for endogenous c-MET and LC3B protein localisation and 
interaction. To increase the chances of detecting autophasosomes, the lysosomotropic 
agent CQ was included to enable their accumulation by preventing their fusion with 
lysosomes and degradation. Even though in both untreated and CQ-treated cells, c-
MET was found to colocalise with LC3B protein, the distribution of colocalising 
domains in the cell differed between the two conditions. In particular, in -CQ conditions 
c-MET staining was mainly observed at the plasma membrane, where it displayed a 
degree of colocalisation with LC3B. After CQ treatment c-MET was observed in 
punctate intracellular structures around the nucleus that colocalised with LC3B (Figure 
4. 17.a). To determine whether this colocalisation pattern applied to another RTK, 
localisation of EGFR was examined upon -/+ CQ treatment in HCT-116 KRAS WT 
cells. It was observed that EGFR was located at the plasma membrane in both -/+CQ 
conditions examined. In -CQ condition, EGFR seemed to colocalise with LC3B at the 
plasma membrane, in accordance with the c-MET/LC3B colocalisation data. In 
contrast to c-MET, EGFR did not accumulate in perinuclear areas upon CQ treatment 
and no colocalisation with LC3B was observed (Figure 4. 17.b). 
As the majority of studies describe LC3B to be mainly cytoplasmic, we decided to 
investigate whether the staining was specific to LC3B protein. HCT-116 KRAS WT 
cells were transiently transfected with two different LC3B siRNAs and it was confirmed 
that intracellular LC3B staining in the +CQ condition was specific since both LC3B 
siRNAs abolished intracellular LC3B signal. Plasma membrane staining of 
endogenous LC3B could not be proved specific since staining was, to some extent, 
retained in cells transfected with LC3B siRNAs (Figure 4. 18). 
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Figure 4. 17: Examination of LC3B colocalisation with a c-MET and b EGFR RTKs. HCT-
116 KRAS WT cells were either treated or not with 10 µM CQ for 6 hours and then fixed. Cells 
were stained for total c-MET (green) or EGFR (green), LC3B (red) and nucleus (Hoechst dye-
blue). Images were acquired using a Zeiss LSM 700 confocal microscope.  
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Figure 4. 18: Examination of LC3B antibody specificity. HCT-116 KRAS WT cells were 
transiently transfected with 10 nM scramble, s22- and s37- LC3B siRNAs using 
lipofectamineRNAiMax reagent. 48 hours post-transfection cells were treated with or without 10 
µM CQ for 6 hours and then fixed. Cells were stained for LC3B (red) and nucleus (Hoechst 
dye-blue). Images were acquired using a Zeiss epifluorescence microscope.   
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4.2.9. c-MET has a putative LIR motif but interaction with LC3B could not be 
proved 
Studies on selective autophagy, where characterised autophagy receptors such as 
p62 and NBR1 function as inter-mediators between cargo and autophagosome 
associated LC3B protein, led to the identification and characterisation of LC3-
Interacting Region (LIR) motifs in proteins interacting with LC3B. LIR motifs are 
characterised by a consensus amino acid sequence of [W/F/Y]xx[L/I/V] where x 
indicates any amino acid (W stands for Tryptophan, F for Phenylalanine, Y for 
Tyrosine, L for Leucine, I for Isoleucine, and V for Valine). New LIR-motif-containing 
proteins are constantly being discovered and in many cases they can function 
differently to an autophagy receptor. Some examples are proteins of the core 
autophagy machinery, proteins associated with autophagosomes and other vesicles 
and signalling proteins that act as substrates for selective autophagy (Birgisdottir et al., 
2013). 
Based on that knowledge and iLIR website (http://repeat.biol.ucy.ac.cy/iLIR/), for in 
silico identification of LIR motifs in proteins (Kalvari et al., 2014), we examined whether 
c-MET and other RTKs contain any possible LIR motifs which would enable direct 
interaction with LC3B protein and consequently autophagosome. The iLIR website 
predicted candidate sequences that could act as LIRs in all RTKs tested (Table 4. 2). 
In the majority of RTKs, including c-MET; sequences located in both extracellular and 
cytoplasmic tyrosine kinase domains of RTKs were predicted to be good candidates 
for interaction with LC3B protein. Probability of good candidates was based on the 
position-specific scoring matrix (PSSM) value provided by iLIR. 
Even though iLIR analysis indicated the presence of possible LIR motifs in c-MET 
and other RTKs, experimental validation of direct interaction between c-MET and 
LC3B was indispensable to eliminate false positive predictions. To this end, 
autophagy-proficient and -compromised HCT-116 KRAS WT total cell lysates were 
immunoprecipitated for total and p-c-MET proteins and the presence of LC3B protein 
in a complex with c-MET was examined using western blotting. CQ treatment was 
applied in both autophagy-proficient and -compromised cells to eliminate LC3-II 
degradation by autophagosomes and enhance LC3B protein detection. LC3B protein 
did not coimmunoprecipitate neither with total MET nor with p-c-MET protein in all 
conditions tested, even though pull-down of both c-MET and p-cMET was successful 
(Figure 4. 19). In summary, even though iLIR server predictions indicated an LC3B-
dependent regulation of c-MET phosphorylation by autophagy, immunoprecipitation 
experiments could not prove a direct interaction between LC3B and c-MET. The latter 
needs further investigation since experimental limitations could have led to negative 
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results. In this respect, different IP conditions could reveal an interaction. Furthermore, 
the use of antibodies against the extracellular domain or a tagged version of c-MET 
could avoid problems related to antibody binding of the putative LIR region and 
therefore interfering with the interaction to LC3B. 
 
Table 4. 2: iLIR server predicts possible LIR motif sequences present in RTKs. The amino 
acid sequence of each RTK was examined for the presence of xLIR motif sequences 
corresponding to the [ADEFGLPRSK][DEGMSTV][WFY][DEILQTV][ADEFHIKLMPSTV][ILV], in 
silico. PSSM stands for position-specific scoring matrix and indicates the probability of a 
functional LIR prediction. The higher the PSSM value, the greater the probability of a functional 
LIR detection is. For the identification of possible LIR motifs, a PSSM value above 10 was used 
as the cut-off. iLIR server uses also the ANCHOR software, which predicts disorder sequences 
able to stabilize upon binding to a target protein. If a sequence is characterized as an anchor 
and has a high PSSM value, the probability of it to be a functional LIR is increased.  
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Figure 4. 19: LC3B does not immunoprecipitate either with total c-MET or with p-c-MET 
Y1234/1235 protein. Autophagy-proficient and -compromised cells 5 days after DOX 
treatment, to efficiently downregulate ATG7 protein expression, were treated with -/+ 10 µM CQ 
for 6 hours and then were lysed. Total cell lysates were subjected to immunoprecipitation with a 
total c-MET and b p-c-MET Y1234/1235 antibodies. Interaction of LC3B protein with 
immunoprecipitated total c-MET and p-c-MET Y1234/1235 was assessed using western 
blotting for LC3B. Total c-MET protein used to assess immunoprecipitation efficiency and 
loading. p-Tyrosine 4G10 used to assess phosphorylation levels of immunoprecipitated c-MET 
protein. 
 
4.2.10. Examination of c-MET, ERK and AKT phosphorylation under LC3B 
protein downregulation conditions  
To determine whether regulation of c-MET RTK, MAPK/ERK- and PI3K-
components phosphorylation requires LC3-II positive autophagosomes, HCT-116 
KRAS WT cells were transfected with control and LC3B siRNAs to inhibit LC3B protein 
expression. I hypothesised that if LC3B protein plays an active role in regulating the 
phosphorylation of the aforementioned proteins, LC3B depletion would recapitulate the 
defects in their phosphorylation observed by ATG7 downregulation. LC3B protein 
expression was abolished and autophagy levels measured by p62 protein expression 
remained stable with both LC3B siRNAs examined (Figure 4. 20.a). Preliminary data 
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showed that LC3B protein downregulation reduced phosphorylation levels of c-MET, 
ERK1/2 and possibly AKT proteins without affecting their total protein levels (Figure 4. 
20). In particular, both LC3B siRNA samples exhibited modest albeit reduced 
phosphorylation levels of c-MET relative to total protein (approximately 16% and 21% 
in s22 and s37 LC3B siRNAs, respectively). ERK 1/2 phosphorylation was reduced 
independently of MEK 1/2 phosphorylation upon LC3B downregulation (s22~ 21% and 
s37~41%). Regarding PI3K pathway, even though s22 LC3B siRNA exhibited reduced 
AKT phosphorylation levels relative to total AKT (~25%), s37 LC3B siRNA upregulated 
AKT phosphorylation levels (~25%) relative to total AKT. Phosphorylation of S6 
ribosomal protein remained stable with both LC3B siRNAs examined. 
Collectively, in line with ATG7 knockdown experiments, LC3B downregulation 
reduced c-MET and ERK 1/2 phosphorylation levels whereas levels of pAKT were 
affected in a siRNA sequence-dependent manner. Additionally, MEK 1/2 and S6 
ribosomal protein phosphorylation was sustained following LC3B siRNA in contrast to 
the attenuated and elevated levels, which were observed following ATG7 
downregulation. Further experiments are warranted to establish whether LC3B protein 
has an active role in regulation of c-MET RTK, MAPK/ERK- and PI3K-components 
phosphorylation. 
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Figure 4. 20: Examination of c-MET, MAPK/ERK and PI3K pathway components 
phosphorylation upon LC3B downregulation. HCT-116 KRAS WT cells were transiently 
transfected with 10 nM scramble, s22- and s37- LC3B siRNAs using lipofectamineRNAiMax 
reagent. 48 hours post-transfection cells were lysed and total cell lysates were subjected to 
western blotting for corresponding proteins. Examination of: a LC3B and p62 protein 
expression levels; b c-MET phosphorylation levels relative to total c-MET protein expression 
levels; c MEK 1/2 and ERK 1/2 phosphorylation levels relative to total MEK 1/2 and ERK 1/2, 
respectively; d AKT S473 and S6 ribosomal protein phosphorylation levels relative to total AKT 
and S6 ribosomal protein, respectively upon LC3B siRNA. Beta-actin used as western blotting 
loading control. Bar plots represent densitometric analysis of p-c-MET/pERK 1/2/pAKT proteins 
relative to their corresponding total proteins. Scr= Scramble siRNA control. Immunoblot images 
depict results of a single experiment. 
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4.2.11. HGF levels are not affected by autophagy inhibition 
Based on previous observations suggesting that LC3-II-positive autophagosomes 
may be responsible for c-MET activation regulation, we aimed to gain insight into the 
functional mechanism by which autophagy regulates phosphorylation of c-MET RTK.  
Ligand binding in RTK extracellular domains initiates RTK dimerisation and 
transphosphorylation of their cytoplasmic-tyrosine kinase domain leading to RTK 
activation (Lemmon and Schlessinger, 2010). Hepatocyte Growth Factor (HGF) is 
responsible for triggering c-MET activation after its binding and leading to 
phosphorylation of c-MET catalytic Y1234/1235 residues. Even though c-MET 
activation in plasma membrane of epithelial cells is mainly catalysed in a paracrine 
manner by HGF that is produced in mesenchymal cells (Trusolino et al., 2010), an 
autocrine activation mechanism of c-MET activation in cancer has been previously 
described (Peruzzi and Bottaro, 2006). To explore whether autophagy suppression 
reduces HGF expression levels and consequently autocrine c-MET activation, 
autophagy-proficient and -compromised HCT-116 KRAS WT cells were examined for 
HGF expression levels using western blotting. Additionally, based on the observation 
that LC3B siRNA-treated cells exhibit slightly reduced c-MET activation, lysates of 
HCT-116 KRAS WT cells with abolished LC3B expression were also subjected to 
western blotting for HGF expression. Sustained HGF expression was observed under 
both autophagy suppression and LC3B siRNA conditions (Figure 4. 21), discouraging 
the hypothesis of a reduced autocrine c-MET activation mechanism upon autophagy 
suppression. 
  
 
 
 
Figure 4. 21: HGF expression levels upon a autophagy suppression and b LC3B siRNA 
conditions in HCT-116 KRAS WT cells. For autophagy suppression experiment, autophagy-
proficient and -compromised HCT-116 KRAS WT cells were treated with 10 ng/ml DOX for 5 
days to efficiently downregulate ATG7 protein expression. At day 5, cells were treated with 10 
µM CQ for 6 hours and followed cell lysis for western blotting examination of HGF protein. For 
LC3B siRNA experiment, HCT-116 KRAS WT cells were transiently transfected with 10 nM 
scramble or s22/s37 LC3B siRNAs using lipofectamineRNAiMax reagent. 48 hours post-
transfection cells were lysed and subjected to western blotting for HGF protein. Beta-actin used 
as loading control. Scr= Scramble siRNA control. Immunoblot in a is representative image of 2 
independent experiments. Immunoblot in b performed once. 
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4.2.12. Endocytosis is not negatively affected upon autophagy inhibition 
Traditionally, endocytosis has been thought to be an attenuation mechanism of 
RTK activation and signalling through removal of the activated RTK from the 
signalling-active plasma membrane and leading to either RTK degradation at 
lysosomes or RTK recycling back to the plasma membrane (Lemmon and 
Schlessinger, 2010). Two distinct endocytosis mechanisms have been described for 
RTKs including clathrin-mediated and caveolae-mediated endocytosis. Even though 
the formation of either clathrin- or caveolin- positive vacuoles from the plasma 
membrane discriminates these endocytosis pathways, the plasma membrane-release 
of vesicles is catalysed in both cases by the action of dynamin protein. c-MET RTK is 
mainly endocytosed in a clathrin-mediated manner (Gherardi et al., 2012). 
Interestingly, a recent publication studying the proteome differences between 
autophagy-proficient and -deficient (ATG5-/- and ATG7-/-) HRAS G12V expressing 
immortalized baby mouse kidney (iBMK) cells under nutrient-replete and -deplete 
conditions, reported that autophagy suppression decreased clathrin but not caveolin 
protein expression levels (Mathew et al., 2014). We hypothesised that autophagy 
suppression may alter endocytosis of RTKs and impair their downstream signalling. To 
study the role of autophagy in RTK endocytosis a labeled-transferrin ligand approach 
was employed to investigate endocytosis differences in clathrin-mediated transferrin 
receptor internalisation between autophagy-proficient and -compromised cells. 
Additionally, two different endocytosis inhibitors were used as positive controls: 
Pitstop2 inhibiting only clathrin-mediated endocytosis and dynasore inhibiting both 
clathrin- and caveolin-mediated endocytosis. Preliminary data suggested that 
endocytosis rates of transferrin receptor were not affected upon autophagy 
suppression (Figure 4. 22). 
In contrast to the attenuation-signalling function of RTK endocytosis, an increasing 
number of studies are reporting endocytosis as a mechanism for sustained 
intracellular signalling of RTKs (Lemmon and Schlessinger, 2010). c-MET has been 
proven as a competent RTK to signal from endosomes and c-MET endosomal 
signalling is important for full ERK1/2 and Rac1 activation upon HGF stimulation 
(Kermorgant et al., 2004, Ménard et al., 2014). Based on our observation that c-MET 
colocalises with LC3B protein in perinuclear regions upon CQ treatment and the work 
of Martinez-Lopez et al., (2013) suggesting autophagosomes to act as intracellular 
signalling-platforms for ERK 1/2, we decided to investigate whether autophagy 
suppression regulates intracellular c-MET accumulation and consequently signalling 
efficiency. To this end, autophagy-proficient and -compromised cells were compared 
for intracellular c-MET accumulation by confocal microscopy imaging. CQ treatment 
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was used to potentiate c-MET accumulation in perinuclear regions and enable 
comparison. Preliminary data suggested that autophagy-compromised cells exhibit 
modestly increased levels of intracellular c-MET (Figure 4. 23), thus potentially 
excluding that decreased c-MET phosphorylation is due to diminished internalisation. 
 
Figure 4. 22: Autophagy suppression does not alter endocytosis. HCT-116 KRAS WT 
autophagy-proficient (shEGFP) and -compromised (shATG7 E8) cells were serum starved for 4 
hours to remove transferrin traces from the medium. Followed treatment with Alexa555-
conjugated transferrin (red) for 15 mins before fixation in 4% formaldehyde. Pitstop2 (10 and 20 
µM) and dynasore (80 µM) endocytosis inhibitors used as negative controls for transferrin 
endocytosis. 100 mins prior transferrin treatment cells were treated with the inhibitors in the 
corresponding conditions. For nucleus staining Hoechst dye (blue) was used. Images were 
acquired using a Zeiss LSM 700 confocal microscope. n= 1.  
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Figure 4. 23: Intracellular c-MET accumulation upon autophagy suppression. HCT-116 
KRAS WT autophagy-proficient (shEGFP) and -compromised (shATG7 E8) cells were treated 
with 10 ng/ml DOX for 5 days to efficiently downregulate ATG7 protein expression. 6 hours 
prior fixation cells were treated with 10 µM CQ to potentiate intracellular c-MET accumulation. 
Cells were stained for total c-MET (green) and nucleus (Hoechst dye-blue). Images were 
acquired using a Zeiss LSM 700 confocal microscope. Bar plot depicts average intensity of 
intracellular c-MET/cell by using Fiji software (ImageJ). Quantification of intracellular c-MET 
was performed by manually specifying the intracellular region of interest (ROI) of every cell in a 
single z-stack image. Plasma membrane staining was excluded from quantification analysis. 
Bars represent mean ± s.e.m. of n= 40 shEGFP and n= 34 shATG7 E8 cells from three 
independent experiments. 
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4.2.13. Examination of c-MET regulation by autophagy upon exogenous hrHGF 
stimulation 
Thus far all previous observations were centred in investigating the role of basal 
autophagy in endogenous c-MET regulation. However, this approach limits detailed 
investigation of RTK trafficking experiments due to the lack of synchronised ligand 
stimulation and internalised-RTK kinetics. To enable robust c-MET trafficking 
investigation, the use of exogenous human recombinant HGF (hrHGF) was required. 
An obstacle to overcome in hrHGF stimulation studies was serum-starvation prior 
hrHGF stimulation that is commonly used in the trafficking field to remove growth 
factors from the medium. Since serum-starvation induces autophagy, this approach 
was not compatible with basal autophagy examination. Instead, we decided to use 
high concentration of hrHGF and avoid serum-starvation in our experiments. By 
following this approach, it was important to examine whether hrHGF without starvation 
follows the typical trafficking route whereby hrHGF bound-c-MET is rapidly internalised 
and within around two hours is located at perinuclear endosomes while progressively 
is getting degraded (Barrow-McGee and Kermorgant, 2014). To this end, HCT-116 
KRAS WT cells were treated with 50 ng/ml HGF for 3 hours and total c-MET 
localisation was examined by immunofluorescence. Concomitant treatment with or 
without CQ was also used in order to enable autophagosome detection in these 
conditions. As is depicted in Figure 4. 24, hrHGF treatment resulted in abolished 
plasma membrane staining and increased intracellular c-MET localisation in 
perinuclear areas, whereas in the untreated condition c-MET staining was more 
abundant in cell-cell contacts at the plasma membrane. In line with previous 
observations, CQ treatment resulted in intracellular c-MET accumulation along with 
plasma membrane staining in untreated conditions and potentiated intracellular c-MET 
accumulation upon hrHGF treatment. Moreover, c-MET was found to be colocalised 
with LC3B in perinuclear areas in both -/+hrHGF conditions upon CQ treatment. 
Activation of c-MET did not seem to alter autophagosome number. To gain a better 
insight in c-MET activation and downstream signalling upon hrHGF stimulation, lysates 
of untreated and hrHGF-treated -/+CQ HCT-116 KRAS WT cells were subjected to 
western blotting. As expected, hrHGF treatment increased c-MET phosphorylation. 
Furthermore, MAPK/ERK, PI3K and mTORC1 pathways activation was upregulated 
upon hrHGF stimulation. In line with immunofluorescence results, LC3B levels were 
retained at the same level between untreated and hrHGF treated cells (Figure 4. 25). 
The aforementioned observations suggest that the intracellular accumulated c-MET 
colocalising with LC3B-positive autophagosomes in CQ treated cells corresponds to 
the kinase-activated c-MET. 
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Figure 4. 24: c-MET localisation upon hrHGF stimulation. HCT-116 KRAS WT cells were 
treated concomitantly with 50 ng/ml hrHGF -/+ 10 µM CQ for 3 hours. CQ treatment was used 
to enable autophagosome detection and differences in autophagosome formation upon hrHGF 
treatment. Cells were stained for total c-MET (green), LC3B (red) and nucleus (Hoechst dye-
blue). Images were acquired using a Zeiss LSM 700 confocal microscope. Single z-stack 
images are shown. 
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Figure 4. 25: Examination of c-MET/downstream signalling activation and autophagy 
induction upon hrHGF treatment. HCT-116 KRAS WT cells were concomitantly treated with 
50 ng/ml hrHGF -/+ 10 µM CQ for 3 hours. CQ treatment was used to enable autophagic flux 
detection between untreated and hrHGF-treated conditions. Cells were lysed and total cell 
lysates were subjected to western blotting for the corresponding proteins. Beta-actin used as 
western blotting loading control. Immunoblot images are from a single experiment. 
 
Ensuing characterisation of c-MET signalling and localisation upon hrHGF 
stimulation, we aimed to investigate c-MET internalisation along with c-MET-LC3B 
interaction upon autophagy suppression post-hrHGF stimulation. To this end, 
autophagy-proficient and -compromised cells were treated with 50 ng/ml hrHGF +CQ 
for 3 hours and subjected to confocal microscopy analysis for total c-MET and LC3B 
protein detection/colocalisation. Preliminary results showed comparable levels of 
intracellular c-MET between autophagy-proficient and -compromised conditions post-
hrHGF stimulation (Figure 4. 26.a and b). Moreover, colocalisation of intracellular c-
MET with LC3B protein was modestly reduced albeit still detectable upon autophagy 
suppression (Figure 4. 26.a, c and d), possibly due to remaining ATG7 protein 
expression enabling LC3B lipidation and autophagosome formation.  
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Figure 4. 26: Examination of internalised c-MET levels and colocalisation with LC3B 
upon autophagy suppression post-hrHGF stimulation. a HCT-116 KRAS WT autophagy-
proficient (shEGFP) and -compromised (shATG7 E8) cells were treated with 10 ng/ml DOX for 
5 days to efficiently downregulate ATG7 protein expression. 3 hours before fixation, cells were 
co-treated with 50 ng/ml hrHGF and 10 µM CQ. Cells were stained for total c-MET (green), 
LC3B (red) and nucleus (Hoechst dye-blue). Images were acquired using a Zeiss LSM 700 
confocal microscope. b Bar plot depicts average intensity of intracellular c-MET/cell by using 
Fiji software (ImageJ). Quantification of intracellular c-MET was performed by manually 
specifying the intracellular region of interest (ROI) of every cell in a single z-stack image. Bars 
represent mean ± s.d. of n= 69 shEGFP and n= 79 shATG7 E8 cells from a single experiment. 
c Bar plot represents mean ± s.d. of Manders’ coefficient for c-MET fraction colocalising with 
LC3B d Bar plot represents mean ± s.d. of Manders’ coefficient for LC3B fraction colocalising 
with c-MET. c-d Colocalisation analysis was performed using ImageJ plugin JACoP enabling 
manual adjustment of threshold of single channel z-stack images to eliminate background 
staining. Threshold settings were identical between individual images. Images for colocalisation 
examination were from a single experiment. 
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4.2.14. c-MET-dependent regulation of autophagy 
Given the observation that possibly activated c-MET colocalises with LC3B-positive 
autophagosomes intracellularly, we aimed to investigate the effect of c-MET inhibition 
in c-MET-LC3B interaction and autophagy induction. Regulation of autophagy 
downstream of RTKs is well studied and the vast majority of publications report 
autophagy induction upon RTKs inhibition, which is caused by loss of the mTORC1-
dependent checkpoint. However, it is currently unclear what the effect of RTK 
inhibition in cells displaying constitutive activation of the PI3K/AKT/mTOR pathway is. 
To address this question, we employed a c-MET inhibitor that targets the tyrosine 
kinase domain and studied potential effects on autophagy. We found that c-MET 
inhibition resulted in reduced autophagic flux (~2-fold reduction, p<0.05); in particular 
LC3-II/LC3-I ratio of METi+CQ condition was lower than non-treated+CQ condition in 
HCT-116 KRAS WT cells (Figure 4. 27.a). Of note, even though autophagosome 
formation was reduced, p62 levels were sustained upon c-MET inhibition. The latter 
observation may suggest that a non-catabolic pool of autophagosomes may exist in 
the cell that is regulated by c-MET activation. 
Additionally, differences in c-MET localisation and interaction with LC3B protein 
upon c-MET inhibitor treatment were examined using confocal microscopy. 
Interestingly, reduced c-MET activation resulted in attenuated intracellular c-MET 
accumulation upon CQ treatment, supporting the observation that intracellular c-MET 
that interacts with autophagosomes is phosphorylated (Figure 4. 27.b and c). In line 
with western blotting results, c-MET inhibition resulted in reduced autophagosome 
formation and consequently interaction with LC3B (Figure 4. 27.a and d). 
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Figure 4. 27: c-MET-dependent regulation of autophagy. HCT-116 KRAS WT cells were 
concomitantly treated with 0.5 µM METi (SGX 523) -/+ 10 µM CQ for 6 hours. CQ treatment 
was used to enable autophagic flux detection between untreated and METi-treated conditions. 
a Western blotting of untreated and METi-treated -/+10 µM CQ total cell lysates. LC3B and p62 
antibodies were used for measuring autophagy induction. Beta-actin used as western blotting 
loading control. Immunoblot images are representative of 3 independent experiments. Bar plot 
represents densitometric quantification of LC3-II/LC3-I ratio normalised to beta-actin loading 
control. The bars represent mean ± s.d.; * p<0.05. Unpaired Student’s t-test statistical analysis 
was conducted. b Confocal images of untreated and 0.5 µM METi treated cells. Cells were 
stained for total c-MET (green), LC3B (red) and nucleus (Hoechst dye-blue). Images were 
acquired using a Zeiss LSM 700 confocal microscope. c Bar plot depicts average intensity of 
intracellular c-MET/cell quantification conducted using Fiji software (ImageJ). Quantification of 
intracellular c-MET was performed by manually specifying the intracellular region of interest 
(ROI) of every cell in a single z-stack image. Bars represent mean ± s.e.m. of n= 223 untreated 
and n= 221 METi-treated cells from 3 independent experiments. d Bar plot represents mean of 
autophagosomes/cell calculated automatically using Imaris software. A manual adjustment of 
threshold of single channel z-stack images to eliminate background staining was performed. 
Threshold settings were identical between individual images from the same experiment. Bars 
represent mean ± s.e.m. of n= 223 untreated and n= 221 METi-treated cells from 3 
independent experiments. 
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4.2.15. Effect of autophagy inhibition on CRC growth and invasion/migration 
Autophagy has been found to play a tumour-promoting role in established tumours 
with various mechanisms regulating such a function. Autophagy may regulate tumour 
growth by fulfilling the elevated nutritional and metabolic demands of cancer cells 
enabling in that way their accelerated proliferation. Additionally, autophagy may 
potentiate tumour cell metastasis by enhancing the capability of cancer cells to migrate 
and invade in distant organs (previously discussed in 1.2.2). These observations 
prompted us to investigate the role of autophagy in CRC growth and 
invasion/migration. We hypothesised that autophagy would promote cancer cell 
survival/proliferation and migration/invasion in CRC and that genetic inhibition of 
autophagy would eliminate cell proliferation and migration/invasion of CRC cells. 
Previous work from our group and others suggested that autophagy promote 
tumour invasion and metastasis (Macintosh et al., 2012, Galavotti et al., 2013, Li et al., 
2013a). To study the role of autophagy in CRC migration/invasion an in vitro model to 
assess the invasive/migratory capacity of CRC cell lines was established using BD 
Biocoat chambers (Figure 4. 28).  
Since KRAS activating mutations are known to promote migration/invasion 
(Campbell and Der, 2004), we investigated whether the presence of the activating 
KRAS mutation affects the migration and/or invasion capacity of CRC cells. To this 
end, HCT-116 KRAS WT and G13D cells were cultured for 60hours in matrigel-coated 
invasion and non-coated migration chambers. As expected, the KRAS G13D activating 
mutation was found to accelerate the invasive and migratory capacity of HCT-116 cells 
(Figure 4. 29.a). 
Having established that the presence of KRAS G13D mutation enhances the 
invasive and migratory capacity of CRC cells (Figure 4. 29.a) and taking into account 
that cells with activating KRAS mutations show enhanced autophagy levels (Guo et 
al., 2011), the HCT-116 KRAS G13D cell line model was selected to examine the role 
of autophagy in regulating invasion and/or migration capacity in CRC cells.  
Autophagy-proficient and -compromised HCT-116 KRAS G13D cells were cultured 
in matrigel-coated invasion and non-coated migration chambers for 60 hours. 
Pharmacological modulation of autophagy by CQ treatment was used in parallel. It 
was found that autophagy downregulation did not affect the invasive and migratory 
capacity of HCT-116 KRAS G13D cells under basal-autophagy conditions. CQ 
treatment was found to inhibit invasive but not migratory capacity of HCT-116 KRAS 
G13D cells (Figure 4. 29.b). 
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Figure 4. 28: In vitro model for studying invasion/migration in CRC cells. Both migration 
and invasion studies performed using BD Biocoat chambers, which are characterised by the 
presence of a PET membrane with 8 µm pores. Only migratory and invasive cells could pass 
through the pores of the membrane. Invasion chambers have a layer of matrigel resembling 
extracellular matrix on top of the PET membrane enabling the examination of invasion in vitro. 
Cells were plated in corresponding chambers in the absence of FBS and let to incubate for 60 
hours. As a chemoattractant, media containing 10% FBS was used in the bottom of the well. 
Non-migrated and non-invaded cells were removed from the top of the PET membrane. Cells 
that passed through the membrane fixed and stained with Hoechst nucleus staining. Counting 
of cells was performed using the automatic programme Cell Profiler. 
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Figure 4. 29: Role of a KRAS oncogene activation in invasion/migration capacity of HCT-116 
CRC cell line and b autophagy suppression in invasion/migration capacity of HCT-116 KRAS 
G13D cells. For both a and b 50000 cells were plated in either migration or invasion chambers 
in the absence of FBS and were incubated for 60 hours. As a chemoattractant, media 
containing 10% FBS was used in the bottom of the well. Non-migrated and non-invaded cells 
were removed from the top of the PET membrane. Migrated and invaded cells that passed 
through the membrane fixed in methanol and stained with Hoechst nucleus staining. Counting 
of cells was performed using the automatic programme Cell Profiler.  
 
To study the role of basal autophagy in CRC cell growth, two different approaches 
were followed. Firstly, the proliferation rates of autophagy-proficient and -compromised 
HCT-116 cells were examined under adhered conditions using SRB assay. It was 
found that autophagy suppression does not alter cell proliferation rate of HCT-116 
KRAS WT and G13D isogenic cells, under adhered conditions (Figure 4. 30.a). 
Another method that established to examine the role of autophagy in CRC cell growth 
was the anchorage-independent cell growth approach using soft agar. Unexpectedly, it 
was found that autophagy suppression potentiates HCT-116 KRAS WT cell growth in 
anchorage-independent conditions (approximately 3-fold; Figure 4. 30.b). 
Overall, it was found that inhibition of basal autophagy does not affect growth of 
HCT-116 KRAS isogenic cells cultured in adhesion whereas it resulted in increased 
anchorage-independent growth of HCT-116 KRAS WT cells. Finally, while basal 
autophagy suppression does not affect migration/invasion capacity of HCT-116 KRAS 
G13D cells, CQ treatment shows a trend in attenuating invasive capacity of CRC cells 
possibly through an autophagy-independent manner.  
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Figure 4. 30: Role of autophagy in CRC cell proliferation in: a adhered-cultured conditions 
and b in anchorage-independent conditions. Cell proliferation was assessed in autophagy-
proficient and -compromised HCT-116 cells using a the SRB proliferation assay. Graphs 
represent mean ± SD of three independent experiments; and b anchorage-independent cell 
growth assay. Graph represent mean ± SD of two independent experiments each of them 
including two internal experimental repeats. Unpaired Student’s t-test statistical analysis was 
conducted. 
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4.3. Discussion 
4.3.1. Basal autophagy suppression attenuates AKT phosphorylation of CRC 
cells in a systematic manner while it affects ERK and other protein 
phosphorylation in a cell-type specific manner 
The function of the autophagosome as a cell signalling regulator has only recently 
been reported in the literature and its role remains elusive. The study by Martinez-
Lopez et al., (2013) was the first to show that autophagy regulates ERK activation in 
brown adipose tissue and liver extracts since inhibition of autophagy resulted in 
decreased pERK levels (Martinez-Lopez et al., 2013). Additionally, Bernard et al., 
(2014) reported that autophagy could regulate AKT activation at S473 residue in 
myofibroblasts upon serum-starved conditions (Bernard et al., 2014). Hitherto, our 
knowledge regarding the role of autophagy in regulation of cell signalling in CRC cells 
is limited and further investigation is needed. Our work reveals for the first time that 
basal autophagy suppression impairs AKT phosphorylation in CRC cell lines under 
endogenous growth factor and nutrient replete conditions. In particular, genetic 
suppression of basal autophagy results in reduced phosphorylation of AKT at S473 
residue in all CRC cell lines utilised and AKT T308 residue in CaCo2 cells, without 
affecting total levels of AKT (Figure 4. 6.a and b). 
 AKT protein is phosphorylated at T308 and S473 residues by two distinct upstream 
kinases, named PDK1 and mTORC2 respectively. Both PDK1 and mTORC2 are 
under the control of growth factor-dependent signalling and they both transmit signals 
downstream of PI3K. However, regulation of mTORC2 under PI3K is still not well 
defined (Laplante and Sabatini, 2012, Efeyan et al., 2015). These observations 
indicate that an upstream regulator of both PDK1 and mTORC2 is regulated by 
autophagy suppression. Interestingly, autophagy suppression reduced pAKT S473 
even in PI3K mutant CRC cells and this downregulation was accelerated when KRAS 
and PI3K activating mutations were both present. The abovementioned results are in 
consistence with the reduced levels of pAKT S473 observed following pharmacological 
inhibition of autophagy by CQ in all CRC cells (Figure 3. 5; discussed in 3.3.5). CQ is a 
neutralising compound, which raises the acidic lysosomal pH and in that way blocks 
degradation of lysosomal content. It has been suggested that CQ could interfere with 
autophagosome fusion to the lysosome (Klionsky et al., 2012). Taken together, this 
observed consistency between genetic- and CQ-mediated inhibition of autophagy 
might point in the direction that late steps of the autophagic process such as 
autophagosome to lysosome fusion are important for autophagy-induced AKT 
activation.  
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Basal autophagy suppression did not alter mTORC1 signalling residing downstream 
of AKT in a consistent manner between cell lines. In fact, autophagy-compromised 
KRAS WT CRC cell lines upregulated mTORC1 activation levels depicted by pS6 
activation, while KRAS mutant cells sustained mTORC1 levels with the exception of 
CaCo2 cells that marginally decreased mTORC1 signalling (Figure 4. 6.c). Altered 
phosphorylation levels of AKT in autophagy-compromised conditions could not be 
correlated to mTORC1 signalling activation. This observation suggests that the pool of 
pAKT being regulated by autophagy might have other downstream signalling targets 
than mTORC1, such as Glycogen Synthase Kinase-3 (GSK-3) and/or Forkhead box O 
(FOXO) proteins (Brunet et al., 1999, Manning and Cantley, 2007, Carracedo and 
Pandolfi, 2008, Hemmings and Restuccia, 2012). Growth factors and amino acids are 
the main regulators of mTORC1 and both are required for its full activation. Amino 
acids are required for lysosomal localisation of mTORC1 and growth factors are 
responsible for AKT-mediated activation of mTORC1 (Laplante and Sabatini, 2012, 
Efeyan et al., 2015). No additional serum or amino acids were added to the cell culture 
medium during our experimental conditions. Hence, increased activation of mTORC1 
upon autophagy suppression in KRAS WT cells could suggest that levels of 
intracellular amino acids or growth factors were elevated. The decreased 
phosphorylation of AKT upon autophagy suppression may rule out the possibility that 
increased levels of growth factors control mTORC1 activity. A possible explanation for 
mTORC1 upregulation upon autophagy suppression would be that the remaining AKT 
activation is sufficient to cooperate with high levels of amino acids to increase 
mTORC1 activity. Future experiments could shed more light on the functional 
consequences of AKT hypo-phosphorylation mediated by basal autophagy 
suppression.  
When signalling pathways other than PI3K/AKT were examined it was found that 
autophagy modulates activation of proteins in a cell type-specific manner. Regarding 
MAPK/ERK pathway it was found that, in contrast to the systematic decrease of AKT 
phosphorylation observed upon autophagy suppression, phosphorylation of ERK and 
MEK was regulated in a cell-type specific manner (Figure 4. 7). In particular, basal 
autophagy suppression resulted in reduced ERK activation in HCT-116 cells 
independently of their KRAS status. However, in DLD-1 cells KRAS activation 
differentially controlled phosphorylation of ERK upon autophagy suppression. In fact, it 
resulted in ERK hypo-phosphorylation in KRAS mutant DLD-1 cells, whereas DLD-1 
KRAS WT cells presented increased ERK activation. CaCo2 cells showed only 
marginally decreased levels in ERK activation. CQ treatment recapitulated genetic 
inhibition of autophagy only in short time treatments (6 hours) in HCT-116 cells (Figure 
3. 11.e). In DLD-1 cells CQ treatment resembled ATG7 downregulation after 24 hours 
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(Figure 3. 10.a) and 6 hours (Figure 3. 18.b) treatment for KRAS WT and KRAS G13D 
cells, respectively. Inconsistency of CQ results between different treatment time points 
prevents us from reaching a conclusion regarding similarity in regulation of ERK 
activation between inhibition of autophagy in early and late steps of the autophagic 
process. When MEK 1/2 residing upstream of ERK 1/2 was tested, it was found that 
autophagy inhibition regulates activation of MEK 1/2 in a similar pattern to ERK1/2 in 
KRAS WT cells; however, this was not observed in KRAS mutant cells (Figure 4. 7.b). 
This suggests that defects in ERK activation following autophagy suppression in KRAS 
WT cells might be indirect and an upstream regulator of both MEK and ERK is 
regulated by autophagy. However, in the study by Martinez-Lopez et al., (2013) 
autophagy-mediated regulation of ERK protein was a direct effect and MEK activation 
levels were not altered (Martinez-Lopez et al., 2013). This supports our results 
showing that ERK activation is directly regulated by autophagy in KRAS mutant cells. 
For other signalling pathways, it was found that activation of STAT3, p38 MAPK 
and Rb proteins was not altered following autophagy suppression. On the contrary, 
autophagy inhibition altered AMPK alpha and SAPK/JNK activity in a cell-type specific 
manner (Figure 4. 9). In particular, autophagy suppression reduced AMPK alpha in 
KRAS mutant CaCo2 and HCT-116 cells, whereas AMPK alpha was increased in 
HCT-116 KRAS WT cells. Given the known role of AMPK alpha as an energy sensor 
in the cell (Efeyan et al., 2015), these observations suggest that autophagy 
suppression might alter metabolism of CRC cells in a KRAS-dependent manner. A 
recent study by Levy et al., (2015) has shown that AMPK alpha is upregulated 
following ATG7-deletion in intestinal epithelial cancer cells with APC deletion (Levy et 
al., 2015). SAPK/JNK kinase phosphorylation was downregulated in HCT-116 cells 
following autophagy inhibition and the presence of KRAS activation further enhanced 
pSAPK/JNK inhibition. CaCo2 cells sustained pSAPK/JNK levels following autophagy 
suppression. The abovementioned were following the same pattern as ERK 1/2 
following autophagy suppression.  
PI3K/AKT, MAPK/ERK, AMPK alpha and JNK1 signalling cascades are known 
regulators of autophagy induction (discussed in 1.1.2.). However, little is known 
regarding the role of autophagy itself in the regulation of these signalling pathways. 
Our findings reveal a novel bi-directional relationship between basal autophagy and 
these signalling kinases. Collectively, we have clearly shown that autophagy plays an 
active role in regulation of AKT phosphorylation of CRC cells in a systematic manner. 
On the other hand, MAPK/ERK, AMPK alpha and SAPK/JNK pathways are regulated 
in a cell-type specific manner upon autophagy-compromised conditions, whereas 
phosphorylation levels of STAT3, p38 and Rb proteins are not affected. The 
inconsistency in the cell signalling defects following autophagy suppression observed 
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in this work exclude the possibility of a general mechanism systematically reducing 
phosphorylation levels of proteins to be controlled via autophagy and point in the 
direction of a specific mechanism by which autophagy controls cell signalling including 
AKT activation in CRC cells. 
 
4.3.2. Basal autophagy suppression inhibits endogenous RTK activation in CRC 
In an attempt to unravel the specific mechanism by which autophagy regulates cell 
signalling in CRC cells, different hypotheses were tested using HCT-116 KRAS WT 
cells as a model system that presented efficient downregulation of both ERK and AKT 
activation following autophagy suppression. This study reveals for the first time that 
genetic inhibition of basal autophagy diminishes endogenous RTK phosphorylation in 
CRC cells regardless of their KRAS mutational status (Figures 4. 13 and 4. 14). Using 
a phospho-RTK array it was observed that phosphorylation of various RTKs was 
reduced upon autophagy suppression in two different CRC cell lines. Amongst the 
various RTKs being de-regulated via autophagy suppression c-MET, c-RET and Dtk 
were common in the two different CRC cell lines tested. Similarity in observations 
between the two different cell lines highlights the reliability of phospho-RTK results. In 
support of this, validation experiments confirmed that endogenous c-MET 
phosphorylation but not EGFR or IGF-I R was reduced upon basal autophagy 
suppression (Figures 4. 15 and 4. 16). The reduction in c-MET phosphorylation was 
not caused by degradation or reduced protein expression since levels of total c-MET 
were sustained upon autophagy suppression (Figure 4. 15.b). These observations 
suggest the presence of a non-catabolic mechanism by which autophagy controls c-
MET phosphorylation.  
But how is c-MET activation regulated by autophagy? To shed light on the 
mechanism by which autophagy regulates c-MET phosphorylation a number of 
hypotheses were tested. Firstly, the autocrine production of HGF upon autophagy 
suppression was examined and it was revealed that HGF production deregulation is 
not responsible for c-MET phosphorylation reduction (Figure 4. 21). However, this 
observation does not exclude the likelihood that ATG7 downregulation attenuates 
secretion of the autocrine-produced HGF and thereby reducing c-MET stimulation and 
phosphorylation. Another possibility tested was whether c-MET endocytosis is de-
regulated upon autophagy suppression. Preliminary data showed that endocytosis was 
not altered upon autophagy suppression (Figure 4. 22). This observation suggests that 
endocytosis might not be responsible for diminished c-MET activation; however, 
additional experiments employing quantification of endocytosed-transferrin-555 are 
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needed to confirm this observation. On the other hand, preliminary data also shows 
that intracellular c-MET might be increased following autophagy suppression (Figure 4. 
23). This observation suggests that recycling or exocytosis of c-MET back to the 
plasma membrane might be attenuated upon autophagy suppression and in that way 
diminished levels of c-MET in the plasma membrane eliminate c-MET activation. 
When localisation of c-MET was examined it was found that intracellular c-MET 
colocalises with LC3B positive autophagosomes (Figure 4. 17.a). Treatment with 
hrHGF was found to increase intracellular c-MET (Figure 4. 24) and conversely 
tyrosine kinase inhibition of c-MET was found to attenuate its intracellular localisation 
(Figure 4. 27). Taken together, all the above suggest that activated internalised c-MET 
colocalises with autophagosomes. Based on the study by Martinez-Lopez et al., 
(2013) showing that autophagosomes act as intracellular scaffolds for maintaining 
ERK signalling (Martinez-Lopez et al., 2013), we could hypothesise that c-MET 
activation is regulated in a similar manner. A possible explanation would be that even 
though c-MET following activation at the plasma membrane is properly endocytosed, 
autophagosomes are needed to sustain c-MET activation intracellularly. In autophagy-
compromised conditions where autophagosomes are not present, the intracellular pool 
of c-MET cannot remain active. Furthermore, the observation that CQ treatment does 
not attenuate c-MET activation in basal and hrHGF-stimulated conditions (Figure 4. 
25) could be in support of this hypothesis. In particular, the presence of the 
autophagosome per se might be important regardless of the functionality of the 
autophagic process. In that respect, we hypothesised that LC3B protein, which resides 
at the outer-membrane of autophagosomes may be a mediator between 
autophagosomes and c-MET. When c-MET and other RTKs identified to be regulated 
by autophagy using the phospho-RTK array were examined in silico (via the iLIR 
server) for the existence of LIR motifs, it was found that all of them were good 
candidates for direct interaction with LC3B protein (Table 4. 2). However, co-
immunoprecipiation studies failed to prove a direct interaction between c-MET/p-c-
MET and LC3B (Figure 4. 19). This observation suggests either limitations in the 
immunoprecipitation protocol used or an indirect interaction between c-MET/p-c-MET 
and LC3B. 
Earlier studies reported RTKs’ interaction with autophagosome precursors 
/autophagosomes (Sandilands et al., 2012, Jones et al., 2014). In particular, the study 
by Jones et al., (2014) proposed that the non-receptor tyrosine kinase Ack1 modulates 
a non-canonical degradative trafficking of a small portion of EGFR to pre-
autophagosomal structures upon EGF stimulation. In particular, they showed that Ack1 
upon serum-stravation conditions is colocalised within ubiquitin rich compartments 
containing p62. EGF stimulation facilitates relocalisation of Ack1 to early endosomal 
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and pre-autophagosomal structures positive for ATG16L1. Even though colocalisation 
of Ack1 with p62 is reduced upon EGF stimulation there is still some small portion of 
Ack1 protein colocalising with p62 and EGFR. The small portion of EGFR colocalising 
with p62 was proposed to be through Ack1 interaction with both proteins (even though 
Ack1 inhibition did not alter this colocalisation). Ack1 inhibition results in increased 
localisation of EGFR to lysosomes upon EGF stimulation that however did not affect 
degradation of EGFR (Jones et al., 2014). Nevertheless, it was not investigated 
whether these p62 structures partially colocalising with EGFR are LC3B positive 
autophagosomal structures. Of note, in our study EGFR was not found to colocalise 
with intracellular LC3B positive autophagosomes (Figure 4. 17.b). The study by 
Sandilands et al., (2012) reported that c-RET RTK colocalises with autophagosomes 
and that autophagy facilitates c-RET degradation in cancer cells with defects or 
reduced FAK signalling. In the latter conditions, c-RET loses its peripheral adhesion 
localisation and presents a cytosolic localisation in autophagosomes with the specific 
mechanism enabling c-RET interaction to autophagosomes remaining unknown 
(Sandilands et al., 2012). c-RET was identified as a promising hit for autophagy-
mediated activation in both cell lines tested in our work; albeit experimental limitations 
that did not allow for validation and localisation experiments. However, based on c-
MET observations and the decreased activation of c-RET following autophagy 
suppression, a catabolic role of autophagy in regulation of c-RET activation could not 
be supported in our study. 
Collectively, this work suggests that autophagy regulates RTK activation including 
c-MET in CRC cells. A novel bi-directional relationship between basal autophagy and 
RTK activation has been established. At this point no conclusion can be made 
regarding the specific mechanism by which basal autophagy could regulate RTK/c-
MET phosphorylation and future investigations are warranted. 
 
4.3.3. Does autophagy regulate cell signalling via attenuation of c-MET RTK 
activation?  
RTKs including c-MET are the starting points for stimulation of various signalling 
cascades (discussed in 1.5.1). c-MET activation and signalling is primed by the 
binding of c-MET ligand, HGF, to the extracellular domain of c-MET at the plasma 
membrane. Dimerisation of two c-MET molecules and transphosphorylation of two 
catalytic tyrosine residues (Y1234 and Y1235) in the tyrosine kinase domain of the 
receptor follows. This leads to the subsequent phosphorylation of the two tyrosine 
residues Y1349 and Y1356 in c-MET carboxy-terminal tail. This forms a 
Basal autophagy and cell signalling in CRC 
182 
“multisubstrate docking site”, which is essential for Met signalling. c-MET regulates the 
activation of MAPK/ERK, PI3K/AKT, JNK, p38 MAPK, STAT and LKB1/AMPK 
downstream signalling pathways either through direct interaction with signalling 
molecules or through adaptor proteins (Vázquez et al., 2009, Trusolino et al., 2010, 
Barrow-McGee and Kermorgant, 2014). 
c-MET activates PI3K/AKT pathway either through direct interaction with its docking 
site or indirectly through RAS (Ponzetto et al., 1994, Trusolino et al., 2010). In our 
work, basal autophagy suppression reduced activation of both c-MET and AKT in 
HCT-116 KRAS WT cells. Moreover, c-MET phosphorylation was also attenuated in 
HCT-116 KRAS G13D cells and both DLD-1 KRAS isogenic cells lines (phospho-RTK 
array observations; Figures 4. 13 and 4. 14) in which pAKT downregulation was also 
observed. These observations suggest that AKT downregulation could be a secondary 
effect caused by the attenuated c-MET activation residing upstream of PI3K pathway. 
However, a recent study has shown that accelerated autophagy upon prolonged 
serum starvation upregulates AKT activation through mTORC2 which drives 
myofibroblast differentiation (Bernard et al., 2014). This may imply that autophagy 
regulates AKT via mTORC2 independently of c-MET in our system. Even though both 
studies observed downregulation of AKT upon autophagy suppression the different 
experimental procedures and in vitro models used may differentiate the mechanism by 
which autophagy controls mTORC2 in serum-replete and deplete conditions. 
Additionally, a recent study has shown that lysosomal associated AKT can modulate 
CMA activation. Lysosomal- mTORC2 and PHLLP1 are responsible for the 
phosphorylation and de-phosphorylation of AKT at lysosomes, respectively (Arias et 
al., 2015). The intracellular AKT might be located at the cytosolic phase of 
autophagosomes. In that case, the latter could function as scaffolds and upon fusion of 
autophagosomes with lysosomes, where mTORC2 resides; activation and 
consequently phosphorylation of AKT could be facilitated. In support of this hypothesis 
is the consistent AKT downregulation between genetic and pharmacological inhibition 
of autophagy that we observed.  
c-MET triggers MAPK/ERK pathway and activates ERK 1/2 through activation of 
the upstream kinase MEK 1/2 via the following pathways: Grb2-SOS-RAS (Ponzetto et 
al., 1994) or SHC-Grb2-SOS-RAS (Pelicci et al., 1995) or Gab1-Shp2-RAS (Maroun et 
al., 2000). In our study, pMEK 1/2 and pERK 1/2 alterations followed the same pattern 
upon autophagy suppression in KRAS WT cells. This observation implies that 
signalling mediated by growth factors is impaired in autophagy-compromised cells. In 
support of this, downregulated MEK 1/2 and ERK 1/2 activation following autophagy 
suppression is following a similar pattern with c-MET in HCT-116 KRAS WT cells. 
However, these findings cannot be generalised in DLD-1 KRAS WT cells since even 
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though c-MET activation was downregulated following autophagy suppression, ERK 
1/2 was hyper-phosphorylated. Additionally, as expected, KRAS mutant cells did not 
present alterations in MEK signalling and the theory of an upstream regulator such as 
c-MET controlling autophagy-regulated cell signalling activation cannot be supported. 
These observations may imply variability in regulation of ERK phosphorylation in a 
KRAS dependent manner but at the same time underline the importance of a 
conserved mechanism for ERK regulation by autophagy. CRC cells harbouring KRAS 
activating mutation may have developed a different mechanism for regulating ERK 
activation independently of growth factor signalling. As suggested in the study by 
Martinez-Lopez et al., (2013) autophagosomes may serve as signalling platforms for 
intracellular ERK independently of MEK regulation and growth factor signalling 
(Martinez-Lopez et al., 2013). 
JNK can be activated by c-MET through RAS-PI3K-RAC pathway (Trusolino et al., 
2010) and JNK downregulation following autophagy suppression could be correlated 
with the reduced levels of c-MET activation in HCT-116 KRAS WT cells. However, in 
KRAS mutant cells the constant activation of KRAS downstream of c-MET may restrict 
a growth factor signalling dependent mechanism by which autophagy regulates JNK 
activation. c-MET has been shown to induce AMPK activation through phosphorylation 
of its upstream kinase LKB1 (Vázquez et al., 2009). Our results have shown that 
autophagy suppression decreases phosphorylation of AMPK alpha in KRAS mutant 
cells. Based on our findings showing reduced activation of c-MET upon autophagy 
suppression, a c-MET-mediated AMPK alpha regulation can be suggested. 
Additional mechanisms by which autophagy could regulate AKT and/or ERK 
activation in CRC cells independently of c-MET were tested mainly in HCT-116 cells 
showing downregulated phosphorylation of both proteins. Initially, we investigated 
mechanisms implicating the catabolic function of autophagy and therefore autophagy-
mediated degradation of phosphatases controlling AKT and/or ERK were tested 
(Figure 4. 10). It was found that autophagy suppression resulted in a slight 
accumulation of PP2A in HCT-116 cells, whereas this increase was not evident in 
autophagy-compromised CaCo2 cells. Both HCT-116 and CaCo2 cells presented 
downregulation of pAKT following autophagy suppression so inconsistency in PP2A 
regulation could exclude the likelihood PP2A accumulation to control AKT activation 
following autophagy suppression. ERK activation following autophagy suppression 
was found reduced in HCT-116 cells, whereas it was maintained in CaCo2 cells. 
These observations could be positively correlated with the slight PP2A accumulation in 
HCT-116 cells and the stable levels of PP2A in CaCo2 cells and may suggest that 
PP2A accumulation may be responsible for pERK inhibition in autophagy-
compromised conditions. However, Martinez-Lopez et al., (2013) have shown that 
Basal autophagy and cell signalling in CRC 
184 
ERK de-activation following autophagy inhibition is PP2A-independent since PP2A 
knockdown by siRNA did not rescue pERK upon ATG7 deletion (Martinez-Lopez et al., 
2013). Our results suggest that autophagy may regulate AKT activation in a PP2A-
independent manner while PP2A accumulation could be implicated in autophagy-
mediated pERK regulation and future investigation with a specific PP2A inhibitor is 
needed.  
Based on previous studies showing that autophagy suppression upregulates 
proteasomal activity (Wang et al., 2013, Liu et al., 2015), the implication of the 
proteasome system in control of pAKT and pERK degradation was tested. However, 
no difference in proteasomal activity between autophagy-proficient and -compromised 
cells was observed (Figure 4. 11.c). In agreement with our findings, autophagy 
suppression via CQ was not found to affect proteasome activity in HCT-116 cells 
under nutrient-replete conditions (Wang et al., 2013). 
The hypothesis that an Ubiquitin E3 ligase responsible for ubiquitination and 
targeting of pAKT and pERK proteins for proteasome degradation to be specifically 
regulated by autophagy was also examined (Figure 4. 11.e and f). We firstly employed 
a proteasome inhibitor approach to examine whether AKT and/or ERK activation is 
rescued upon autophagy-compromised conditions. Preliminary data showed total 
rescue of ERK activation in autophagy-compromised conditions in the presence of a 
proteasome inhibitor. However, when ubiquitination of pERK protein was tested by 
immunoprecipitation the results were inconclusive. Even though pERK 
immunoprecipitation was successful, the presence of ubiquitination in pERK protein 
could not be verified. Additionally, ERK activation levels were not rescued this time in 
the presence of the proteasome inhibitor. The inconsistency of the abovementioned 
observations restricts us from reaching a conclusion regarding the implication of an 
Ubiquitin E3 ligase in control of AKT and/or ERK activation following autophagy 
suppression and future experiments are still needed. 
Collectively, this work suggests that reduction in AKT and/or other signalling 
cascades via autophagy suppression might be regulated through autophagy-mediated 
regulation of c-MET activation.  
 
4.3.4. c-MET kinase activation may control basal autophagy levels in CRC 
RTKs have been extensively described as indirect negative modulators of 
autophagy induction through mTOR, AKT and ERK downstream pathways activation. 
Interestingly, EGFR has been recently described by two different groups to regulate 
autophagy induction through direct regulation of autophagic machinery components 
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via either kinase-dependent or -independent mechanisms (Wei et al., 2013, Tan et al., 
2015) (previously discussed in 1.1.2.2.). As previously described for EGFR RTK, it is 
generally accepted that RTK inhibition induces autophagy. In our study, while EGFR 
inhibition did not alter levels of autophagy in HCT-116 KRAS WT cells (Figure 3. 6 and 
Figure 3. 12), inhibition of c-MET reduced a portion of basal autophagy (Figure 4. 27). 
In line with our observations another group showed negative regulation of autophagy 
upon IGF-I tyrosine kinase inhibition (by picropodophyllin) and IGF-I genetic 
knockdown (by IGF-I siRNA in HeLa cells and heterozygous deletion in MEFs) (Renna 
et al., 2013). However, a contradictory study by Humbert et al., (2013) reports that c-
MET inhibition upregulates cytoprotective autophagy in human gastric 
adenocarcinoma cells (Humbert et al., 2013). Discrepancies between studies could be 
attributed to cell type-specific effects in regulation of autophagy downstream of c-MET. 
Additionally, variability in results could also be due to c-MET inhibitor-specific effects 
since different pharmacological compounds were used. Future experiments using 
different c-MET inhibitors and c-MET downregulation approaches are needed to shed 
light on the regulation and the role of autophagy downstream of c-MET in CRC. 
Our study implies heterogeneity in regulation of autophagy downstream of RTKs 
and contradicts the traditional belief describing autophagy to be induced following RTK 
inhibition. Additionally, even though autophagosome formation was reduced, p62 
levels were sustained upon c-MET inhibition (Figure 4. 27). The latter observation 
could suggest that a non-catabolic pool of autophagosomes regulated by c-MET 
activation may exist. Based on the observation that c-MET inhibition suppresses basal 
autophagy, we hypothesised that growth factor stimulation would instead induce 
autophagy. However, no further increase in levels of basal autophagy was observed 
upon hrHGF stimulation in our study (Figure 4. 25). This could further suggest that 
activated c-MET is responsible solely for the regulation of basal autophagy. 
Interestingly, difference in tyrosine kinase activation status of c-MET resulted in 
disparate localisation; hrHGF stimulation increased perinuclear, while tyrosine kinase 
inhibition increased plasma membrane localisation (Figures 4. 24 and 4. 27). The loss 
of c-MET intracellular localisation may be responsible for the reduction of basal 
autophagy levels observed following c-MET inhibition. How could c-MET tyrosine 
kinase inhibition or localisation reduce levels of basal autophagy in CRC? 
A potential scenario could be that tyrosine kinase activation of c-MET represents 
the initial step that facilitates intracellular translocation of c-MET whereby it interacts 
with autophagosome initiation precursors thus enabling autophagosome biogenesis. 
Upon hrHGF stimulation, active c-MET is rapidly internalised and soon (approximately 
after two hours) it is located at perinuclear endosomes (Barrow-McGee and 
Kermorgant, 2014). Regulation of autophagy initiation by RTKs at endosomes has 
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been previously described for EGFR (Wei et al., 2013, Tan et al., 2015). In particular, 
the study by Tan et al., (2015) reported decreased basal autophagy levels upon EGFR 
downregulation, however not evident for c-MET. Notably, regulation of autophagy 
upon c-MET tyrosine kinase inhibition was not investigated. Additionally, c-MET 
similarly to EGFR was found to colocalise with LAMPT4B-positive endosomes while 
LAMPT4B downregulation altered c-MET localisation (Tan et al., 2015). Future 
experiments are warranted to investigate the specific localisation of c-MET and its 
interaction with potential target proteins in intracellular compartments important for 
regulation of autophagy.  
Another explanation would be that c-MET tyrosine kinase inhibition results in 
mTORC2 activity downregulation, which in turn inhibits PKC alpha activity. PKC alpha 
could derange actin cytoskeleton and suppress rates of endocytosis resulting in this 
way to formation inhibition of autophagosome precursors from the plasma membrane, 
such as ATG16L1. This mechanism was previously described by Renna et al., (2013) 
in IGF-I-mediated autophagy inhibition (Renna et al., 2013). Since c-MET downstream 
pathways were not tested following tyrosine kinase inhibition we cannot exclude the 
possibility that an mTORC2-PKC alpha mechanism controls autophagy 
downregulation in our system too. However, results may differ due to the experimental 
approaches (i.e. prolonged serum deprivation) followed.  
Finally, c-MET-driven transcriptional regulation of autophagy related genes would 
be another possible mechanism by which c-MET activation/localisation could alter 
autophagosome biogenesis. A recent publication by Perera et al., (2015) described 
that increased levels of autophagy, which characterise pancreatic ductal 
adenocarcinoma (PDA), is controlled by accelerated nuclear translocation and 
consequent activation of the MiT/TFE proteins that concomitantly regulate lysosome 
biogenesis. Interestingly, RNA-sequencing data across 10 solid cancers, revealed high 
relative expression of TFE3 factor in CRC (Perera et al., 2015). Earlier studies have 
shown that MiT and TFE proteins transcriptionally upregulate MET signalling (McGill et 
al., 2006, Tsuda et al., 2007) and we cannot exclude the possibility that a feedback 
loop exists where c-MET regulates MiT/TFE activation and or localisation. 
In conclusion, this work shows that c-MET tyrosine kinase inhibition results in 
reduced levels of basal autophagy and the specific mechanism regulating c-MET-
induced basal autophagy remains to be identified.  
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4.3.5. Basal autophagy plays a tumour suppressive role in HCT-116 cells under 
anchorage-independent cell growth conditions  
The role of autophagy in cancer remains debatable. The general model suggested 
describes a tumour suppressive role for autophagy in cancer initiation whereas 
autophagy is considered to be a tumour-promoting mechanism in cancer progression. 
Even though important progress in deconvoluting the role of autophagy in cancer has 
been made the last years, the role of autophagy in CRC initiation and progression 
remains elusive. Our work shows that inhibition of basal autophagy does not affect 
growth of HCT-116 cells in adhesion (Figures 4. 30.a and 3. 7.a). The main 
disadvantage of in vitro culture systems in adhesion is their inadequacy to resemble 
the tumour microenvironment. For that reason, 3D culture systems and anchorage 
independent cell growth assays are used alongside with experimental models in 
adhesion. The aforementioned assays are better correlated with tumourigenicity in 
animal models (2012). In this study we employed an anchorage independent cell 
growth assay, which examined the ability of cancer cells to grow and survive in the 
absence of attachment to extracellular matrix and neighboring cells. In contrast to the 
sustained proliferation of HCT-116 cells in adhesion, autophagy inhibition resulted in 
increased anchorage-independent growth of HCT-116 KRAS WT cells (Figure 4. 
30.b); an observation supporting a tumour suppressive role of autophagy in CRC 
progression. This observation is inconsistent with a recent study by Levy et al., (2015) 
showing that autophagy plays a tumour-promoting role in both early and later stages of 
CRC development (Levy et al., 2015). Nevertheless, these differences could be 
explained by the different experimental approaches and the genetic differences of the 
samples utilised. Levy et al., (2015) used an in vivo model for CRC cancer initiation 
and progression where autophagy was suppressed (ATG7 deletion) along with 
heterozygous deletion of APC gene in intestinal epithelial cells. This model differs from 
our in vitro assessment of cell growth in established CRC cell lines. In our model, 
autophagy is downregulated in already transformed cells whereas in their study the 
inhibition of autophagy precedes malignant transformation. Moreover, Levy et al., 
(2015) studied autophagy under APC deletion whereas HCT-116 cells were found not 
to harbour any frameshift mutation in APC gene (Cosmic website). It is possible that 
autophagy in CRC progression plays a tumour-promoting role mainly under an APC-
dependent context. Of note, in our model autophagy suppression using CQ was found 
to attenuate cell growth of DiFi cells (Figure 3. 7.e), which are expressing a truncated 
version of APC gene (Olive et al., 1993). Autophagy has been previously shown to 
decrease DNA damage and maintain genomic integrity of a cell (Karantza-Wadsworth 
et al., 2007). In that way autophagy may function as a barrier for cancer cells to lose 
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their genomic stability and accumulate further mutations leading to more aggressive 
cancer progression. CRC it is anyway characterised by increased genomic instability 
(Al-Sohaily et al., 2012) and particularly HCT-116 cells are characterised as high MSI 
(He et al., 2015). The tumour suppressive role of autophagy observed in HCT-116 
cells in anchorage-independent conditions could be attributed to the high genomic 
instability caused by autophagy suppression. Differences in cell growth phenotypes 
upon autophagy suppression between adherent and anchorage-independent 
conditions have been previously reported (Guo et al., 2011). Our findings on RTK and 
cell signalling in autophagy-compromised conditions cannot explain the increased cell 
growth phenotype of HCT-116 KRAS WT cells in anchorage-independent conditions. 
Based on earlier studies showing that AKT, ERK and JNK signalling downstream of c-
MET confers cell proliferation and survival (Lamorte et al., 2000, Xiao et al., 2001), it 
would have been expected the reduced RTK and AKT/ERK/JNK signalling to 
attenuate cell growth of cells. However our observations are inversely correlated. A 
possible explanation for these contradictory results could be that the signalling defects 
we observed in attached cultured conditions upon autophagy suppression were not 
present in anchorage-independent conditions of in vitro model systems. Future studies 
would be valuable to investigate whether the signalling defects on p-c-MET, pAKT and 
pERK following autophagy suppression in adherent-cultured conditions are also 
sustained upon anchorage-independent growth.  
Collectively, autophagy seems to play a tumour suppressive role in CRC 
progression in anchorage-independent conditions. In vivo studies investigating the role 
of autophagy in cancer progression of KRAS-driven tumours consistently show that 
autophagy enables cancer cell survival. However, the tumour-promoting role of 
autophagy in cancer progression switches to tumour suppressive when p53 gene is 
deleted concurrently with KRAS activating mutations. These observations highlight a 
context-dependent role of autophagy in cancer progression (discussed in 1.2.2.). 
Further investigations are warranted to investigate how the inhibition of autophagy 
affects the progression of different cancer types with variable mutational signatures. In 
CRC future in vivo work to characterise the role of autophagy under the presence of 
KRAS and PI3K activating mutations, important in CRC development and responsible 
for cancer therapy resistance, would be valuable. 
 
4.3.6. Basal autophagy is not implicated in invasion/migration of CRC cells 
Autophagy has been found to regulate migration/invasion in cancer (Macintosh et 
al., 2012, Galavotti et al., 2013, Li et al., 2013a) with the precise mechanism being 
Basal autophagy and cell signalling in CRC 
189 
less defined. It has been shown that autophagy inhibition could suppress 
invasion/migration in glioma cells (Macintosh et al., 2012, Galavotti et al., 2013) and 
Epithelial to Mesenchymal Transition (EMT) in hepatocellular carcinoma (Li et al., 
2013a). Currently, the role of autophagy in migration/invasion of CRC is elusive. Our 
work in accordance with the literature has shown that the presence of KRAS activating 
mutation accelerates migration/invasion of cancer cells (Campbell and Der, 2004). In 
particular, higher invasion and migration capacity was observed in HCT-116 KRAS 
G13D cells compared to their isogenic WT version (Figure 4. 29.a). Cancer cell 
invasion and metastasis is a process with high metabolic requirements. Based on the 
abovementioned findings and the known role of KRAS activation in increasing levels of 
basal autophagy and enabling cancer cell survival (Guo et al., 2011), we hypothesised 
that aggressive tumours characterised by KRAS activation could use autophagy not 
only to survive but also to invade extracellular matrix and then metastasise and 
colonise to distant organs. HCT-116 KRAS G13D autophagy-proficient and -
compromised cells were used as a model system to assess the role of autophagy in 
migration/invasion capacity of CRC cells in vitro. In contrast to the previously reported 
invasion-promoting role of autophagy, this study reveals that basal autophagy is not 
controlling CRC migration/invasion (Figure 4. 29.b). Discrepancies between studies 
could be attributed to cell-type and cancer-type specific effects. Earlier studies have 
shown that activation of c-MET, AKT and/or ERK pathways is positively correlated with 
increased invasion/migration of cancer cells, including CRC cells (Takeuchi et al., 
2003, Samuels et al., 2005, Cancer Genome Atlas, 2012, Zhu et al., 2012, Caramel et 
al., 2013, Pérez-Vargas et al., 2013, Urosevic et al., 2014, Ye et al., 2014). Based on 
the reduced RTKs, AKT and ERK activation that was observed in our study following 
autophagy suppression, it would have been expected autophagy suppression to 
diminish migration/invasion of CRC cells. However, our results were not indicative of 
such a correlation.  
 
4.3.7. Summary 
The work presented in this chapter aimed to unravel the role of basal autophagy in 
regulating cell signalling in CRC cells. Our findings establish a novel bi-directional 
relationship between basal autophagy and RTK activation and cell signalling. In 
particular basal autophagy is implicated in c-MET activation and vice versa c-MET 
tyrosine-kinase inhibition attenuates basal autophagy levels; however, the exact 
mechanism of this interplay remains to be determined. Basal autophagy was found to 
play an active role in regulation of AKT phosphorylation of CRC cells in a systematic 
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manner. On the other hand, MAPK/ERK, AMPK alpha and SAPK/JNK pathways are 
regulated in a cell-type specific manner upon autophagy-compromised conditions. Our 
work suggests that basal autophagy regulates AKT, ERK, JNK and AMPK alpha 
phosphorylation through regulating RTK activation. While basal autophagy was found 
to play a tumour suppressive role in HCT-116 cells under anchorage-independent cell 
growth conditions, this was not evident in adhered-cultured conditions. Finally, basal 
autophagy was not implicated in invasion/migration of CRC cells. 
The main conclusions and future directions of this work are presented in Chapter 5. 
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5. Conclusions and Future Perspectives 
This study aimed to define the role of autophagy in CRC in two different but 
interconnected contexts: a) upon EGFR targeted therapy and b) upon basal non-
induced autophagy conditions. It was identified that PI3K activating mutations and high 
AKT activation levels render CRC cells refractory to autophagy induction following 
pharmacological inhibition or downregulation of EGFR. Additionally, concomitant 
EGFR and autophagy inhibition did not potentiate EGFR-targeted therapy response. 
Only PI3K WT cells with deactivated AKT signalling following EGFR inhibition were 
found to induce cyto-protective autophagy. Even though PI3K mutated CRC cells are 
refractory to EGFR-mediated autophagy induction, they display basal levels of 
autophagy despite the presence of constitutive PI3K/mTOR signalling. Genetic 
inhibition of basal autophagy results in downregulation of AKT and/or ERK 
phosphorylation possibly through hypo-phosphorylation of several RTKs, including c-
MET. Interestingly, vice versa c-MET activation was found to regulate basal autophagy 
induction since c-Met inhibition results in reduction of basal autophagy. While inhibition 
of basal autophagy did not affect growth of CRC cells cultured in adhesion, it resulted 
in increased anchorage-independent growth. Finally, autophagy suppression did not 
affect migration/invasion capacity of CRC cells. 
In this work, EGFR inhibition targeted therapy with the use of the monoclonal 
antibody Cetuximab has been shown to yield a largely varied and differential response 
when tested in CRC cells. Resistant, intermediate-response, sensitive and highly-
sensitive cell lines were identified and associated with activation levels of EGFR 
downstream pathways. MAPK/ERK and PI3K/AKT activation was found to inversely 
correlate with Cetuximab treatment response. Cetuximab resistant cell lines were 
characterized by high AKT and ERK activation while highly sensitive to Cetuximab 
cells demonstrated decreased AKT and ERK activation following EGFR inhibition. 
Intermediate resistant and sensitive cells were shown to exhibit solely ERK 
downregulation. We suggest that following EGFR inhibition, ERK activation regulates 
cell proliferation and AKT activation determines cell death. To further investigate and 
prove this hypothesis a number of purpose-designed experiments can be conducted. 
Cell viability testing on the aforementioned cell lines under EGFR inhibition will allow 
for discrimination and correlation of the cytostatic and the cytotoxic effects of ERK and 
AKT, respectively. A fluorescence-based cell Live/Dead double staining assay could 
be utilised to this purpose. Additional experimental conditions where MEK, ERK and/or 
AKT inhibitors are assessed in combination with Cetuximab should be conducted in 
resistant cells (HCT-116 and CaCo2) to further explore response to EGFR inhibition. 
In turn, we could constitutively activate MEK and/or AKT (myr_AKT) proteins in 
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Cetuximab sensitive cell lines to assess reversibility of cytostatic and/or cytotoxic 
effects, respectively. Should our hypotheses proven to be valid, the cell cycle 
positioning (via BrdU assay) and the type of cell death (via Annexin V staining) upon 
Cetuximab treatment will be further defined and quantified using flow cytometry.  
The majority of CRC cell lines were found to be refractory to autophagy induction 
following EGFR targeted therapy and did not benefit from EGFR-autophagy 
combinational treatment. PI3K/AKT pathway was found to regulate autophagy 
induction following EGFR inhibition. All CRC cells harbouring PI3K mutations were 
refractory to autophagy induction, with the exception of PI3K WT DiFi cells. 
Specifically, PI3K mutations were positively correlated with AKT activation levels, 
which in turn were inversely correlated with autophagy induction. On the other hand, 
AKT inhibition approaches reversed the impotency of PI3K mutant cells to autophagy 
induction. To exploit the direct link between PI3K mutational status, AKT activation and 
autophagy induction in CRC cells it would be fundamental to use PI3K isogenic cell 
lines. In vivo experiments are warranted to establish the role of PI3K mutational status 
in Cetuximab treatment response in combination with autophagy inhibition, which will 
pave the way to future clinical trials.  
Which factor controls autophagy induction downstream of PI3K/AKT upon EGFR 
targeted therapy? In order to address this, DiFi cells could be used as a model system 
since they were found capable of inducing autophagy. Two kinases residing 
downstream of AKT, namely mTORC1 and Beclin1, will be assessed for their ability to 
induce autophagy upon EGFR inhibition as follows: i) To exploit whether an mTORC1-
dependent mechanism regulates Cetuximab-induced autophagy in CRC cells we 
should first evaluate mTORC1 activation levels as depicted by phosphorylation of S6 
using western blotting. To further prove a direct link of mTORC1 in the regulation of 
Cetuximab-induced autophagy we could either constitutively activate mTORC1 or 
downregulate Raptor in both control and myr_AKT-expressing DiFi cells treated with 
Cetuximab. We expect the constitutively activated mTORC1 cells not to induce 
autophagy and vice versa the Raptor downregulated DiFi cells to induce autophagy 
even in the presence of constitutively active myr_AKT. ii) To define whether an 
mTORC1-independent mechanism controls autophagy induction upon EGFR 
inhibition, Beclin1 protein will be examined. Firstly, immunoprecipitation of Beclin1 
protein in control and myr_AKT cells -/+ Cetuximab and phosphorylation of Beclin1 will 
be assessed using western blotting with an anti-phosphoserine antibody. The rationale 
behind the phosphoserine antibody selection resides to the fact that AKT 
phosphorylates Beclin 1 at S295 residue and thus inactivates autophagy induction. 
myr_AKT cells are expected to have increased phosphorylation (inactivation) of 
Beclin1 in comparison to control cells following Cetuximab treatment in accordance to 
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reduced autophagy levels. In addition, a Beclin1 downregulation approach via siRNA 
could be utilised in order to examine whether autophagy induction is reversed, 
following Cetuximab treatment in DiFi cells.   
Basal autophagy is controlled in an mTORC1-independent manner in CRC cells, 
despite the presence of PI3K activating mutations and mTORC1 activation. 
Interestingly, c-MET tyrosine kinase inhibition resulted in reduced levels of basal 
autophagy in our system. These findings suggest a novel function of c-MET RTK in 
controlling basal autophagy in CRC independently of mTORC1 activation. Based on 
our observations and other studies, the following two hypotheses can be suggested: i) 
c-MET-driven transcriptional regulation of autophagy might be a possible mechanism 
by which c-MET activation regulates autophagosome biogenesis. Basal autophagy in 
PDA is controlled by accelerated nuclear translocation and consequent activation of 
the MiT/TFE proteins and interestingly high relative expression of TFE3 factor is 
present in CRC (Perera et al., 2015). Since MiT and TFE proteins are transcriptionally 
upregulating MET signalling (McGill et al., 2006, Tsuda et al., 2007) we could 
hypothesise that a feedback loop exists where c-MET regulates MiT/TFE activation 
and or localisation. To exploit whether c-MET transcriptionally regulates autophagy 
induction we could initially examine the expression of MiT/TFE in CRC cells. Following 
that, siRNA downregulation will be used to investigate whether basal levels of 
autophagy are abolished through MiT/TFE deletion. ii) c-MET intracellular activation 
and/or localisation might be another factor regulating basal autophagy in CRC since 
reduction of intracellular localised c-MET upon tyrosine kinase inhibition attenuated 
autophagosome biogenesis. Earlier studies have shown that autophagy induction is 
directly regulated by EGFR at intracellular endosomal compartments where 
autophagosome precursors and regulators reside. To exploit this hypothesis we could 
specifically restrict c-MET internalisation and subsequent localisation at intracellular 
compartments independently of its activation levels. To this end, endocytosis inhibitors 
(Dynasore and Pitstop2) could be used under c-MET tyrosine kinase-stimulated and -
inhibited conditions to examine levels of basal autophagy. In addition and in order to 
further investigate whether c-MET regulates basal autophagy in a tyrosine kinase-
independent manner, siRNA could be utilised to downregulate c-MET expression and 
assess levels of basal autophagy.  
We showed for the first time that genetic inhibition of basal autophagy diminishes 
endogenous RTK activation in CRC cells, an effect evident even in the presence of 
KRAS activating mutations. This mechanism was proven by focusing on c-MET, a 
highly expressed and activated RTK and also known contributor of acquired 
Cetuximab resistance in CRC cells. The activated c-MET was found to intracellularly 
colocalise with autophagosomes. Despite the fact that these organelles are commonly 
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implicated in protein degradation, total c-MET levels remained stable, thus signifying 
that a non-catabolic mechanism by which autophagy controls c-MET and possibly 
other RTK activation exists. In order to further investigate the potential mechanism by 
which basal autophagy regulates c-MET RTK activation we could examine the 
following hypotheses: i) Basal autophagy-mediated regulation of protein-tyrosine 
phosphatases controls c-MET phosphorylation and activation. Protein-tyrosine 
phosphatases are reversing c-MET phosphorylation and activation (Trusolino et al., 
2010). Specifically, PTP1B and PTPN2 phosphatases are responsible for the de-
phosphorylation of the catalytic tyrosines of c-MET (Y1234/1235) (Sangwan et al., 
2008). A general pharmacological inhibitor of protein-tyrosine phosphatases could be 
used in autophagy-proficient and -compromised cells. Additionally, PTP1B and PTPN2 
phosphatases can be specifically downregulated using a siRNA approach. ii) Since c-
MET colocalises with autophagosome the latter could potentially function as a 
signalling scaffold for c-MET activation. To prove such a mechanism we firstly need to 
examine whether there is a direct interaction between autophagosomes and c-MET. 
To this end, we can overexpress GFP-tagged c-MET in autophagy-proficient and -
compromised CRC cells and follow a co-immunoprecipitation approach for pulling 
down GFP and detecting LC3B using western blotting. It is expected that only 
proficient cells will interact with LC3B. If such an interaction is proven we could 
overexpress a lipidated-deficient LC3B mutant (LC3BΔG) in CRC autophagy-proficient 
cells. Since non-lipidated LC3B protein cannot bind to autophagosomes we expect 
autophagy- proficient LC3BΔG expressing cells to recapitulate the attenuation of c-MET 
activation that was observed in autophagy-compromised cells. In turn, to rescue p-c-
MET inhibition in autophagy-compromised cells we could downregulate ATG4B protein 
responsible for LC3B de-lipidation. In that way we expect increased levels and 
localisation of LC3B-II on autophagosomes and an increase in c-MET phosphorylation. 
iii) Basal-autophagy-mediated regulation of HGF secretion controls c-MET activation. 
ELISA could examine differences in secretion of HGF regulated by basal autophagy 
using a quantitative assessment of HGF. It is expected that autophagy-compromised 
cells with reduced c-MET activation to present lower levels of HGF. iv) Basal 
autophagy decreases RTK exocytosis and RTK plasma membrane activation. If our 
preliminary data, which indicate increased levels of intracellular c-MET following basal 
autophagy suppression, are confirmed we could further exploit regulation of exocytosis 
in autophagy-proficient and -compromised conditions. To this end, Vamp2-pluorin 
and/or Vamp7-pluorin constructs would be overexpressed in autophagy-proficient and 
-compromised cells to monitor differences in exocytosis (Mohankumar et al., 2015). v) 
proteasome-mediated degradation of p-c-MET is potentially controlled by basal 
autophagy. This can be further examined by using the proteasome inhibitor MG132 in 
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autophagy-proficient and -compromised cells and examine whether c-MET 
downregulation is rescued in autophagy-compromised cells using western blotting.  
Our work suggests that basal autophagy regulates cell signalling through RTKs and 
more specifically c-MET in CRC cells. In particular, inhibition of c-MET activation was 
positively correlated with inhibition of c-MET downstream kinases, namely PI3K/AKT, 
MAPK/ERK, JNK, and AMPK alpha in autophagy-compromised conditions. Amongst 
the above kinases, activation of AKT was the one consistently regulated by basal 
autophagy in all CRC cell lines tested. To investigate whether autophagy modulates 
cell signalling via c-MET we could examine AKT activation in autophagy-proficient and 
-compromised cells in the absence of growth factors. To this end, prolonged serum 
starved conditions and additionally HGF siRNA in serum-replete conditions could be 
applied to abolish HGF-induced c-MET activation. If c-MET acts as the intermediate 
effector, discrepancies in cell signalling between autophagy-proficient and -
compromised cells will not be observed. In parallel a potential c-MET independent 
mechanism controlling AKT activation via autophagy could be examined. An ideal 
candidate for this would be mTORC2 as it is a known regulator of AKT activation at 
S473 residue. If mTORC2 activity is regulated by basal autophagy, downstream 
signalling effectors other than AKT could also be affected. To this purpose, serum- and 
glucocorticoid-induced protein kinase 1 (SGK1) and PKC alpha will be examined in 
autophagy-proficient and -compromised cells using western blotting. Additionally an 
mTORC2 downregulation approach through siRNA of Rictor (a component of 
mTORC2 complex) will allow us to examine differences in AKT. 
This study also highlights the importance of a later step in the autophagic process 
controlling AKT activation since both genetic and pharmacological inhibition of 
autophagy consistently downregulated AKT phosphorylation. This later step was 
suggested to be the autophagosome to lysosome fusion whereby the former acts as 
scaffold for AKT. Based on this and on the fact that mTROC2 signalling can be 
present on lysosomes it would be valuable to examine colocalisation of pAKT with 
autophagosome (LC3B), lysosomes (LAMP1) and mTORC2 (Rictor) in autophagy-
proficient and -compromised cells using immunofluorescence.  
We have also described that growth of CRC cells in adhesion is not affected upon 
basal autophagy inhibition and that a tumour suppressive role is evident under 
anchorage-independent cell growth conditions. Signalling defects present in adhered 
culture conditions upon autophagy suppression but not in anchorage-independent 
conditions could be a possible hypothesis. To further investigate how c-MET and cell 
signalling activation is regulated by autophagy in an anchorage independent milieu, 
CRC cells in detached conditions can be cultured aiming to evaluate phosphorylation 
of RTKs and cell signalling effectors using western blotting. 
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Conclusion 
RTKs are commonly overactivated or overexpressed in a variety of cancer types 
including CRC. RTKs activation and downstream signalling has been correlated with 
tumourigenesis, metastatic potential, poor survival and resistance to therapy. Basal 
autophagy is activated in a variety of cancer types including CRC and confers to 
tumour progression. A fine interplay between RTKs and basal autophagy was 
illustrated in this work. Basal autophagy suppression results in inhibition of RTKs 
activation and downstream signalling. The presence of a dynamic equilibrium between 
basal autophagy and cancer is suggesting that aberrant activation of autophagy leads 
to cancer cells “addiction” to RTK activation and AKT signalling. However, CRC cell 
growth on anchorage-independent conditions is potentiated following basal autophagy 
suppression, suggesting a tumour suppressive role of basal autophagy in CRC 
progression. It would be crucial to determine in the future whether basal autophagy-
mediated regulation of RTK and cell signalling in CRC is responsible for the tumour 
suppressive role of basal autophagy. Regarding the role of autophagy in RTK targeted 
therapy; it is generally believed that inhibition of autophagy can potentially sensitize 
cancer cells to treatment. However, autophagy regulation downstream of RTKs and 
specifically EGFR and c-MET is complex and characterized by variability. Similarly, 
variability is also present in autophagy induction between CRC cells. Autophagy 
inhibition via targeted therapy is considered a promising therapeutic approach and 
increasing number of clinical trials are using autophagy inhibitors in combination with 
conventional cancer therapy. PI3K activating mutations are present in 18% of non-
hypermutated CRC and are associated with tumour aggressiveness. Our work 
highlights the importance of PI3K screening when using autophagy inhibitors in 
combination with EGFR targeted therapy in CRC. Only PI3K WT CRC cells may 
benefit from autophagy inhibition and Cetuximab combinational treatment, whereas 
PI3K mutant cells might remain unresponsive.  
Care should be taken before using autophagy-modulating compounds into the 
therapeutic approaches used for the treatment of CRC patients. Most certainly, 
purpose-designed in vivo studies must be conducted before implementing bench-top 
model findings into the clinical practice. Autophagy inhibition approaches could be 
detrimental for PI3K mutant CRC patients, which do not induce autophagy following 
EGFR targeted therapy, due to a tumour suppressive role of basal autophagy in PI3K 
mutant CRC. 
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Table 1: Clinical trials using autophagy inhibitors in combination with Targeted Therapy agents 
 
A/A Cancer Type Autophagy Inhibitor Cancer Therapy Status Title 
1 Advance Solid Tumors HCQ Vorinostat Recruiting Hydroxychloroquine + Vorinostat in Advanced Solid Tumors 
2 Advanced Malignancies HCQ Sirolimus or Vorinostat Recruiting Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer 
3 Breast Cancer CQ - Recruiting A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer (CUBiC) 
4 Chronic Myeloid Leukemia HCQ Imatinib Mesylate Recruiting Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia 
5 Colorectal cancer HCQ FOLFOX Bevacizumab Recruiting FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer 
6 Colorectal Cancer HCQ Regorafenib Vorinostat Recruiting Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer 
7 Ductal Carcinoma in Situ CQ - Recruiting Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) 
8 
Glioma, Intrahepatic 
Cholangiocarcinoma or 
Chondrosarcoma 
CQ Metformin Not yet recruiting Metformin And Chloroquine in IDH1/2-mutated Solid Tumors (MACIST) 
9 Lung Cancer HCQ Paclitaxel Carboplatin Bevacizumab Recruiting 
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small 
Cell Lung Cancer - Phase II 
10 Lung Cancer HCQ Paclitaxel Carboplatin Bevacizumab 
Active, Not yet 
recruiting 
Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumb in Non-
Small Cell Lung Cancer (NSCLC) 
11 Lung Cancer HCQ Paclitaxel Carboplatin Bevacizumab Terminated 
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Treating 
Patients With Recurrent Advanced Non-Small Cell Lung Cancer 
12 Lung Cancer HCQ Gefitinib Recruiting Hydroxychloroquine and Gefitinib to Treat Lung Cancer 
13 Lung Cancer HCQ Erlotinib Terminated Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC) 
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A/A Cancer Type Autophagy Inhibitor Cancer Therapy Status Title 
14 Lung Cancer HCQ Erlotinib Active, Not yet 
recruiting 
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced 
NSCLC and (EGFR) Mutations 
15 Melanoma HCQ Vemurafenib Recruiting A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma 
16 Melanoma HCQ Dabrafenib Trametinib Recruiting 
The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic 
Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and 
Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma 
17 Metastatic colorectal cancer HCQ Capecitabine Oxaliplatin Bevacizumab Recruiting 
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in 
Treating Patients With Metastatic Colorectal Cancer 
18 Metastatic Solid Tumours HCQ Temsirolimus Unknown Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment 
19 Myeloma HCQ Cyclophosphamid Pulse Dexamethasone Rapamycin Terminated 
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or 
Hydroxychloroquine 
20 Myeloma HCQ Cyclophosphamide Dexamethasone Rapamycin Recruiting 
Cyclophosphamide(Cy)/ Dexamethasone(Dex)/Rapamycin 
(Rapa)/Hydroxychloroquine (HCQ) for Relapsed or Refractory 
Myeloma(Rel/Ref MM) 
21 Myeloma HCQ Bortezomib Unknown Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed 
or Refractory Multiple Myeloma 
22 Prostate cancer HCQ ABT-263 Abiraterone Not yet recruiting Phase II Study of ABT-263/Abiraterone or ABT-263/Abiraterone/Hydroxychloroquine in Prostrate Cancer 
23 Prostate or Kidney Cancer HCQ MK2206 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors or Prostate or Kidney Cancer 
24 Renal Cancer HCQ Aldesleukin Recruiting Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) 
 231 
A/A Cancer Type Autophagy Inhibitor Cancer Therapy Status Title 
25 Renal Cell Carcinoma HCQ RAD001 Recruiting 
Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of 
RAD001 and Hydroxychloroquine in Patients With Previously Treated 
Renal Cell Carcinoma 
26 Sarcoma HCQ Sirolimus Recruiting A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Drug Refractory Advanced Sarcoma 
27 Solid Tumors, Melanoma, Renal and Prostate Cancer HCQ MK-2206 Recruiting 
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With 
Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer 
28 Solid Tumours HCQ Sorafenib Recruiting Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors 
29 Solid Tumours HCQ Sunitinib Malate Active, Not yet 
recruiting 
Sunitinib Malate and Hydroxychloroquine in Treating Patients With 
Advanced Solid Tumors That Have Not Responded to Chemotherapy 
Information for Clinical trials obtained by Clinicaltrials.gov website 
 
Bevacizumab = VEGF-A inhibitor, Gefitinib & Erlotinib = EGFR inhibitors, Temsirolimus/Sirolimus/Rapamycin & RAD001 = mTOR inhibitor, Vorinostat = histone deacetylase HDAC inhibitor, 
Sorafenib = KIT, VEGFR, PDGFR and MAPK/ERK serine/threonine kinases inhibitor, Sunitinib Malate = VEGFR2, PDGFRb, c-kit and FLT3 tyrosine kinases inhibitor, ABT-263 =Bcl-2 inhibitor, 
MK2206 = AKT inhibitor, Vemurafenib = BRAF inhibitor, Imatinib Mesylate = BCR/ABL, c-KIT and PDGFR inhibitor,  Aldesleukin = IL-2 Receptor activator, Dabrafenib = B-raf inhibitor, 
Trametinib = MEC inhibitor, Regorafenib = VEGFR2-TIE2 tyrosine kinase inhibitor 
 
 
 
